DDI-DrugBank.d420.s12	Drug NN 0	/ '' 0	Laboratory NNP B-noun.other	Test NNP I-noun.other	Interactions NNPS I-noun.other	A DT B-adv.all	false JJ I-adv.all	- : 0	positive JJ B-adj.all	reaction NN B-noun.process	for IN 0	ketones NNS B-noun.communication	in IN 0	the DT 0	urine NN B-noun.location	may MD 0	occur VB B-verb.stative	with IN 0	tests NNS B-noun.person	using VBG B-verb.consumption	nitroprusside NN I-verb.consumption	, , 0	but CC 0	not RB B-adv.all	with IN 0	those DT 0	using VBG B-verb.consumption	nitroferricyanide NN I-verb.consumption	. . 0	. . 0
DDI-DrugBank.d185.s5	John NNP B-noun.person	s PRP$ 0	wort NN B-noun.body	) ) 0	may MD 0	increase VB B-verb.change	the DT 0	formation NN B-noun.act	of IN 0	dapsone_hydroxylamine NN B-noun.location	, , 0	a DT 0	metabolite NN B-noun.attribute	of IN 0	dapsone NN 0	associated VBN B-verb.cognition	with IN 0	hemolysis NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d562.s6	Antacids NNS B-noun.person	or CC 0	sucralfate VB B-verb.cognition	substantially RB B-adv.all	interfere VB B-verb.social	with IN 0	the DT 0	absorption NN B-noun.artifact	of IN 0	some DT 0	quinolones NNS B-noun.communication	, , 0	resulting VBG B-verb.stative	in RB 0	low JJ B-adj.all	urine NN B-noun.body	levels NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d60.s2	Prior JJ B-adj.all	administration NN B-noun.time	of IN 0	succinylcholine NN B-noun.person	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	duration NN 0	of IN 0	neuromuscular JJ B-adj.all	block NN B-noun.substance	following VBG B-verb.stative	initial JJ B-adj.all	or CC 0	maintenance NN B-noun.possession	bolus JJ B-adj.all	doses NNS B-noun.event	of IN 0	NIMBEX NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d347.s2	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	FACTIVE NNP B-noun.group	with IN 0	probenecid NN B-noun.person	resulted VBD B-verb.communication	in IN 0	a DT 0	45 CD 0	% NN 0	increase NN B-noun.event	in IN 0	systemic JJ B-adj.all	exposure NN B-noun.cognition	to TO 0	gemifloxacin VB B-verb.motion	. . 0	. . 0
DDI-DrugBank.d397.s6	Erythromycin NNP B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	decrease VB B-verb.communication	the DT 0	clearance NN B-noun.act	of IN 0	triazolam NN B-noun.act	and CC 0	midazolam NN B-noun.body	and CC 0	thus RB 0	may MD 0	increase VB B-verb.change	the DT 0	pharmacologic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	these DT 0	benzodiazepines NNS B-noun.communication	. . 0	. . 0
DDI-MedLine.d83.s9	Several JJ B-adj.all	studies NNS B-noun.communication	indicate VBP B-verb.communication	that IN 0	olanzapine NN B-noun.person	has VBZ B-verb.possession	benefits NNS B-noun.attribute	against IN 0	symptoms NNS B-noun.person	of IN 0	aggression NN B-noun.act	and CC 0	agitation NN B-noun.person	, , 0	while IN 0	other JJ B-adj.all	studies NNS B-noun.person	strongly RB B-adv.all	support VB B-verb.contact	the DT 0	effectiveness NN B-noun.cognition	of IN 0	olanzapine NN B-noun.person	in IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	depressive JJ B-adj.all	symptomatology NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d330.s1	Caution NN B-noun.person	should MD 0	also RB B-adv.all	be VB 0	taken VBN B-verb.cognition	in IN 0	concurrent JJ B-adj.all	or CC 0	serial JJ B-adj.all	use NN 0	of IN 0	other JJ 0	aminoglycosides NNS B-noun.person	and CC 0	polymyxins NNS B-noun.cognition	because IN 0	they PRP 0	may MD 0	enhance VB B-verb.social	neomycin NN B-noun.act	s PRP 0	nephrotoxicity NN B-noun.person	and/or CC 0	ototoxicity NN B-noun.attribute	and CC 0	potentiate VB B-verb.stative	neomycin_sulfate JJ B-adj.all	neuromuscular NN B-noun.state	blocking VBG B-verb.change	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d73.s6	Concomitant JJ B-adj.all	use NN 0	of IN 0	prostaglandin NN B-noun.substance	synthase NN 0	inhibiting VBG B-verb.change	drugs NNS B-noun.artifact	, , 0	eg UH 0	, , 0	indomethacin NN B-noun.person	, , 0	may MD 0	decrease VB B-verb.cognition	the DT 0	hypotensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	beta_blockers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d437.s8	Nelfinavir NNP B-noun.person	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	Cmax NNP B-noun.person	, , 0	A.C. NNP B-noun.person	and CC 0	Cmin NNP B-noun.person	were VBD 0	increased VBN B-verb.change	by IN 0	12 CD B-adj.all	% NN 0	, , 0	15 CD B-adj.all	% NN 0	, , 0	and CC 0	14 CD B-adj.all	% NN 0	, , 0	respectively RB B-adv.all	, , 0	by IN 0	concomitant JJ B-adj.all	amprenavir NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d434.s35	Effects NNS B-noun.phenomenon	of IN 0	Antacids NNP B-noun.person	on IN 0	Felbatol NNP B-noun.person	_ : 0	The DT 0	rate NN B-noun.time	and CC 0	extent NN B-noun.act	of IN 0	absorption NN B-noun.process	of IN 0	a DT 0	2400 CD 0	mg NN B-noun.quantity	dose NN B-noun.quantity	of IN 0	Felbatol NNP B-noun.person	_ ( 0	as IN 0	monotherapy NN 0	given VBN B-verb.possession	as IN 0	tablets NNS B-noun.artifact	was VBD B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	when WRB 0	coadministered VBN B-verb.communication	with IN 0	antacids NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d196.s32	Nursing NN 0	Mothers NNS 0	It PRP 0	is VBZ B-verb.stative	not RB B-adv.all	known VBN B-verb.cognition	whether IN 0	peginterferon NN B-noun.person	or CC 0	ribavirin VB B-verb.motion	or CC 0	its PRP$ 0	components NNS B-noun.person	are VBP 0	excreted VBN B-verb.stative	in IN 0	human JJ B-adj.all	milk NN B-noun.body	. . 0	. . 0
DDI-DrugBank.d219.s25	Thus RB 0	, , 0	concomitant JJ B-adj.all	therapy NN B-noun.person	with IN 0	warfarin NN B-noun.act	and CC 0	Lodine NNP B-noun.location	should MD 0	not RB B-adv.all	require VB B-verb.consumption	dosage NN B-noun.food	adjustment NN B-noun.act	of IN 0	either DT 0	drug NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d26.s0	Patients NNS B-noun.person	receiving VBG B-verb.communication	other JJ B-adj.all	narcotic_analgesics NNS B-noun.person	, , 0	general JJ B-adj.all	anesthetics NNS B-noun.person	, , 0	phenothiazines NNS B-noun.body	, , 0	tranquilizers NNS B-noun.person	, , 0	sedative JJ B-adj.all	- : 0	hypnotics NNS B-noun.person	, , 0	tricyclic_antidepressants NNS B-noun.plant	or CC 0	other JJ B-adj.all	CNS_depressants NNS B-noun.person	( ( 0	including VBG B-verb.emotion	alcohol NN I-verb.emotion	) ) 0	concomitantly RB B-adv.all	with IN 0	DILAUDID NNP B-noun.group	may MD 0	exhibit VB B-verb.stative	an DT 0	additive JJ B-adj.all	CNS NNP B-noun.group	depression NN B-noun.feeling	. . 0	. . 0
DDI-MedLine.d104.s2	injection NN B-noun.act	of IN 0	phencyclidine NN B-noun.phenomenon	( ( 0	PCP NNP 0	) ) 0	were VBD 0	observed VBN B-verb.perception	by IN 0	measuring VBG B-verb.cognition	locomotor NN 0	activity NN B-noun.state	and CC 0	stereotyped VBD B-verb.possession	behavior NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d341.s2	In IN 0	a DT 0	study NN B-noun.artifact	in IN 0	which WDT 0	patients NNS B-noun.person	with IN 0	active JJ B-adj.all	RA NNP B-noun.group	were VBD 0	treated VBN B-verb.social	for IN 0	up RB 0	to TO 0	24 CD B-adj.all	weeks NNS B-noun.time	with IN 0	concurrent JJ B-adj.all	ENBREL NNP B-noun.group	_ : 0	and CC 0	anakinra NN B-noun.body	therapy NN 0	, , 0	a DT 0	7 CD B-adj.all	% NN 0	rate NN B-noun.time	of IN 0	serious JJ B-adj.all	infections NNS B-noun.person	was VBD 0	observed VBN B-verb.perception	, , 0	which WDT 0	was VBD B-verb.stative	higher JJR B-adj.all	than IN 0	that DT 0	observed VBN B-verb.perception	with IN 0	ENBREL NNP B-noun.group	_ , 0	alone RB B-adv.all	( ( 0	0 CD B-noun.quantity	% NN 0	) ) 0	. . 0	. . 0
DDI-MedLine.d3.s1	The DT 0	objective NN B-noun.cognition	of IN 0	this DT 0	study NN B-noun.artifact	was VBD 0	to TO 0	determine VB B-verb.communication	if IN 0	there EX 0	is VBZ B-verb.stative	a DT 0	pharmacokinetic JJ B-adj.all	interaction NN B-noun.event	when WRB 0	amprenavir NN B-noun.person	is VBZ 0	given VBN B-verb.possession	with IN 0	rifabutin NN B-noun.substance	or CC 0	rifampin VB B-verb.motion	and CC 0	to TO 0	determine VB B-verb.communication	the DT 0	effects NNS B-noun.phenomenon	of IN 0	these DT 0	drugs NNS B-noun.artifact	on IN 0	the DT 0	erythromycin NN 0	breath NN 0	test NN 0	( ( 0	ERMBT NNP B-noun.group	) ) 0	. . 0	. . 0
DDI-DrugBank.d438.s24	Hydrocodone NNP B-noun.person	increases VBZ B-verb.change	gabapentin NN B-noun.animal	AUC NNP B-noun.group	values NNS B-noun.attribute	by IN 0	14 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d65.s0	Sulfacetamide NN B-noun.person	preparations NNS I-noun.person	are VBP B-verb.stative	incompatible JJ B-adj.all	with IN 0	silver JJ B-adj.all	preparations NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d85.s8	Inhibition NNP B-noun.person	of IN 0	renal JJ B-adj.all	lithium NN B-noun.phenomenon	clearance NN B-noun.phenomenon	leading VBG B-verb.motion	to TO 0	increases NNS B-noun.act	in IN 0	plasma NN B-noun.plant	lithium NN B-noun.body	concentrations NNS B-noun.attribute	has VBZ 0	also RB B-adv.all	been VBN 0	reported VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d454.s2	- : 0	Lofexidine NN B-noun.location	may MD 0	enhance VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	anti NNS B-noun.person	- : 0	hypertensive_drug NN 0	therapy NN 0	. . 0
DDI-DrugBank.d179.s8	- : 0	Chloroquine NN B-noun.person	( ( 0	e.g. UH 0	, , 0	Aralen NNP B-noun.person	) ) 0	or CC 0	. . 0
DDI-DrugBank.d334.s7	Reports NNS B-noun.person	suggest VBP B-verb.communication	that IN 0	NSAIDs NNP B-noun.person	may MD 0	diminish VB B-verb.change	the DT 0	antihypertensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	ACE_inhibitors NNS B-noun.person	, , 0	including VBG B-verb.change	lisinopril NN I-verb.change	. . 0	. . 0
DDI-DrugBank.d81.s8	If IN 0	isradipine JJ B-adj.all	therapy NN B-noun.person	is VBZ 0	initiated VBN B-verb.creation	in IN 0	a DT 0	patient NN B-noun.person	currently RB B-adv.all	receiving VBG B-verb.perception	cimetidine NN I-verb.perception	careful JJ B-adj.all	monitoring NN B-verb.perception	for IN 0	adverse JJ B-adj.all	reactions NNS B-noun.person	is VBZ 0	advised VBN B-verb.communication	and CC 0	downward JJ B-adj.all	dose NN B-noun.act	adjustment NN B-noun.act	may MD 0	be VB 0	required VBN B-verb.stative	. . 0	. . 0
DDI-DrugBank.d86.s0	The DT 0	concurrent JJ B-adj.all	use NN 0	of IN 0	two CD 0	or CC 0	more JJR B-noun.quantity	drugs NNS B-noun.person	with IN 0	anticholinergic JJ B-adj.all	activity NN B-noun.state	-- : 0	such JJ 0	as IN 0	an DT 0	antipsychotic_drug NN B-noun.attribute	( ( 0	eg UH 0	, , 0	chlorpromazine NN 0	) ) 0	, , 0	an DT 0	antiparkinsonian_drug NN B-noun.attribute	( ( 0	eg UH 0	, , 0	trihexyphenidyl NN 0	) ) 0	, , 0	and/or CC 0	a DT 0	tricyclic_antidepressant JJ 0	( ( 0	eg UH 0	, , 0	amitriptyline)--commonly RB B-adv.all	results VBZ B-verb.stative	in IN 0	excessive JJ B-adj.all	anticholinergic JJ B-adj.pert	effects NNS B-noun.phenomenon	, , 0	including VBG B-verb.change	dry JJ B-noun.artifact	mouth NN I-noun.artifact	and CC 0	associated VBN B-verb.cognition	dental JJ B-adj.all	complications NNS B-noun.person	, , 0	blurred VBD B-verb.cognition	vision NN B-noun.person	, , 0	and CC 0	, , 0	in IN 0	patients NNS B-noun.person	exposed VBD B-verb.communication	to TO 0	high JJ B-adj.all	temperature NN B-noun.attribute	and CC 0	humidity NN B-noun.feeling	, , 0	hyperpyrexia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d480.s29	Concomitant JJ B-adj.all	use NN 0	of IN 0	clozapine NN B-noun.person	with IN 0	other JJ 0	drugs NNS B-noun.person	metabolized VBN B-verb.social	by IN 0	cytochrome JJ B-noun.person	P450 NN I-noun.person	2D6 WDT 0	may MD 0	require VB B-verb.stative	lower JJR B-adj.all	doses NNS B-noun.person	than IN 0	usually RB B-adv.all	prescribed VBN B-verb.communication	for IN 0	either DT 0	clozapine NN B-noun.state	or CC 0	the DT 0	other JJ B-adj.all	drug NN B-noun.person	. . 0	. . 0
DDI-MedLine.d4.s0	[ IN 0	The DT 0	effect NN B-noun.cognition	of IN 0	sandimmune NN B-noun.person	on IN 0	the DT 0	activity NN B-noun.process	of IN 0	mixed JJ B-adj.all	- : 0	function NN B-noun.act	mono NN B-noun.substance	- : 0	oxidases NNS B-noun.person	in IN 0	the DT 0	liver NN B-noun.body	microsomes NNS I-noun.body	] . 0	_ : 0	The DT 0	effects NNS B-noun.phenomenon	of IN 0	the DT 0	immunodepressant JJ B-adj.all	-- : 0	the DT 0	drug NN B-noun.group	sandimmune NN B-noun.person	-- : 0	on IN 0	hepatic JJ B-adj.all	microsomal JJ B-adj.all	monooxygenase NN B-noun.person	activities NNS B-noun.person	were VBD 0	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d5.s12	Drugs NNS B-noun.person	Metabolized VBN I-noun.person	by IN 0	Cytochrome NNP B-noun.person	P450IID6 NNP I-noun.person	( ( I-noun.person	CYP2D6 NNP I-noun.person	) ) 0	, , 0	Many JJ 0	drugs NNS B-noun.person	, , 0	including VBG B-verb.change	most JJS 0	antidepressants NNS B-noun.person	( ( 0	SSRIs NNP 0	, , 0	many JJ 0	tricyclics NNS B-noun.act	) ) 0	, , 0	beta JJ 0	- : 0	blockers NNS B-noun.person	, , 0	antiarrhythmics NNS B-noun.person	, , 0	and CC 0	antipsychotics NNS B-noun.person	are VBP 0	metabolized VBN B-verb.cognition	by IN 0	the DT 0	CYP2D6 JJ B-adj.all	isoenzyme NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d438.s7	Phenytoin NN B-noun.person	, , 0	In IN 0	a DT 0	single JJ B-adj.all	( ( 0	400 CD 0	mg NN B-noun.quantity	) ) 0	and CC 0	multiple JJ B-adj.all	dose NN B-noun.quantity	( ( 0	400 CD 0	mg IN 0	TID NNP 0	) ) 0	study NN B-noun.quantity	of IN 0	Neurontin NNP B-noun.person	in IN 0	epileptic JJ B-adj.all	patients NNS B-noun.person	( ( 0	N=8 NNP 0	) ) 0	maintained VBN B-verb.stative	on IN 0	phenytoin NN B-noun.person	monotherapy NN B-noun.person	for IN 0	at IN 0	least JJS 0	2 CD B-adj.all	months NNS B-noun.person	, , 0	gabapentin NN B-noun.communication	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	trough NN B-noun.act	plasma NN I-noun.act	concentrations NNS B-noun.cognition	of IN 0	phenytoin NN B-noun.food	and CC 0	phenytoin NN B-noun.person	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	gabapentin NN B-adj.all	pharmacokinetics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d269.s4	Clonidine NN B-noun.person	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	clonidine NN B-noun.person	with IN 0	agents_with_b SYM 0	- : 0	blocking_properties NNS B-noun.group	may MD 0	potentiate VB B-verb.stative	blood NN B-noun.act	- : 0	pressure- JJ B-noun.person	and CC 0	heart NN B-noun.body	- : 0	rate NN B-noun.time	- : 0	lowering VBG B-verb.communication	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-MedLine.d56.s5	When WRB 0	ouabain NN B-noun.person	was VBD 0	applied VBN B-verb.consumption	to TO 0	the DT 0	muscle NN B-noun.body	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	phentolamine NN B-noun.person	, , 0	both DT 0	first JJ B-noun.person	and CC 0	second JJ B-adj.all	contractile JJ B-adj.all	responses NNS B-noun.act	to TO 0	PTX NNP 0	were VBD 0	abolished VBN B-verb.contact	. . 0	. . 0
DDI-DrugBank.d73.s4	If IN 0	the DT 0	two CD 0	drugs NNS B-noun.artifact	are VBP 0	coadministered VBN B-verb.communication	, , 0	the DT 0	beta_blocker JJR B-noun.other	should MD 0	be VB 0	withdrawn VBN B-verb.contact	several JJ B-adj.all	days NNS B-noun.phenomenon	before IN 0	the DT 0	gradual JJ B-adj.all	withdrawal NN B-noun.act	of IN 0	clonidine NN B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d96.s0	Dimenhydrinate NNP B-noun.person	may MD 0	decrease VB B-verb.change	emetic JJ B-adj.all	response NN B-noun.communication	to TO 0	apomorphine VB B-verb.social	. . 0	. . 0
DDI-DrugBank.d463.s3	In IN 0	a DT 0	study NN B-noun.artifact	in IN 0	normal JJ B-adj.all	volunteers NNS B-noun.person	, , 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	buspirone_HCl NNP B-noun.person	and CC 0	haloperidol NN B-noun.person	resulted VBD B-verb.social	in IN 0	increased VBN B-verb.change	serum NN B-noun.body	haloperidol NN B-noun.body	concentrations NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d320.s7	Dosage NN 0	adjustment NN 0	may MD 0	be VB 0	warranted VBN B-verb.consumption	when WRB 0	levobupivacaine NN B-noun.state	is VBZ B-verb.stative	concurrently RB B-adv.all	administered VBN B-verb.possession	with IN 0	CYP3A4 JJ B-adj.all	inhibitors NNS B-noun.person	and CC 0	CYP1A2 JJ B-adj.all	inhibitors NNS B-noun.person	as IN 0	systemic JJ B-adj.all	levobupivacaine NN B-noun.state	levels NNS B-noun.state	may MD 0	rise VB 0	resulting VBG B-verb.stative	in IN 0	toxicity NN 0	. . 0	. . 0
DDI-DrugBank.d312.s1	In IN 0	Study NNP B-noun.other	1 CD I-noun.other	, , 0	patients NNS B-noun.person	with IN 0	colorectal JJ B-adj.all	cancer NN B-noun.state	were VBD 0	given VBN B-verb.possession	irinotecan/5-FU RP 0	/ DT 0	leucovorin NN B-noun.substance	( ( 0	bolus FW 0	- : 0	IFL NNP B-noun.group	) ) 0	with IN 0	or CC 0	without IN 0	AVASTIN NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d78.s1	Administration NN B-noun.person	of IN 0	quinolones NNS B-noun.communication	with IN 0	antacids NNS B-noun.substance	containing VBG B-verb.stative	aluminum NN I-verb.stative	, , 0	magnesium NN B-noun.person	, , 0	or CC 0	calcium NN B-noun.artifact	, , 0	with IN 0	sucralfate NN B-noun.person	, , 0	with IN 0	metal NN B-noun.artifact	cations NNS B-noun.artifact	such JJ 0	as IN 0	iron NN B-noun.person	, , 0	or CC 0	with IN 0	multivitamins NNS B-noun.person	containing VBG B-verb.communication	iron NN B-noun.person	or CC 0	zinc NN B-noun.artifact	, , 0	or CC 0	with IN 0	formulations NNS B-noun.communication	containing VBG B-verb.stative	divalent NN B-noun.substance	and CC 0	trivalent NN B-noun.act	cations NNS B-noun.state	such JJ 0	as IN 0	VIDEX NNP B-noun.group	( ( 0	didanosine NN 0	) ) 0	chewable NN B-noun.communication	/ : 0	buffered VBN B-verb.creation	tablets NNS B-noun.artifact	or CC 0	the DT 0	pediatric JJ B-adj.pert	powder NN B-noun.state	for IN 0	oral JJ B-adj.all	solution NN B-noun.cognition	, , 0	may MD 0	substantially RB B-verb.possession	interfere VB 0	with IN 0	the DT 0	absorption NN B-noun.artifact	of IN 0	quinolones NNS B-noun.communication	, , 0	resulting VBG B-verb.stative	in IN 0	systemic JJ B-adj.all	concentrations NNS B-noun.person	considerably RB B-adv.all	lower JJR B-adj.all	than IN 0	desired VBN B-verb.emotion	. . 0	. . 0
DDI-DrugBank.d514.s2	Toxicology NNP B-noun.person	studies NNS I-noun.person	of IN 0	heroin NN B-noun.person	- : 0	related JJ B-adj.all	deaths NNS B-noun.person	reveal VB B-verb.social	frequent JJ B-adj.all	involvement NN B-noun.person	of IN 0	other JJ B-adj.all	central_nervous_system_depressants NNS B-noun.location	, , 0	including VBG B-verb.emotion	alcohol NN I-verb.emotion	, , 0	benzodiazepines NNS 0	such JJ 0	as IN 0	diazepam NN B-noun.person	( ( 0	Valium NNP B-noun.location	) ) 0	, , 0	and CC 0	, , 0	to TO 0	a DT 0	rising VBG B-adj.all	degree NN B-noun.communication	, , 0	methadone NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d249.s14	Diuretics NNS B-noun.person	, , 0	Diclofenac NNP B-noun.person	and CC 0	other JJ B-adj.all	NSAIDs NNPS B-noun.person	can MD 0	inhibit VB B-verb.change	the DT 0	activity NN B-noun.process	of IN 0	diuretics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d17.s26	Therefore RB 0	, , 0	when WRB 0	hydroflumethiazide NN 0	and CC 0	nonsteroidal_anti JJ B-noun.person	- : 0	inflammatory_agents NNS B-noun.person	are VBP 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	, , 0	the DT 0	patient NN B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	closely RB B-adv.all	to TO 0	determine VB B-verb.communication	if IN 0	the DT 0	desired VBN B-verb.emotion	effect NN 0	of IN 0	the DT 0	diuretic NN B-noun.person	is VBZ 0	obtained VBN B-verb.possession	. . 0	) ) 0	. . 0
DDI-DrugBank.d395.s18	The DT 0	oral JJ B-adj.all	bioavailability NN B-noun.cognition	of IN 0	enoxacin NN B-noun.person	is VBZ 0	reduced VBN B-verb.change	by IN 0	60 CD B-adj.all	% NN 0	with IN 0	coadministration NN B-noun.person	of IN 0	ranitidine NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d238.s21	Concomitant JJ B-adj.all	use NN 0	of IN 0	agents NNS B-noun.person	in IN 0	the DT 0	tricyclic_antidepressant_class NNP B-noun.group	( ( 0	which WDT 0	includes VBZ B-verb.stative	Anafranil NNP 0	) ) 0	with IN 0	drugs NNS B-noun.artifact	that WDT 0	can MD 0	inhibit VB B-verb.possession	cytochrome JJ B-noun.person	P450 NN I-noun.person	2D6 WDT 0	may MD 0	require VB B-verb.stative	lower JJR B-adj.all	doses NNS B-noun.person	than IN 0	usually RB B-adv.all	prescribed VBN B-verb.communication	for IN 0	either CC 0	the DT 0	tricyclic_antidepressant_agent CD B-noun.other	or CC 0	the DT 0	other JJ B-adj.all	drug NN B-noun.person	. . 0	. . 0
DDI-MedLine.d12.s7	These DT 0	results NNS B-noun.communication	suggest VBP B-verb.communication	that IN 0	both DT 0	dexamethasone NN B-noun.person	and CC 0	retinyl_acetate NNP B-noun.person	, , 0	and CC 0	possibly RB B-adj.all	other JJ 0	glucocorticoids NNS B-noun.person	and CC 0	retinoids NNS B-noun.person	, , 0	may MD 0	regulate VB B-verb.communication	the DT 0	proliferation NN B-noun.act	of IN 0	prostate NN B-noun.person	epithelium NN B-noun.person	by IN 0	a DT 0	dose NN B-noun.person	- : 0	dependent JJ B-adj.all	modification NN B-noun.person	of IN 0	the DT 0	activity NN B-noun.process	of IN 0	insulin NN B-noun.food	and CC 0	EGF NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d205.s0	Since IN 0	Zarontin NNP B-noun.person	( ( 0	ethosuximide NN 0	) ) 0	may MD 0	interact VB B-verb.change	with IN 0	concurrently RB B-adv.all	administered VBN B-verb.emotion	antiepileptic_drugs NNS I-verb.emotion	, , 0	periodic JJ B-adj.all	serum NN B-noun.body	level NN B-noun.attribute	determinations NNS B-noun.process	of IN 0	these DT 0	drugs NNS B-noun.artifact	may MD 0	be VB B-verb.stative	necessary JJ B-adj.all	( ( 0	eg UH 0	, , 0	ethosuximide NN 0	may MD 0	elevate VB B-verb.emotion	phenytoin NN I-verb.emotion	serum NN B-noun.body	levels NNS B-noun.attribute	and CC 0	valproic_acid NNP B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	both DT 0	increase NN B-noun.event	and CC 0	decrease VB B-verb.change	ethosuximide JJ B-adj.all	levels NNS B-noun.attribute	) ) 0	. . 0	. . 0
DDI-DrugBank.d429.s6	Cyclosporin NNP B-noun.person	, , 0	After IN 0	introduction NN B-noun.act	of IN 0	chloroquine NN B-noun.phenomenon	( ( 0	oral JJ B-adj.all	form NN B-noun.body	) ) 0	, , 0	a DT 0	sudden JJ B-adj.all	increase NN B-noun.event	in IN 0	serum NN 0	cyclosporin NN 0	level NN B-noun.attribute	has VBZ 0	been VBN 0	reported VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d425.s6	It PRP 0	is VBZ B-verb.stative	important JJ B-adj.all	for IN 0	older JJR B-adj.all	adults NNS B-noun.animal	to TO 0	be VB B-verb.stative	aware JJ B-adj.all	of IN 0	the DT 0	relationship NN B-noun.state	between IN 0	folic_acid JJ B-noun.shape	and CC 0	vitamin_B12 NNP B-noun.person	because IN 0	they PRP 0	are VBP B-verb.stative	at IN 0	greater JJR B-adj.all	risk NN B-noun.person	of IN 0	having VBG B-verb.social	a DT 0	vitamin NN 0	B12 JJ 0	deficiency NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d526.s14	Rarely RB B-adv.all	salicylate JJ B-adj.all	toxicity NN B-noun.location	may MD 0	occur VB B-verb.stative	in IN 0	patients NNS B-noun.person	who WP 0	discontinue VBP B-verb.cognition	steroids NNS B-noun.communication	after IN 0	concurrent JJ B-adj.pert	high JJ B-noun.group	- : 0	dose NN 0	aspirin NN 0	therapy NN 0	. . 0	. . 0
DDI-DrugBank.d219.s21	Phenytoin NN B-noun.person	, , 0	Etodolac NNP B-noun.person	has VBZ B-verb.possession	no DT 0	apparent JJ B-adj.all	pharmacokinetic JJ B-adj.all	interaction NN B-noun.event	when WRB 0	administered VBN B-verb.possession	with IN 0	phenytoin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d558.s27	Other JJ 0	Drug NNP B-noun.group	Interaction NNP I-noun.group	Information NNP I-noun.group	Digoxin NNP I-noun.group	, , 0	Studies NNPS B-noun.person	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	have VBP 0	shown VBN B-verb.cognition	that IN 0	TIKOSYN NNP B-noun.group	does VBZ 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	digoxin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d107.s9	This DT 0	interaction NN B-noun.act	should MD 0	be VB 0	given VBN B-verb.possession	consideration NN B-noun.attribute	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	NSAIDs NNP B-noun.person	concomitantly RB B-adv.all	with IN 0	ACE_inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d547.s2	Lithium NNP B-noun.person	Reversible NNP I-noun.person	increases NNS B-noun.event	in IN 0	serum NN B-adj.all	lithium NN B-noun.artifact	concentrations NNS B-noun.artifact	and CC 0	toxicity NN B-noun.attribute	have VBP 0	been VBN 0	reported VBN B-verb.communication	during IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	lithium NN B-noun.substance	with IN 0	ACE_inhibitors NNS B-noun.person	, , 0	and CC 0	with IN 0	some DT 0	angiotensin_II_receptor_antagonists NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d356.s0	When WRB 0	amiloride IN 0	HCl NNP B-noun.person	is VBZ 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	an DT 0	angiotensin NN B-noun.person	- : 0	converting_enzyme_inhibitor NN B-noun.other	, , 0	the DT 0	risk NN 0	of IN 0	hyperkalemia NN B-noun.animal	may MD 0	be VB 0	increased VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d501.s9	Antibiotics NNS B-noun.person	, , 0	No DT 0	human JJ B-adj.all	drug NN B-noun.artifact	interaction NN B-noun.act	studies NNS B-noun.artifact	with IN 0	antibiotics NNS B-noun.person	were VBD 0	conducted VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d133.s4	Although IN 0	verapamil RB B-adv.all	administered VBN B-verb.possession	at IN 0	either DT 0	dose NN B-noun.person	had VBD 0	little JJ 0	or CC 0	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	enhancement NN B-noun.person	of IN 0	intestinal JJ B-adj.all	carcinogenesis NN B-noun.cognition	by IN 0	bombesin NN B-noun.substance	or CC 0	on IN 0	the DT 0	location NN B-noun.location	, , 0	histologic JJ B-adj.all	type NN B-noun.person	, , 0	depth NN B-noun.attribute	of IN 0	involvement NN B-noun.person	, , 0	labeling VBG B-verb.communication	index NN B-noun.communication	, , 0	apoptotic JJ B-adj.all	index NN B-noun.communication	or CC 0	tumor VB B-verb.motion	vascularity NN B-noun.attribute	of IN 0	intestinal JJ B-adj.all	cancers NNS B-noun.person	, , 0	it PRP 0	significantly RB B-adv.all	decreased VBD B-verb.change	the DT 0	incidence NN B-noun.event	of IN 0	cancer NN B-noun.state	metastasis NN I-noun.state	. . 0	. . 0
DDI-DrugBank.d124.s18	Garlic NNP B-noun.person	Capsules NNP I-noun.person	Garlic NNP I-noun.person	capsules NNS I-noun.person	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	while IN 0	taking VBG 0	saquinavir NN B-noun.person	( ( 0	FORTOVASE NNP 0	) ) 0	as IN 0	the DT 0	sole JJ B-adj.all	protease_inhibitor NN 0	due JJ 0	to TO 0	the DT 0	risk NN 0	of IN 0	decreased VBN B-verb.communication	saquinavir NN B-noun.person	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d485.s36	Rifampin NNP B-noun.person	, , 0	Rifampin NNP B-noun.person	increases VBZ B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	ethinyl_estradiol NN B-noun.food	and CC 0	some DT 0	progestins NNS B-noun.person	( ( 0	norethindrone NN 0	) ) 0	resulting VBG B-verb.stative	in IN 0	decreased VBN B-verb.change	contraceptive JJ B-adj.all	effectiveness NN B-noun.cognition	and CC 0	increased VBD B-verb.change	menstrual JJ B-noun.body	irregularities NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d434.s36	Effects NNS B-noun.phenomenon	of IN 0	Erythromycin NNP B-noun.person	on IN 0	Felbatol NNP B-noun.person	_ : 0	The DT 0	coadministration NN B-noun.person	of IN 0	erythromycin NN B-noun.substance	( ( 0	1000 CD 0	mg RB B-noun.quantity	/ JJ 0	day NN 0	) ) 0	for IN 0	10 CD B-adj.all	days NNS B-noun.person	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	pharmacokinetic JJ B-adj.all	parameters NNS B-noun.event	of IN 0	Cmax NNP B-noun.person	, , 0	Cmin NNP B-noun.person	, , 0	AUC NNP 0	, , 0	CI NNP 0	/ , 0	kg PRP 0	or CC 0	tmax NN B-noun.substance	at IN 0	felbamate JJ B-adj.all	daily JJ B-adj.pert	doses NNS B-noun.event	of IN 0	3000 CD 0	or CC 0	3600 CD 0	mg RB 0	/ JJ 0	day NN 0	in IN 0	10 CD B-adj.all	otherwise RB B-adv.all	healthy JJ B-adj.all	subjects NNS B-noun.person	with IN 0	epilepsy NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d179.s32	- : 0	Sulfoxone NN 0	( ( 0	e.g. UH 0	, , 0	Diasone NNP B-noun.person	) ) 0	or CC 0	. . 0
DDI-DrugBank.d196.s39	Clinical JJ B-adj.all	studies NNS B-noun.communication	of IN 0	PEGASYS NNP B-noun.group	alone RB 0	or CC 0	in IN 0	combination NN 0	with IN 0	COPEGUS NNP B-noun.group	did VBD 0	not RB B-adv.all	include VB B-verb.change	sufficient JJ B-adj.all	numbers NNS B-noun.attribute	of IN 0	subjects NNS B-noun.person	aged VBN B-verb.consumption	65 CD 0	or CC 0	over IN 0	to TO 0	determine VB B-verb.communication	whether IN 0	they PRP 0	respond VBP B-verb.cognition	differently RB B-adv.all	from IN 0	younger JJR B-adj.all	subjects NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d31.s5	Propranolol NNP B-noun.person	increases VBZ B-verb.change	hydralazines NNS B-noun.animal	serum VBP B-verb.stative	concentrations NNS I-verb.stative	. . 0	. . 0
DDI-DrugBank.d353.s0	Ethanol NNP B-noun.person	, , 0	Clinical JJ B-adj.all	evidence NN B-noun.attribute	has VBZ 0	shown VBN B-verb.cognition	that DT 0	etretinate NN B-noun.person	can MD 0	be VB 0	formed VBN B-verb.social	with IN 0	concurrent JJ B-adj.all	ingestion NN B-noun.act	of IN 0	acitretin NN B-noun.person	and CC 0	ethanol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d82.s22	Therefore RB 0	, , 0	when WRB 0	INDOCIN NNP B-noun.group	and CC 0	digoxin NN B-noun.person	are VBP 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	, , 0	serum NN B-noun.body	digoxin NN I-noun.body	levels NNS B-noun.attribute	should MD 0	be VB B-verb.stative	closely RB B-adj.all	monitored VBN I-adj.all	. . 0	. . 0
DDI-DrugBank.d87.s1	TAMBOCOR NNP B-noun.group	has VBZ 0	been VBN 0	administered VBN B-verb.perception	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.communication	digitalis_preparations NNS B-noun.person	or CC 0	beta JJ B-noun.body	- : 0	adrenergic_blocking_agents NNS B-noun.person	without IN 0	adverse JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d14.s2	Marked VBN B-verb.cognition	symptomatic JJ B-adj.all	orthostatic JJ B-adj.all	hypotension NN B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	when WRB 0	calcium_channel_blockers NNS B-noun.person	and CC 0	organic JJ B-adj.all	nitrates NNS B-noun.person	were VBD 0	used VBN B-verb.consumption	in IN 0	combination NN 0	. . 0	. . 0
DDI-DrugBank.d437.s15	For IN 0	comprehensive JJ B-adj.all	information NN B-noun.cognition	concerning VBG B-verb.stative	laboratory NN B-noun.possession	test NN B-adj.all	alterations NNS B-noun.cognition	associated VBN B-verb.cognition	with IN 0	ritonavir NN B-noun.person	, , 0	physicians NNS B-noun.person	should MD 0	refer VB B-verb.cognition	to TO 0	the DT 0	complete JJ B-adj.all	prescribing VBG B-verb.communication	information NN B-noun.cognition	for IN 0	NORVIR NNP B-noun.person	( ( 0	ritonavir NN B-noun.person	) ) 0	. . 0	. . 0
DDI-DrugBank.d316.s13	Digoxin NN B-noun.person	_ '' 0	When WRB 0	given VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	PLENDIL NNP B-noun.group	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	digoxin NN B-noun.food	in IN 0	patients NNS B-noun.person	with IN 0	heart NN B-noun.body	failure NN B-noun.person	were VBD B-verb.stative	not RB B-adv.all	significantly RB B-adv.all	altered VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d143.s0	Amiodarone NNP B-noun.person	is VBZ 0	metabolized VBN B-verb.cognition	to TO 0	desethylamiodarone NN 0	by IN 0	the DT 0	cytochrome NN 0	P450 NN 0	( ( 0	CYP450 NNP 0	) ) 0	enzyme NN B-noun.location	group NN B-noun.person	, , 0	specifically RB B-adv.all	cytochromes VBZ B-verb.change	P450 JJ 0	3A4 NN 0	( ( 0	CYP3A4 NNP 0	) ) 0	and CC 0	CYP2C8 NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d15.s4	In IN 0	an DT 0	in IN 0	vitro NN B-noun.artifact	study NN B-noun.artifact	in IN 0	human JJ B-adj.all	liver NN B-noun.body	microsomes NNS I-noun.body	, , 0	inhibition NN 0	of IN 0	CYP2A6 JJ B-noun.phenomenon	hydroxylation NN I-noun.phenomenon	of IN 0	coumarin NN B-noun.food	by IN 0	fondaparinux NN B-noun.person	( ( 0	200 CD 0	m NN B-noun.quantity	m IN 0	M NNP B-noun.group	i.e. NNP I-noun.group	, , 0	350 CD 0	mg NN B-noun.quantity	/ '' 0	L NNP 0	) ) 0	was VBD B-verb.stative	17 CD B-adj.all	- : 0	28 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d386.s14	Concomitant JJ B-adj.all	use NN 0	of IN 0	tricyclic_antidepressants NNS B-noun.plant	with IN 0	drugs NNS B-noun.artifact	that WDT 0	can MD 0	inhibit VB B-verb.possession	cytochrome JJ B-noun.person	P450 NN I-noun.person	2D6 WDT 0	may MD 0	require VB B-verb.stative	lower JJR B-adj.all	doses NNS B-noun.person	than IN 0	usually RB B-adv.all	prescribed VBN B-verb.communication	for IN 0	either CC 0	the DT 0	tricyclic_antidepressant JJ B-adj.all	or CC 0	the DT 0	other JJ B-adj.all	drug NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d253.s2	Antiarrhythmic_agents,_class_I JJ 0	( ( 0	such JJ 0	as IN 0	flecainide NN 0	, , 0	lidocaine NN B-noun.person	, , 0	or CC 0	quinidine VB B-verb.social	) ) 0	, , 0	concurrent JJ B-adj.all	use NN 0	with IN 0	arbutamine NN B-noun.person	may MD 0	have VB B-verb.stative	a DT 0	proarrhythmic JJ B-adj.all	effect NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d179.s30	- : 0	Quinidine NN B-noun.location	( ( 0	e.g. UH 0	, , 0	Quinidex NNP B-noun.location	) ) 0	or CC 0	. . 0
DDI-DrugBank.d461.s0	Additive JJ B-adj.all	depressant NN B-noun.person	effect NN 0	when WRB 0	used VBN B-verb.consumption	with IN 0	general JJ B-adj.all	anesthetics NNS B-noun.person	, , 0	sedatives NNS B-noun.person	, , 0	antianxiety_drugs NNS B-noun.object	, , 0	hypnotics NNS B-noun.person	, , 0	alcohol NN B-noun.person	, , 0	and CC 0	other JJ B-adj.all	opiate_analgesics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d419.s0	The DT 0	concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	allopurinol NN B-noun.animal	and CC 0	ampicillin JJ B-adj.all	increases NNS B-noun.event	substantially RB B-adv.all	the DT 0	incidence NN B-noun.event	of IN 0	rashes NNS B-noun.food	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	both DT 0	drugs NNS B-noun.artifact	as IN 0	compared VBN 0	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.perception	ampicillin NN I-verb.perception	alone RB 0	. . 0	. . 0
DDI-DrugBank.d48.s2	In IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	treatment NN I-verb.communication	with IN 0	SPRYCEL NNP B-noun.group	, , 0	close JJ B-adj.all	monitoring NN B-verb.perception	for IN 0	toxicity NN B-noun.attribute	and CC 0	a DT 0	SPRYCEL NNP B-noun.artifact	dose NN I-noun.artifact	reduction NN B-noun.process	should MD 0	be VB 0	considered VBN B-verb.cognition	if IN 0	systemic JJ B-adj.all	administration NN B-noun.time	of IN 0	a DT 0	potent JJ B-noun.person	CYP3A4 NNP I-noun.person	inhibitor NN I-noun.person	can MD 0	not RB B-adv.all	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d269.s8	In IN 0	about IN 0	30 CD B-adj.all	% NN 0	of IN 0	patients NNS B-noun.person	, , 0	the DT 0	dose NN B-noun.quantity	of IN 0	cyclosporine NN B-noun.person	had VBD 0	to TO 0	be VB 0	reduced VBN B-verb.change	in IN 0	order NN 0	to TO 0	maintain VB B-verb.possession	cyclosporine JJ B-adj.all	concentrations NNS B-noun.phenomenon	within IN 0	the DT 0	therapeutic JJ B-adj.pert	range NN B-noun.state	, , 0	while IN 0	in IN 0	the DT 0	remainder NN B-noun.person	no DT 0	adjustment NN B-noun.person	was VBD 0	needed VBN B-verb.consumption	. . 0	. . 0
DDI-DrugBank.d415.s2	Aspirin NNP B-noun.person	, , 0	Animal NNP B-noun.person	studies NNS I-noun.person	wshow VBP B-verb.cognition	that DT 0	aspirin NN B-noun.person	given VBN B-verb.possession	with IN 0	nonsteroidal_anti JJ B-noun.group	- : I-noun.group	inflammatory_agents NNS I-noun.group	, , 0	including VBG B-verb.social	ibuprofen NN B-noun.person	, , 0	yields VBZ B-verb.possession	a DT 0	net JJ B-adj.all	decrease NN B-noun.state	in IN 0	anti NNS B-noun.person	- : 0	inflammatory JJ B-adj.all	activity NN B-noun.process	with IN 0	lowered VBN B-verb.motion	blood NN B-noun.location	levels NNS B-noun.state	of IN 0	the DT 0	non NN B-noun.person	- : 0	aspirin NN B-noun.artifact	drug NN I-noun.artifact	. . 0	. . 0
DDI-DrugBank.d289.s6	Hormonal_Contraceptives NNS B-noun.artifact	, , 0	Including NNP B-noun.person	Oral NNP I-noun.person	, , 0	Injectable NNP B-noun.person	, , 0	Transdermal NNP B-noun.person	, , 0	and CC 0	Implantable NNP B-noun.group	Contraceptives NNPS I-noun.group	, , 0	An DT 0	interaction NN B-noun.act	study NN B-noun.artifact	demonstrated VBD B-verb.communication	that IN 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	bosentan NN B-noun.food	and CC 0	the DT 0	oral JJ B-adj.all	hormonal_contraceptive NNP B-noun.other	Ortho NNP I-noun.other	- : 0	Novum NNP B-noun.person	produced VBD B-verb.creation	average JJ B-adj.all	decreases NNS B-noun.person	of IN 0	norethindrone NN B-noun.person	and CC 0	ethinyl_estradiol JJ B-adj.all	levels NNS B-noun.attribute	of IN 0	14 CD B-adj.all	% NN 0	and CC 0	31 CD 0	% NN 0	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-MedLine.d45.s0	Selective JJ B-adj.all	survival NN B-noun.state	in IN 0	pentazocine NN 0	and CC 0	tripelennamine NN B-noun.act	of IN 0	Pseudomonas NNP B-noun.other	aeruginosa NN 0	serotype NN 0	O11 NN 0	from IN 0	drug NN B-noun.animal	addicts NNS B-noun.location	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d17.s12	( ( 0	Concurrent JJ 0	use NN 0	with IN 0	thiazide_diuretics NNS B-noun.group	may MD 0	enhance VB B-verb.change	the DT 0	possibility NN B-noun.state	of IN 0	digitalis NN B-noun.phenomenon	toxicity NN B-noun.attribute	associated VBN B-verb.cognition	with IN 0	hypokalemia NN B-noun.person	. . 0	) ) 0	. . 0
DDI-DrugBank.d288.s11	Hypersensitivity NNP B-noun.person	Reactions NNP I-noun.person	, , 0	Patients NNPS B-noun.person	with IN 0	a DT 0	history NN B-noun.cognition	of IN 0	severe JJ B-adj.all	hypersensitivity NN B-noun.phenomenon	reactions NNS B-noun.motive	to TO 0	products NNS B-noun.person	containing VBG B-verb.communication	Cremophor NNP B-noun.person	_ NNP I-noun.person	EL NNP I-noun.person	( ( 0	eg UH 0	, , 0	cyclosporin NN B-noun.person	for IN 0	injection NN B-noun.act	concentrate NN B-noun.person	and CC 0	teniposide NN B-noun.attribute	for IN 0	injection NN B-noun.act	concentrate NN B-noun.cognition	) ) 0	should MD 0	not RB 0	be VB 0	treated VBN B-verb.change	with IN 0	TAXOL NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d283.s12	Therefore RB 0	, , 0	fenofibrate NN B-noun.location	should MD 0	be VB 0	taken VBN B-verb.possession	at IN 0	least JJS 0	1 CD B-adj.all	hour NN 0	before IN 0	or CC 0	4 CD B-adj.all	- : 0	6 CD B-adj.all	hours NNS B-noun.time	after IN 0	a DT 0	bile_acid_binding_resin NN B-noun.communication	to TO 0	avoid VB B-verb.social	impeding VBG B-verb.change	its PRP$ 0	absorption NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d279.s8	The DT 0	incidence NN B-noun.relation	of IN 0	akathisia NN B-noun.food	in IN 0	clinical JJ B-adj.all	trials NNS B-noun.cognition	of IN 0	the DT 0	weekly JJ B-adj.all	dosage NN B-noun.communication	schedule NN B-noun.person	was VBD B-verb.stative	greater JJR B-adj.all	( ( 0	8.5 CD 0	% NN 0	, , 0	4/47 CD 0	patients NNS B-noun.location	) ) 0	when WRB 0	prochlorperazine NN B-noun.person	was VBD 0	administered VBN B-verb.possession	on IN 0	the DT 0	same JJ B-adj.all	day NN B-noun.person	as IN 0	CAMPTOSAR NNP 0	than IN 0	when WRB 0	these DT 0	drugs NNS B-noun.artifact	were VBD 0	given VBN B-verb.possession	on IN 0	separate JJ B-adj.all	days NNS B-noun.phenomenon	( ( 0	1.3 CD 0	% NN 0	, , 0	1/80 CD 0	patients NNS B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d350.s4	CANCIDAS NNP B-noun.group	has VBZ B-verb.possession	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	itraconazole NN B-noun.shape	, , 0	amphotericin_B JJ 0	, , 0	or CC 0	the DT 0	active JJ B-adj.all	metabolite NN B-noun.attribute	of IN 0	mycophenolate NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d97.s22	HMG SYM 0	- : 0	CoA_Reductase_inhibitors NNS B-noun.person	, , 0	lovastatin NN B-noun.person	, , 0	simvastatin NN B-noun.person	. . 0
DDI-DrugBank.d180.s3	Although IN 0	there EX 0	is VBZ B-verb.stative	little JJ 0	published VBN B-verb.creation	information NN B-noun.cognition	on IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	lidocaine NN B-noun.person	and CC 0	Bretylium_Tosylate NNP B-noun.person	, , 0	these DT 0	drugs NNS B-noun.artifact	are VBP 0	often RB B-adv.all	administered VBN B-verb.perception	concurrently RB B-adv.all	without IN 0	any DT 0	evidence NN B-noun.attribute	of IN 0	interactions NNS B-noun.possession	resulting VBG B-verb.stative	in IN 0	adverse JJ B-adj.all	effects NNS B-noun.phenomenon	or CC 0	diminished JJ B-adj.all	efficacy NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d194.s1	High NNP B-noun.group	- : 0	dose RB 0	cyclosporin_A JJ 0	resulting VBG B-verb.stative	in IN 0	concentrations NNS B-noun.substance	above IN 0	2000 CD 0	ng NN B-noun.quantity	/ : 0	mL CC 0	administered VBN B-verb.possession	with IN 0	oral JJ B-adj.all	etoposide NN 0	has VBZ 0	led VBN B-verb.stative	to TO 0	an DT 0	80 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	etoposide JJ B-adj.all	exposure NN B-noun.person	with IN 0	a DT 0	38 CD 0	% NN 0	decrease NN B-noun.act	in IN 0	total JJ B-adj.all	body NN 0	clearance NN B-noun.attribute	of IN 0	etoposide NN 0	compared VBN B-verb.cognition	to TO 0	etoposide VB B-verb.stative	alone RB I-verb.stative	. . 0	. . 0
DDI-MedLine.d12.s6	However RB 0	, , 0	retinyl_acetate NNP B-noun.person	stimulated VBD B-verb.communication	, , 0	but CC 0	did VBD 0	not RB B-adv.all	significantly RB B-adv.all	inhibit VB B-verb.change	, , 0	proliferation NN B-noun.person	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	insulin NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d410.s9	There EX 0	have VBP 0	been VBN B-verb.stative	no DT 0	reported VBN B-verb.communication	cases NNS B-noun.person	from IN 0	spontaneous JJ B-adj.all	reports NNS B-noun.communication	of IN 0	drug NN B-noun.artifact	interaction NN B-noun.act	between IN 0	SSRIs NNP B-noun.location	and CC 0	D.H.E._45 NNP B-noun.person	_ . 0	( ( 0	dihydroergotamine_mesylate JJ 0	) ) 0	Injection NN B-noun.location	, , 0	USP NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d535.s1	Antiretroviral_Agents NNS B-noun.artifact	, , 0	No DT 0	drug NN B-noun.act	interactions NNS I-noun.act	with IN 0	other JJ B-adj.all	antiretroviral_medications NNS B-noun.artifact	have VBP 0	been VBN 0	identified VBN B-verb.cognition	that WDT 0	would MD 0	warrant VB B-verb.communication	alteration NN B-noun.act	of IN 0	either CC 0	the DT 0	enfuvirtide NN B-noun.location	dose NN B-noun.state	or CC 0	the DT 0	dose NN B-noun.quantity	of IN 0	the DT 0	other JJ B-adj.all	antiretroviral_medication NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d438.s39	It PRP 0	is VBZ 0	recommended VBN B-verb.communication	that IN 0	gabapentin NN 0	be VB 0	taken VBN B-verb.possession	at IN 0	least JJS 0	2 CD B-adj.all	hours NNS B-noun.artifact	following VBG 0	Maalox NNP B-noun.person	administration NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d483.s4	As IN 0	with IN 0	other JJ 0	cephalosporins NNS B-noun.person	, , 0	high JJ B-adj.all	concentrations NNS B-noun.attribute	of IN 0	cefotetan NN B-noun.animal	may MD 0	interfere VB B-verb.stative	with IN 0	measurement NN B-noun.attribute	of IN 0	serum NN B-noun.person	and CC 0	urine NN 0	creatinine NN 0	levels NNS B-noun.attribute	by IN 0	Jaffe NNP B-noun.person	_ POS 0	reaction NN B-noun.cognition	and CC 0	produce VB B-verb.cognition	false JJ B-adj.all	increases NNS B-noun.event	in IN 0	the DT 0	levels NNS B-noun.state	of IN 0	creatinine NN B-noun.person	reported VBD B-verb.communication	. . 0	. . 0
DDI-DrugBank.d172.s17	This DT 0	increase NN B-noun.event	is VBZ B-verb.stative	due JJ 0	to TO 0	the DT 0	inhibition NN B-noun.attribute	of IN 0	celecoxib JJ B-adj.all	metabolism NN B-noun.attribute	via IN 0	P450 NN 0	2C9 CD 0	by IN 0	fluconazole NN B-noun.substance	( ( 0	see VB 0	CLINICAL NNP B-noun.group	PHARMACOLOGY NNP I-noun.group	; : 0	Pharmacokinetics NNS B-noun.person	, , 0	Metabolism NNP B-noun.location	) ) 0	. . 0	. . 0
DDI-MedLine.d40.s0	Studies NNS B-noun.person	on IN 0	the DT 0	mechanism NN B-noun.attribute	of IN 0	action NN B-noun.process	of IN 0	miconazole NN B-noun.shape	, , 0	effect NN B-noun.cognition	of IN 0	miconazole NN B-noun.animal	on IN 0	respiration NN B-noun.act	and CC 0	cell NN B-noun.body	permeability NN 0	of IN 0	Candida NNP B-noun.person	albicans NNS B-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d3.s5	In IN 0	a DT 0	study NN B-noun.artifact	involving VBG B-verb.stative	12 CD B-adj.all	adult NN B-noun.act	volunteers NNS B-noun.artifact	, , 0	TORADOLORAL NNP B-noun.person	was VBD 0	coadministered VBN B-verb.contact	with IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	25 CD B-adj.all	mg NN B-noun.quantity	warfarin NN B-noun.act	, , 0	causing VBG B-verb.communication	no DT 0	significant JJ B-adj.all	changes NNS B-noun.relation	in IN 0	pharmacokinetics NNS B-noun.time	or CC 0	pharmacodynamics NNS B-noun.person	of IN 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d57.s1	Even RB B-adv.all	when WRB 0	an DT 0	aminoglycoside NN B-noun.artifact	and CC 0	a DT 0	penicillin NN B-noun.person	- : 0	type JJ B-noun.person	drug NN I-noun.person	are VBP 0	administered VBN B-verb.body	separately RB B-adv.all	by IN 0	different JJ B-adj.all	routes NNS B-noun.artifact	, , 0	a DT 0	reduction NN B-noun.act	in IN 0	aminoglycoside JJ B-adj.all	serum NN B-noun.person	half NN B-noun.person	- : 0	life NN B-noun.time	or CC 0	serum NN B-noun.body	levels NNS B-noun.attribute	has VBZ 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.person	with IN 0	impaired VBN B-verb.change	renal JJ B-adj.all	function NN B-noun.act	and CC 0	in IN 0	some DT 0	patients NNS B-noun.person	with IN 0	normal JJ B-adj.all	renal JJ B-noun.phenomenon	function NN I-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d257.s4	Most JJS 0	cases NNS B-noun.event	of IN 0	serious JJ B-adj.all	or CC 0	fatal JJ B-adj.all	adverse JJ 0	events NNS 0	involving VBG B-verb.stative	Levo NNP B-noun.person	- : 0	Dromoran NN B-noun.person	reported VBD B-verb.communication	to TO 0	the DT 0	manufacturer NN B-noun.person	or CC 0	the DT 0	FDA NNP B-noun.group	have VBP 0	involved VBN B-verb.stative	either CC 0	the DT 0	administration NN B-noun.time	of IN 0	large JJ B-adj.all	initial JJ B-adj.all	doses NNS B-noun.possession	or CC 0	too RB B-adj.all	frequent JJ B-adj.all	doses NNS B-noun.act	of IN 0	the DT 0	drug NN B-noun.person	to TO 0	nonopioid JJ B-adj.all	tolerant NN B-noun.person	patients NNS B-noun.person	, , 0	or CC 0	the DT 0	simultaneous JJ B-adj.all	administration NN B-noun.act	of IN 0	levorphanol NN B-noun.state	with IN 0	other JJ 0	drugs NNS B-noun.artifact	affecting VBG B-verb.change	respiration NN B-noun.act	. . 0	. . 0
DDI-MedLine.d88.s4	The DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	either DT 0	cocaine NN B-noun.location	or CC 0	amphetamine NN B-noun.artifact	, , 0	compounds NNS B-noun.person	which WDT 0	inhibit VBP B-verb.stative	neuronal JJ B-adj.all	reuptake NN B-noun.act	of IN 0	norepinephrine NN B-noun.person	, , 0	disrupts VBZ B-verb.change	the DT 0	behavioral JJ B-adj.all	response NN B-noun.communication	of IN 0	the DT 0	genetically RB B-adv.all	nervous JJ B-adj.all	E NNP 0	- : 0	strain JJ B-adj.all	subjects NNS B-noun.person	to TO 0	a DT 0	far RB B-adv.all	greater JJR B-adj.all	extent NN B-noun.person	than IN 0	the DT 0	stable NN B-noun.group	A SYM 0	- : 0	strain JJ B-adj.all	subjects NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d99.s8	While IN 0	all PDT 0	the DT 0	selective JJ B-adj.all	serotonin_reuptake_inhibitors NNS B-noun.person	( ( 0	SSRIs NNP 0	) ) 0	, , 0	e.g. NNP B-noun.person	, , 0	fluoxetine NN B-noun.person	, , 0	sertraline NN B-noun.person	, , 0	and CC 0	paroxetine NN B-noun.person	, , 0	inhibit VBP B-verb.stative	P450 JJ 0	2D6 NN 0	, , 0	they PRP 0	may MD 0	vary VB B-verb.stative	in IN 0	the DT 0	extent NN B-noun.attribute	of IN 0	inhibition NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d20.s1	A DT 0	pharmacokinetic JJ B-adj.all	study NN B-noun.artifact	evaluating VBG B-verb.communication	the DT 0	administration NN B-noun.time	of IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	INSPRA NNP B-noun.group	100 CD 0	mg NN B-noun.quantity	with IN 0	ketoconazole NN B-noun.communication	200 CD 0	mg IN 0	BID NNP B-noun.group	, , 0	a DT 0	potent JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	the DT 0	CYP3A4 JJ B-adj.all	pathway NN B-noun.location	, , 0	showed VBD B-verb.communication	a DT 0	1.7-fold JJ B-adj.all	increase NN B-noun.event	in IN 0	Cmax NNP B-noun.location	of IN 0	eplerenone NN B-noun.person	and CC 0	a DT 0	5.4-fold JJ B-adj.all	increase NN B-noun.event	in IN 0	AUC NNP 0	of IN 0	eplerenone NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d448.s6	Antacids NNS B-noun.person	increase VBP B-verb.change	the DT 0	rate NN B-noun.time	of IN 0	absorption NN B-noun.process	of IN 0	pseudoephedrine NN B-noun.person	, , 0	while IN 0	kaolin NN B-noun.person	decreases VBZ B-verb.cognition	it PRP 0	. . 0	. . 0
DDI-DrugBank.d175.s12	Beta SYM 0	- : 0	adrenergic_blocking_drugs NNS B-noun.person	add VBP B-verb.communication	some DT 0	further JJ B-adj.all	antihypertensive JJ B-adj.all	effect NN B-noun.cognition	to TO 0	captopril VB B-verb.contact	, , 0	but CC 0	the DT 0	overall JJ B-adj.all	response NN B-noun.communication	is VBZ B-verb.stative	less JJR B-noun.quantity	than IN 0	additive JJ 0	. . 0	. . 0
DDI-MedLine.d104.s0	The DT 0	effects NNS B-noun.phenomenon	of IN 0	DCG NNP B-noun.group	- : 0	IV NNP 0	and CC 0	L NNP 0	- : 0	CCG-1 NN B-noun.other	upon IN 0	phencyclidine NN B-noun.person	( ( 0	PCP)-induced JJ B-adj.all	locomotion NN B-noun.artifact	and CC 0	behavioral JJ B-noun.body	changes NNS I-noun.body	in IN 0	mice NNS B-noun.animal	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d314.s24	Nonsteroidal_anti SYM 0	- : 0	inflammatory_agents NNS B-noun.person	( ( 0	NSAIDS NNP B-noun.group	) ) 0	, , 0	Concomitant JJ 0	use NN 0	of IN 0	aspirin NN B-noun.substance	( ( 0	or CC 0	other JJ B-adj.all	nonsteroidal_antiinflammatory_agents NNS B-noun.location	) ) 0	and CC 0	corticosteroids NNS B-noun.communication	increases VBZ B-verb.change	the DT 0	risk NN 0	of IN 0	gastrointestinal JJ B-adj.all	side NN B-noun.body	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d305.s1	However RB 0	, , 0	neither CC 0	phenobarbital JJ B-adj.all	nor CC 0	diazepam NN B-noun.attribute	appears VBZ B-verb.cognition	to TO 0	affect VB B-verb.change	Dantrium NNP 0	metabolism NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d216.s6	Drugs NNS B-noun.artifact	That IN 0	Inhibit NNP B-noun.person	CYP3A4 NNP I-noun.person	( ( 0	Ketoconazole NNP B-noun.person	) ) I-noun.person	CYP3A4 NNP I-noun.person	is VBZ B-verb.stative	a DT 0	major JJ B-adj.all	metabolic JJ B-adj.pert	pathway NN B-noun.location	for IN 0	elimination NN B-noun.act	of IN 0	eszopiclone NN 0	. . 0	. . 0
DDI-DrugBank.d529.s14	Diuretics NNS B-noun.person	, , 0	Studies NNPS B-noun.person	in IN 0	normal JJ B-adj.all	volunteers NNS B-noun.person	have VBP 0	shown VBN B-verb.cognition	that DT 0	flurbiprofen NN B-noun.person	like IN 0	other JJ 0	nonsteroidal_anti JJ 0	- : 0	inflammatory_drugs NNS B-noun.time	, , 0	can MD 0	interfere VB B-verb.stative	with IN 0	the DT 0	effects NNS B-noun.phenomenon	of IN 0	furosemide NN B-noun.artifact	. . 0	. . 0
DDI-MedLine.d39.s0	Effect NN 0	of IN 0	estradiol NN B-noun.act	on IN 0	endotoxin NN B-noun.person	- : 0	induced VBN B-verb.creation	changes NNS B-noun.artifact	in IN 0	steroid JJ B-adj.all	hormone NN B-noun.body	levels NNS B-noun.attribute	and CC 0	lethality NN B-noun.communication	in IN 0	male NN B-noun.animal	rats NNS I-noun.animal	. . 0	. . 0
DDI-DrugBank.d283.s16	The DT 0	atorvastatin NN B-noun.person	Cmax NNP I-noun.person	values NNS I-noun.person	were VBD B-verb.stative	not RB B-adv.all	significantly RB B-adv.all	affected VBN B-verb.change	by IN 0	fenofibrate NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d404.s4	Thiazides NNS B-noun.person	, , 0	Thiazides NNS 0	are VBP 0	known VBN B-verb.cognition	to TO 0	induce VB B-verb.cognition	hypercalcemia NN B-noun.person	by IN 0	the DT 0	reduction NN B-noun.act	of IN 0	calcium NN B-adj.all	excretion NN B-noun.act	in IN 0	urine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d219.s1	This DT 0	interaction NN B-noun.act	should MD 0	be VB 0	given VBN B-verb.possession	consideration NN B-noun.attribute	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	NSAIDs NNP B-noun.person	concomitantly RB B-adv.all	with IN 0	ACE NNP B-noun.group	- : 0	inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d210.s4	In IN 0	a DT 0	12-week JJ 0	endoscopy NN B-noun.phenomenon	study NN B-noun.artifact	conducted VBN B-verb.communication	in IN 0	OA NNP 0	patients NNS B-noun.artifact	there EX 0	was VBD B-verb.stative	no DT 0	difference NN B-noun.cognition	in IN 0	the DT 0	cumulative JJ B-adj.all	incidence NN B-noun.event	of IN 0	endoscopic JJ B-adj.all	gastroduodenal JJ B-adj.all	ulcers NNS B-noun.person	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	low JJ I-verb.social	- : 0	dose NN B-noun.quantity	( ( 0	81 CD 0	mg NN B-noun.quantity	) ) 0	enteric JJ B-adj.all	coated JJ B-adj.all	aspirin NN B-noun.person	plus IN 0	VIOXX NNP B-noun.communication	25 CD B-adj.all	mg NN B-noun.quantity	daily RB B-adv.all	, , 0	as IN 0	compared VBN 0	to TO 0	those DT 0	taking VBG 0	ibuprofen JJ 0	2400 CD 0	mg NN B-noun.quantity	daily RB 0	alone RB 0	. . 0	. . 0
DDI-DrugBank.d415.s5	Methotrexate NNP B-noun.person	, , 0	Ibuprofen NNP B-noun.person	, , 0	as RB 0	well RB 0	as IN 0	other JJ 0	nonsteroidal_anti JJ 0	- : 0	inflammatory_drugs NNS B-noun.time	, , 0	probably RB B-adv.all	reduces VBZ B-verb.change	the DT 0	tubular JJ B-adj.all	secretion NN B-noun.act	of IN 0	methotrexate NN B-noun.attribute	based VBN B-verb.cognition	on IN 0	in IN 0	vitro NN B-noun.animal	studies NNS I-noun.animal	in IN 0	rabbit NN B-noun.act	kidney NN I-noun.act	slices NNS B-noun.act	. . 0	. . 0
DDI-DrugBank.d115.s16	Systemic JJ B-adj.all	exposure NN B-noun.cognition	to TO 0	acetaminophen VB B-verb.social	is VBZ 0	expected VBN B-verb.cognition	to TO 0	be VB 0	increased VBN B-verb.change	when WRB 0	coadministered VBN B-verb.communication	with IN 0	Gleevec NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d40.s17	- : 0	Although IN 0	not RB 0	a DT 0	true JJ B-adj.all	drug NN 0	interaction NN 0	, , 0	tricyclic_antidepressants NNS B-noun.person	may MD 0	precipitate VB B-verb.cognition	seizures NNS B-noun.person	in IN 0	susceptible JJ B-adj.all	patients NNS B-noun.person	and CC 0	Cerebyx NNP B-noun.person	dosage NN I-noun.person	may MD 0	need VB 0	to TO 0	be VB 0	adjusted VBN B-verb.change	. . 0
DDI-MedLine.d67.s1	The DT 0	influence NN B-noun.cognition	of IN 0	midazolam NN B-noun.food	and CC 0	diazepam NN B-noun.person	on IN 0	antinociceptive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	morphine NN B-noun.phenomenon	( ( 0	10 CD 0	mg PRP 0	/ : 0	kg LS 0	) ) 0	, , 0	metamizol NN B-noun.person	( ( 0	500 CD 0	mg PRP 0	/ : 0	kg LS 0	) ) 0	and CC 0	indomethacin NN B-noun.person	( ( 0	10 CD 0	mg PRP 0	/ : 0	kg LS 0	) ) 0	was VBD 0	investigated VBN B-verb.communication	in IN 0	a DT 0	mouse NN B-noun.act	model NN B-noun.person	using VBG B-verb.consumption	the DT 0	tail NN B-noun.body	- : 0	flick NN B-noun.person	and CC 0	hot JJ 0	- : 0	plate NN B-noun.person	tests NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d324.s16	Multiple JJ B-noun.person	- : 0	dose JJ B-adj.all	administration NN B-noun.time	of IN 0	the DT 0	potent JJ B-noun.person	CYP3A4 NNP I-noun.person	inducer NN I-noun.person	rifampin NN B-noun.person	( ( 0	600 CD 0	mg IN 0	every DT 0	24 CD B-adj.all	hours NNS B-noun.artifact	, , 0	q24h NNP B-noun.person	, , 0	for IN 0	14 CD B-adj.all	days NNS B-noun.act	) ) 0	, , 0	however RB 0	, , 0	reduced VBN B-verb.change	zaleplon NN 0	Cmax NNP B-noun.person	and CC 0	AUC NNP B-noun.group	by IN 0	approximately RB B-noun.time	80 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d282.s0	DOSTINEX NNP B-noun.group	should MD 0	not RB 0	be VB 0	administered VBN B-verb.possession	concurrently RB B-adv.all	with IN 0	D2-antagonists NNS B-noun.person	, , 0	such JJ 0	as IN 0	phenothiazines NNS B-noun.artifact	, , 0	butyrophenones NNS 0	, , 0	thioxanthines NNS 0	, , 0	or CC 0	metoclopramide NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d358.s1	Pharmacokinetic JJ B-adj.all	studies NNS B-noun.group	have VBP 0	demonstrated VBN B-verb.cognition	that IN 0	omeprazole NN B-noun.person	and CC 0	erythromycin NN B-noun.person	significantly RB B-adv.all	increased VBD B-verb.change	the DT 0	systemic JJ B-adj.all	exposure NN B-noun.cognition	of IN 0	cilostazol NN B-noun.act	and/or CC 0	its PRP$ 0	major JJ B-adj.all	metabolites NNS B-noun.object	. . 0	. . 0
DDI-DrugBank.d365.s0	Medroxyprogesterone_Acetate JJ B-adj.all	; : 0	L SYM 0	- : 0	histidine NN B-noun.person	was VBD 0	observed VBN B-verb.perception	to TO 0	enhance VB B-verb.social	( ( 0	in IN 0	tissue NN B-adj.all	culture NN B-noun.cognition	) ) 0	the DT 0	effect NN B-noun.cognition	of IN 0	medroxyprogesterone_acetate NNP B-noun.person	in IN 0	reducing VBG B-verb.change	the DT 0	number NN B-noun.quantity	of IN 0	human JJ B-adj.all	breast NN 0	cancer NN B-noun.body	cells NNS B-noun.body	that WDT 0	were VBD B-verb.stative	in IN 0	the DT 0	S NNP 0	phase NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d516.s9	This DT 0	did VBD 0	not RB B-adv.all	result VB B-verb.stative	in IN 0	any DT 0	statistically RB B-noun.communication	or CC 0	clinically RB B-adj.all	relevant JJ B-adj.pert	changes NNS B-noun.relation	in IN 0	the DT 0	pharmacokinetic JJ B-adj.all	parameters NNS B-noun.event	of IN 0	either DT 0	caffeine NN B-noun.location	or CC 0	its PRP$ 0	major JJ B-adj.all	metabolite NN B-noun.attribute	, , 0	paraxanthine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d226.s7	Thus RB 0	, , 0	smaller JJR B-adj.all	doses NNS B-noun.person	of IN 0	adenosine NN B-noun.act	may MD 0	be VB B-verb.stative	effective JJ B-adj.all	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	dipyridamole NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d82.s18	As IN 0	a DT 0	consequence NN B-noun.person	, , 0	when WRB 0	INDOCIN NNP B-noun.group	and CC 0	lithium NN B-noun.person	are VBP 0	given VBN B-verb.possession	concomitantly RB B-adv.all	, , 0	the DT 0	patient NN B-noun.person	should MD 0	be VB 0	carefully RB B-adv.all	observed VBN B-verb.perception	for IN 0	signs NNS B-noun.communication	of IN 0	lithium NN B-noun.phenomenon	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d420.s4	Probenecid NNP B-noun.person	, , 0	As IN 0	with IN 0	other JJ 0	b SYM 0	- : 0	lactam_antibiotics NNS B-noun.person	, , 0	probenecid NN B-noun.person	inhibits VBZ B-verb.stative	the DT 0	renal JJ B-adj.all	excretion NN B-noun.act	of IN 0	cefdinir NN B-noun.location	, , 0	resulting VBG B-verb.stative	in IN 0	an DT 0	approximate JJ B-adj.all	doubling NN B-noun.person	in IN 0	A.C. NNP 0	a DT 0	54 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	peak JJ B-adj.all	cefdinir NN B-noun.location	plasma NN B-noun.state	levels NNS B-noun.state	, , 0	and CC 0	a DT 0	50 CD B-adj.all	% NN 0	prolongation NN B-noun.attribute	in IN 0	the DT 0	apparent JJ B-adj.all	elimination NN B-noun.person	half NN B-noun.person	- : 0	life NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d85.s5	Similarly RB B-adv.all	, , 0	patients NNS B-noun.person	receiving VBG B-verb.communication	the DT 0	drug NN B-noun.artifact	and CC 0	a DT 0	hydantoin NN B-noun.person	, , 0	sulfonamide NN 0	or CC 0	sulfonylurea NN B-noun.substance	should MD 0	be VB 0	observed VBN B-verb.perception	for IN 0	signs NNS B-noun.communication	of IN 0	toxicity NN B-noun.attribute	to TO 0	these DT 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d76.s12	Other NNP 0	Potentially NNP B-noun.person	Important NNP I-noun.person	Drug NNP I-noun.person	Interactions NNP I-noun.person	, , 0	Benzodiazepines NNP B-noun.person	, , 0	Benzodiazepines NNS B-noun.person	metabolized VBN B-verb.social	by IN 0	hepatic JJ B-adj.all	oxidation NN B-noun.cognition	( ( 0	e.g. UH 0	, , 0	alprazolam NN B-noun.person	, , 0	midazolam NN B-noun.person	, , 0	triazolam NN 0	elc NN 0	. . 0	) ) 0	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	caution NN B-noun.act	because IN 0	the DT 0	clearance NN B-noun.act	of IN 0	these DT 0	drugs NNS B-noun.artifact	is VBZ B-verb.stative	likely JJ B-adj.all	to TO 0	be VB 0	reduced VBN B-verb.change	by IN 0	fluvoxamine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d176.s4	Potassium NN B-noun.person	- : 0	sparing_diuretics NNS B-noun.person	( ( 0	spironolactone NN 0	, , 0	amiloride IN 0	, , 0	triamterene NN B-noun.person	, , 0	and CC 0	others NNS 0	) ) 0	or CC 0	potassium NN B-noun.person	supplements NNS B-noun.person	can MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	hyperkalemia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d258.s3	No DT 0	effects NNS B-noun.phenomenon	on IN 0	plasma NN B-verb.creation	concentrations NNS B-noun.attribute	of IN 0	cimetidine NN B-noun.act	or CC 0	ketoconazole NN B-noun.group	were VBD 0	observed VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d288.s0	In IN 0	a DT 0	Phase NN B-noun.person	I PRP 0	trial VBP B-verb.cognition	using VBG B-verb.consumption	escalating VBG B-verb.communication	doses NNS B-noun.person	of IN 0	TAXOL NNP B-noun.group	( ( 0	110 CD 0	- : 0	200 CD 0	mg NN B-noun.quantity	/ : 0	m2 LS 0	) ) 0	and CC 0	cisplatin NN B-noun.person	( ( 0	50 CD B-adj.all	or CC 0	75 CD 0	mg NN B-noun.quantity	/ : 0	m2 LS 0	) ) 0	given VBN B-verb.possession	as IN 0	sequential JJ B-adj.all	infusions NNS B-noun.cognition	, , 0	myelosuppression NN B-noun.person	was VBD B-verb.stative	more RBR B-adv.all	profound JJ B-adj.all	when WRB 0	TAXOL NNP B-noun.person	was VBD 0	given VBN B-verb.possession	after IN 0	cisplatin NN B-noun.person	than IN 0	with IN 0	the DT 0	alternate JJ B-adj.all	sequence NN B-noun.artifact	( ( 0	ie UH 0	, , 0	TAXOL NNP B-noun.group	before IN 0	cisplatin NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d492.s1	Antihistamines NNS B-noun.animal	may MD 0	have VB B-verb.change	additive JJ B-adj.all	effects NNS B-noun.phenomenon	with IN 0	alcohol NN B-noun.person	and CC 0	other JJ B-adj.all	CNS_depressants NNS B-noun.person	, , 0	e.g. NNP B-noun.person	, , 0	hypnotics NNS B-noun.person	, , 0	sedatives NNS B-noun.person	, , 0	tranquilizers NNS B-noun.person	, , 0	antianxiety_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d480.s8	Although IN 0	it PRP 0	has VBZ 0	not RB 0	been VBN 0	established VBN B-verb.cognition	that IN 0	there EX 0	is VBZ B-verb.stative	an DT 0	interaction NN B-noun.act	between IN 0	Clozapine NNP B-noun.person	and CC 0	benzodiazepines NNS B-noun.artifact	or CC 0	other JJ B-adj.all	psychotropics NNS B-noun.person	, , 0	caution NN B-noun.cognition	is VBZ 0	advised VBN B-verb.communication	when WRB 0	clozapine NN B-noun.person	is VBZ 0	initiated VBN B-verb.creation	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	a DT 0	benzodiazepine NN B-noun.person	or CC 0	any DT 0	other JJ B-adj.all	psychotropic_drug NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d309.s2	Monoamine_oxidase_(MAO)_inhibitors NNS B-noun.person	prolong VBP B-verb.stative	and CC 0	intensify VB B-verb.change	the DT 0	anticholinergic JJ B-adj.pert	effects NNS B-noun.phenomenon	of IN 0	antihistamines NNS B-noun.object	. . 0	. . 0
DDI-DrugBank.d498.s2	Local JJ B-adj.all	and CC 0	some DT 0	general JJ B-adj.all	anesthetics NNS B-noun.person	, , 0	antiarrhythmic_agents NNS B-noun.person	and CC 0	other JJ B-adj.all	drugs NNS B-noun.artifact	that WDT 0	interfere VBP B-verb.stative	with IN 0	neuromuscular JJ B-adj.all	transmission NN B-noun.communication	should MD 0	be VB 0	used VBN B-verb.consumption	cautiously RB B-adv.all	, , 0	if IN 0	at IN 0	all DT 0	, , 0	in IN 0	patients NNS B-noun.person	with IN 0	myasthenia NN B-noun.person	gravis NN B-noun.location	, , 0	. . 0
DDI-DrugBank.d233.s1	Patients NNS B-noun.person	receiving VBG B-verb.communication	azathioprine NN B-noun.person	and CC 0	allopurinol VB B-verb.communication	concomitantly RB B-adv.all	should MD 0	have VB B-verb.stative	a DT 0	dose NN B-noun.event	reduction NN B-noun.process	of IN 0	azathioprine NN B-noun.person	, , 0	to TO 0	approximately RB B-verb.consumption	1/3 CD 0	to TO 0	1/4 CD 0	the DT 0	usual JJ B-adj.all	dose NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d426.s3	Selective_serotonin_reuptake_inhibitors NNS B-noun.person	( ( 0	SSRIs NNP 0	) ) 0	( ( 0	e.g. UH 0	, , 0	fluoxetine NN B-noun.person	, , 0	fluvoxamine NN B-noun.person	, , 0	paroxetine NN B-noun.person	, , 0	sertraline NN B-noun.body	) ) 0	have VBP 0	been VBN 0	reported VBN B-verb.communication	, , 0	rarely RB B-adv.all	, , 0	to TO 0	cause VB B-verb.emotion	weakness NN I-verb.emotion	, , 0	hyperreflexia NN B-noun.person	, , 0	and CC 0	incoordination NN B-noun.time	when WRB 0	coadministered VBN B-verb.communication	with IN 0	5-HT1_agonists NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d318.s12	Skeletal_muscle_relaxants NNS B-noun.person	, , 0	amphotericin_B JJ B-noun.person	- : 0	induced VBN B-verb.creation	hypokalemia NN 0	may MD 0	enhance VB B-verb.change	the DT 0	curariform NN B-noun.cognition	effect NN 0	of IN 0	skeletal_muscle_relaxants NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	tubocurarine NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d132.s4	Tolbutamide NNP 0	, , 0	In IN 0	diabetic JJ B-adj.all	patients NNS B-noun.person	receiving VBG B-verb.communication	diflunisal NN B-noun.person	and CC 0	tolbutamide NN 0	, , 0	no DT 0	significant JJ B-adj.all	effects NNS B-noun.phenomenon	were VBD 0	seen VBN B-verb.perception	on IN 0	tolbutamide NN 0	plasma NN B-noun.substance	levels NNS B-noun.state	or CC 0	fasting VBG B-verb.social	blood NN B-noun.act	glucose NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d382.s16	Although IN 0	there EX 0	was VBD B-verb.stative	no DT 0	effect NN B-noun.cognition	of IN 0	Aprepitant NNP B-noun.person	on IN 0	the DT 0	plasma NN B-noun.group	AUC NNP B-noun.group	of IN I-noun.group	R(+ NNP I-noun.group	) ) 0	or CC 0	S(-)_warfarin NN B-noun.person	determined VBD B-verb.communication	on IN 0	Day NN 0	3 CD 0	, , 0	there EX 0	was VBD B-verb.stative	a DT 0	34 CD 0	% NN 0	decrease NN B-noun.act	in IN 0	S(-)warfarin NNP 0	( ( 0	a DT 0	CYP2C9 JJ B-adj.all	substrate NN I-adj.all	) ) 0	trough NN 0	concentration NN 0	accompanied VBN B-verb.stative	by IN 0	a DT 0	14 CD B-adj.all	% NN 0	decrease NN B-noun.act	in IN 0	the DT 0	prothrombin NN B-adj.all	time NN B-noun.time	( ( 0	reported VBN B-verb.communication	as IN 0	International NNP B-noun.other	Normalized NNP I-noun.other	Ratio NNP I-noun.other	or CC 0	INR NNP B-noun.group	) ) 0	5 CD B-adj.all	days NNS B-noun.act	after IN 0	completion NN B-noun.act	of IN 0	dosing VBG B-verb.social	with IN 0	Aprepitant NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d209.s3	Other JJ 0	concomitant JJ B-adj.all	therapy NN 0	Although IN 0	specific JJ B-adj.all	interaction NN B-noun.act	studies NNS B-noun.artifact	were VBD B-verb.stative	not RB B-adv.all	performed VBN B-verb.social	, , 0	finasteride JJ B-adj.all	doses NNS B-noun.event	of IN 0	1 CD B-adj.all	mg CD B-noun.quantity	or CC 0	more JJR B-noun.quantity	were VBD 0	concomitantly RB B-adv.all	used VBN B-verb.consumption	in IN 0	clinical JJ B-adj.all	studies NNS B-noun.communication	with IN 0	acetaminophen NN B-noun.person	, , 0	acetylsalicylic_acid NNP B-noun.person	, , 0	a SYM 0	- : 0	blockers NNS B-noun.person	, , 0	analgesics NNS B-noun.person	, , 0	angiotensin NN B-noun.person	- : 0	converting_enzyme_(ACE)_inhibitors NNS B-noun.person	, , 0	anticonvulsants NNS B-noun.person	, , 0	benzodiazepines NNS B-noun.person	, , 0	beta_blockers NNS B-noun.person	, , 0	calcium NN B-noun.person	- : 0	channel_blockers NNS B-noun.person	, , 0	cardiac JJ B-adj.all	nitrates NNS B-noun.person	, , 0	diuretics NNS B-noun.person	, , 0	H2_antagonists NNS B-noun.person	, , 0	HMG NNP B-noun.group	- : 0	CoA_reductase_inhibitors NNS B-noun.person	, , 0	prostaglandin_synthetase_inhibitors NNS B-noun.person	( ( 0	also RB B-adv.all	referred VBD B-verb.perception	to TO 0	as IN 0	NSAIDs NNP B-noun.location	) ) 0	, , 0	and CC 0	quinolone_anti NNS B-noun.person	- : 0	infectives NNS B-noun.time	without IN 0	evidence NN B-noun.time	of IN 0	clinically RB B-adv.all	significant JJ B-adj.all	adverse JJ B-adj.all	interactions NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d220.s13	When WRB 0	Mefloquine NNP B-noun.person	is VBZ 0	taken VBN 0	concurrently RB B-adv.all	with IN 0	oral JJ B-adj.all	live_typhoid_vaccines NNS B-noun.body	, , 0	attenuation NN B-noun.act	of IN 0	immunization NN B-noun.person	can MD 0	not RB B-adv.all	be VB 0	excluded VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d270.s39	A DT 0	dose NN B-noun.event	increase NN B-noun.process	of IN 0	lopinavir NN B-noun.quantity	/ : 0	ritonavir NN B-noun.person	to TO 0	533/133 CD 0	mg IN 0	twice RB 0	daily RB 0	with IN 0	food NN B-noun.food	isrecommended VBD B-verb.change	in IN 0	combination NN 0	with IN 0	nevirapine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d88.s4	Patients NNS B-noun.person	taking VBG B-verb.social	coumarin NN B-noun.person	- : 0	derivative_anticoagulants NNS B-noun.person	concomitantly RB B-adv.all	with IN 0	capecitabine NN B-noun.act	should MD 0	be VB 0	monitored VBN B-verb.perception	regularly RB B-adv.all	for IN 0	alterations NNS B-noun.act	in IN 0	their PRP$ 0	coagulation NN B-noun.artifact	parameters NNS B-noun.person	( ( 0	PT NNP 0	or CC 0	INR NNP B-noun.group	) ) 0	. . 0	. . 0
DDI-MedLine.d18.s7	Survanta NNP B-noun.person	also RB B-adv.all	increased VBN B-verb.change	rate NN B-noun.time	of IN 0	dissolution NN B-noun.act	, , 0	in IN 0	a DT 0	manner NN B-noun.person	similar JJ B-adj.all	to TO 0	sodium_dodecyl_sulfate VB B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d556.s1	Drug NN 0	/ '' 0	Laboratory NNP B-noun.other	Test NNP I-noun.other	Interactions NNPS I-noun.other	As IN 0	with IN 0	cephalothin NN 0	, , 0	high JJ B-adj.all	concentrations NNS B-noun.attribute	of IN 0	cefoxitin NN B-noun.substance	( ( 0	100 CD 0	micrograms NNS B-noun.quantity	/ : 0	mL LS 0	) ) 0	may MD 0	interfere VB B-verb.stative	with IN 0	measurement NN B-noun.attribute	of IN 0	serum NN B-noun.person	and CC 0	urine NN 0	creatinine NN 0	levels NNS B-noun.attribute	by IN 0	the DT 0	Jaff NNP B-noun.person	_ POS 0	reaction NN B-noun.cognition	, , 0	and CC 0	produce VB B-verb.cognition	false JJ B-adj.all	increases NNS B-noun.event	of IN 0	modest JJ B-adj.all	degree NN B-noun.communication	in IN 0	the DT 0	levels NNS B-noun.state	of IN 0	creatinine NN B-noun.person	reported VBD B-verb.communication	. . 0	. . 0
DDI-DrugBank.d340.s30	Rifabutin NNP B-noun.person	, , 0	Coadministration NNP B-noun.person	of IN 0	rifabutin NN B-noun.food	and CC 0	VIRACEPT NNP B-noun.person	resulted VBD B-verb.communication	in IN 0	a DT 0	32 CD 0	% NN 0	decrease NN B-noun.act	in IN 0	nelfinavir JJ B-adj.all	plasma NN B-noun.person	AUC NNP I-noun.person	and CC 0	a DT 0	207 CD 0	% NN 0	increase NN B-noun.event	in IN 0	rifabutin JJ B-adj.all	plasma NN B-noun.substance	A.C. NNP 0	. . 0
DDI-MedLine.d83.s3	In IN 0	large JJ B-adj.all	, , 0	well RB 0	controlled JJ B-adj.all	trials NNS B-noun.person	in IN 0	patients NNS B-noun.person	with IN 0	schizophrenia NN B-noun.person	or CC 0	related VBN B-verb.cognition	psychoses NNS B-noun.person	, , 0	olanzapine JJ 0	5 CD 0	to TO 0	20 CD B-adj.all	mg RB B-noun.quantity	/ JJ 0	day NN B-noun.person	was VBD B-verb.stative	significantly RB B-adv.all	superior JJ B-adj.all	to TO 0	haloperidol VB B-verb.consumption	5 CD 0	to TO 0	20 CD B-adj.all	mg RB B-noun.quantity	/ JJ 0	day NN 0	in IN 0	overall JJ B-adj.all	improvements NNS B-noun.person	in IN 0	psychopathology NN B-noun.animal	rating NN I-noun.animal	scales NNS B-noun.relation	and CC 0	in IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	depressive JJ B-adj.all	and CC 0	negative JJ B-adj.all	symptoms NNS B-noun.body	, , 0	and CC 0	was VBD B-verb.stative	comparable JJ B-adj.all	in IN 0	effects NNS B-noun.phenomenon	on IN 0	positive JJ B-adj.all	psychotic JJ B-adj.all	symptoms NNS B-noun.body	. . 0	. . 0
DDI-DrugBank.d241.s5	However RB 0	, , 0	patients NNS B-noun.person	on IN 0	digoxin NN B-noun.person	may MD 0	show VB B-verb.communication	elevations NNS B-noun.person	of IN 0	digoxin NN B-noun.act	concentrations NNS I-noun.act	after IN 0	initiation NN B-noun.time	of IN 0	therapy NN 0	with IN 0	FLOLAN NNP B-noun.group	, , 0	which WDT 0	may MD 0	be VB B-verb.stative	clinically RB B-adv.all	significant JJ B-adj.all	in IN 0	patients NNS B-noun.artifact	prone JJ 0	to TO 0	digoxin VB B-verb.social	toxicity NN I-verb.social	. . 0	. . 0
DDI-DrugBank.d485.s4	Acitretin NNP B-noun.person	, , 0	Interferes VBZ 0	with IN 0	the DT 0	contraceptive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	microdosed JJ B-adj.all	progestin NN B-noun.person	- : 0	containing VBG B-verb.stative	minipill NN 0	preparations NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d334.s15	Use NNP B-noun.person	of IN 0	PRINIVIL NNP B-noun.group	with IN 0	potassium NN B-noun.person	- : 0	sparing_diuretics NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	spironolactone NN 0	, , 0	triamterene NN B-noun.person	, , 0	or CC 0	amiloride VB B-verb.social	) ) 0	, , 0	potassium NN B-noun.person	supplements NNS B-noun.artifact	, , 0	or CC 0	potassium NN B-noun.person	- : 0	containing VBG B-verb.communication	salt NN B-noun.act	substitutes NNS B-noun.artifact	may MD 0	lead VB B-verb.cognition	to TO 0	significant JJ B-adj.all	increases NNS B-noun.event	in IN 0	serum NN B-adj.all	potassium NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d179.s26	- : 0	Furazolidone NN 0	( ( 0	e.g. UH 0	, , 0	Furoxone NNP B-noun.location	) ) 0	or CC 0	. . 0
DDI-DrugBank.d529.s19	Although IN 0	there EX 0	was VBD B-verb.stative	a DT 0	slight JJ B-adj.all	reduction NN B-noun.process	in IN 0	blood NN B-adj.all	sugar NN B-noun.artifact	concentrations NNS B-noun.artifact	during IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	flurbiprofen NN B-noun.person	and CC 0	hypoglycemic_agents NNS B-noun.person	, , 0	there EX 0	were VBD B-verb.stative	no DT 0	signs NNS B-noun.communication	or CC 0	symptoms NNS B-noun.communication	of IN 0	hypoglycemia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d415.s3	Single JJ B-adj.all	dose NN B-noun.event	bioavailability NN B-noun.phenomenon	studies NNS B-noun.artifact	in IN 0	normal JJ B-adj.all	volunteers NNS B-noun.person	have VBP 0	failed VBN B-verb.social	to TO 0	wshow VB B-verb.communication	an DT 0	effect NN B-noun.cognition	of IN 0	aspirin NN B-noun.person	on IN 0	ibuprofen JJ B-adj.all	blood NN B-noun.body	levels NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d279.s3	Lymphocytopenia NNP B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	CAMPTOSAR NNP B-noun.group	, , 0	and CC 0	it PRP 0	is VBZ B-verb.stative	possible JJ B-adj.all	that IN 0	the DT 0	administration NN B-noun.time	of IN 0	dexamethasone NN 0	as IN 0	antiemetic JJ B-adj.all	prophylaxis NN B-noun.artifact	may MD 0	have VB 0	enhanced VBN B-verb.change	the DT 0	likelihood NN B-noun.location	of IN 0	this DT 0	effect NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d172.s19	Lithium NNP B-noun.person	, , 0	In IN 0	a DT 0	study NN B-noun.artifact	conducted VBN B-verb.communication	in IN 0	healthy JJ B-adj.all	subjects NNS B-noun.person	, , 0	mean VB B-verb.stative	steady JJ B-adj.all	- : 0	state NN B-adj.all	lithium NN B-noun.substance	plasma NN B-noun.plant	levels NNS B-noun.body	increased VBD B-verb.change	approximately RB B-adv.all	17 CD B-adj.all	% NN 0	in IN 0	subjects NNS B-noun.artifact	receiving VBG B-verb.communication	lithium NN B-noun.communication	450 CD 0	mg IN 0	BID NNP 0	with IN 0	CELEBREX NNP B-noun.group	200 CD 0	mg IN 0	BID NNP 0	as IN 0	compared VBN 0	to TO 0	subjects NNS B-noun.person	receiving VBG B-verb.social	lithium NN I-verb.social	alone RB 0	. . 0	. . 0
DDI-DrugBank.d28.s1	Results NNS B-noun.person	from IN 0	existing VBG B-verb.stative	clinical JJ B-adj.all	trials NNS B-noun.communication	suggest VBP B-verb.communication	no DT 0	significant JJ B-adj.all	interactions NNS B-noun.relation	between IN 0	COPAXONE NNP B-noun.group	_ : 0	and CC 0	other JJ 0	therapies NNS 0	commonly RB B-adv.all	used VBN B-verb.consumption	in IN 0	MS NNP 0	patients NNS B-noun.artifact	, , 0	including VBG B-verb.change	the DT 0	concurrent JJ B-adj.all	use NN 0	of IN 0	corticosteroids NNS B-noun.food	for IN 0	up RB 0	to TO 0	28 CD B-adj.all	days NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d384.s11	Corticosteroids NNS B-noun.person	, , 0	A DT 0	relationship NN B-noun.state	of IN 0	functional JJ B-adj.all	antagonism NN B-noun.attribute	exists VBZ B-verb.stative	between IN 0	vitamin_D_analogues NNS B-noun.location	, , 0	which WDT 0	promote VBP B-verb.stative	calcium NN B-adj.all	absorption NN B-noun.artifact	, , 0	and CC 0	corticosteroids NNS B-noun.person	, , 0	which WDT 0	inhibit VBP B-verb.stative	calcium NN B-adj.all	absorption NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d204.s0	When WRB 0	administered VBN B-verb.communication	concurrently RB B-adv.all	, , 0	the DT 0	following VBG 0	drugs NNS B-noun.animal	may MD 0	interact VB B-verb.change	with IN 0	beta JJ B-noun.body	- : 0	adrenergic_receptor_blocking_agents NNS B-noun.person	, , 0	Anesthetics NNP B-noun.person	, , 0	general JJ B-adj.all	, , 0	exaggeration NN 0	of IN 0	the DT 0	hypotension NN 0	induced VBN B-verb.creation	by IN 0	general JJ B-adj.all	anesthetics NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d131.s3	It PRP 0	was VBD 0	shown VBN B-verb.cognition	that DT 0	neurotensin NN B-noun.person	antagonized VBN B-verb.cognition	evidently RB B-adv.all	the DT 0	antinociceptive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	enkephalins NNS B-noun.person	and CC 0	their PRP$ 0	analogue NN 0	. . 0	. . 0
DDI-DrugBank.d546.s0	Drug NN B-noun.person	Interactions NNS I-noun.person	with IN 0	Beta JJ B-noun.person	- : 0	Blockers NNS B-noun.person	, , 0	Concomitant JJ 0	use NN 0	of IN 0	fenoldopam NN B-noun.person	with IN 0	beta JJ B-noun.body	- : 0	blockers NNS B-noun.person	should MD 0	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d536.s4	Intestinal_adsorbents NNS B-noun.relation	( ( 0	e. FW 0	g. FW 0	, , 0	charcoal NN B-noun.artifact	) ) 0	and CC 0	digestive_enzyme_preparations NNS B-noun.person	containing VBG B-verb.social	carbohydrate NN I-verb.social	- : 0	splitting NN B-verb.contact	enzymes NNS B-noun.person	( ( 0	e. FW 0	g. FW 0	, , 0	amylase NN B-noun.person	, , 0	pancreatin NN B-noun.location	) ) 0	may MD 0	reduce VB B-verb.change	the DT 0	effect NN B-noun.cognition	of IN 0	Acarbose NNP B-noun.person	and CC 0	should MD 0	not RB 0	be VB 0	taken VBN B-verb.cognition	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d468.s8	Cyclosporine NNP B-noun.person	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	nicardipine NN B-noun.person	and CC 0	cyclosporine JJ B-adj.all	levels NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d430.s3	Products NNS B-noun.artifact	containing VBG B-verb.stative	calcium NN B-noun.substance	and CC 0	other JJ B-adj.all	multivalent_cations NNS B-noun.person	likely RB B-adv.all	will MD 0	interfere VB B-verb.stative	with IN 0	absorption NN B-noun.act	of IN 0	alendronate JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d334.s19	Lithium NNP B-noun.person	toxicity NN I-noun.person	was VBD B-verb.stative	usually RB B-adv.all	reversible JJ B-adj.all	upon IN 0	discontinuation NN B-noun.act	of IN 0	lithium NN B-noun.substance	and CC 0	the DT 0	ACE_inhibitor NN B-noun.other	. . 0	. . 0
DDI-DrugBank.d303.s4	Probenecid NNP B-noun.person	, , 0	As IN 0	with IN 0	other JJ 0	b SYM 0	- : 0	lactams NNS B-noun.animal	, , 0	the DT 0	renal JJ B-adj.all	excretion NN B-noun.act	of IN 0	cephalexin NN B-noun.food	is VBZ 0	inhibited VBN B-verb.change	by IN 0	probenecid NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d567.s9	Gemfibrozil NNP B-noun.person	Other NNP I-noun.person	fibrates VBZ B-verb.communication	Niacin NNP B-noun.person	( ( I-noun.person	nicotinic_acid JJ I-noun.person	) ) 0	( ( 0	= SYM 0	1 CD B-adj.all	g RB 0	/ JJ 0	day NN 0	) ) 0	. . 0
DDI-MedLine.d17.s9	There EX 0	is VBZ 0	thus RB 0	an DT 0	enhancement NN B-noun.person	effect NN B-noun.cognition	of IN 0	PGF2alpha NNP 0	upon IN 0	the DT 0	reaction NN B-noun.process	of IN 0	placental JJ B-adj.all	vessels NNS B-noun.body	to TO 0	oxytocin VB B-verb.change	in IN 0	vitro NN B-noun.animal	. . 0	. . 0
DDI-DrugBank.d162.s9	Lithium NNP B-noun.person	, , 0	generally RB B-adv.all	should MD 0	not RB 0	be VB 0	given VBN B-verb.possession	with IN 0	diuretics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d548.s3	Inhibitors NNS B-noun.person	of IN 0	CYP2D6 NNP B-noun.person	, , 0	Because IN 0	CYP2D6 NNP B-noun.person	is VBZ B-verb.stative	involved VBN B-verb.stative	in IN 0	duloxetine JJ B-adj.all	metabolism NN B-noun.attribute	, , 0	concomitant JJ B-adj.all	use NN 0	of IN 0	duloxetine NN B-noun.location	with IN 0	potent JJ B-adj.all	inhibitors NNS B-noun.person	of IN 0	CYP2D6 NNP B-noun.group	may MD 0	result VB B-verb.stative	in IN 0	higher JJR B-adj.all	concentrations NNS B-noun.attribute	of IN 0	duloxetine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d509.s16	Aripiprazole NNP B-noun.person	dose NN I-noun.person	should MD 0	be VB 0	reduced VBN B-verb.change	to TO 0	one CD 0	- : 0	half NN B-noun.quantity	of IN 0	its PRP$ 0	normal JJ B-adj.all	dose NN B-noun.quantity	when WRB 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	quinidine NN B-noun.location	with IN 0	aripiprazole NN B-noun.communication	occurs VBZ B-verb.stative	. . 0	. . 0
DDI-DrugBank.d148.s2	Aspirin NNP B-noun.person	/ NNP I-noun.person	Acetaminophen NNP I-noun.person	, , 0	Pharmacokinetic JJ B-noun.person	or CC 0	pharmacodynamic JJ B-adj.all	drug NN B-noun.person	- : 0	drug NN B-noun.person	interactions NNS I-noun.person	have VBP 0	not RB 0	been VBN 0	demonstrated VBN B-verb.perception	between IN 0	Argatroban NNP B-noun.person	and CC 0	concomitantly RB B-adv.all	administered VBN B-verb.possession	aspirin NN B-noun.person	( ( 0	162.5 CD 0	mg NN B-noun.quantity	orally RB B-adv.all	given VBN B-verb.possession	26 CD B-adj.all	and CC 0	2 CD B-adj.all	hours NNS B-noun.person	prior RB 0	to TO 0	initiation NN B-noun.act	of IN 0	Argatroban NNP B-noun.communication	1 CD B-adj.all	_ CD 0	g FW 0	/ FW 0	kg FW 0	/ FW 0	min FW 0	. . 0	over IN 0	4 CD B-adj.all	hours NNS B-noun.artifact	) ) 0	or CC 0	acetaminophen VB B-verb.social	( ( 0	1000 CD 0	mg NN B-noun.quantity	orally RB B-adv.all	given VBN B-verb.possession	12 CD B-adj.all	, , 0	6 CD B-adj.all	and CC 0	0 CD B-adj.all	hours NNS B-noun.person	prior RB 0	to TO 0	, , 0	and CC 0	6 CD B-adj.all	and CC 0	12 CD B-adj.all	hours NNS B-noun.person	subsequent JJ B-adj.all	to TO 0	, , 0	initiation NN B-noun.act	of IN 0	Argatroban JJ 0	1.5 CD 0	_ FW 0	g FW 0	/ FW 0	kg FW 0	/ FW 0	min FW 0	. . 0	over IN 0	18 CD B-adj.all	hours NNS B-noun.artifact	) ) 0	. . 0	. . 0
DDI-DrugBank.d94.s2	Agents NNS B-noun.person	that IN 0	Inhibit NNP B-noun.person	Cytochrome NNP I-noun.person	P450 NNP I-noun.person	Isoenzymes NNPS I-noun.person	and/or NNP I-noun.person	Epoxide NNP I-noun.person	Hydrolase NNP I-noun.person	Carbamazepine NNP I-noun.person	is VBZ 0	metabolized VBN B-verb.cognition	mainly RB B-adv.all	by IN 0	cytochrome JJ B-adj.all	P450 NN 0	( ( 0	CYP NNP 0	) ) 0	3A4 NN 0	to TO 0	the DT 0	active JJ B-adj.all	carbamazepine_10,11-epoxide NN B-noun.group	, , 0	which WDT 0	is VBZ B-verb.stative	further RBR B-adv.all	metabolized VBN B-verb.communication	to TO 0	the DT 0	trans NNS B-noun.person	- : 0	diol NN B-noun.person	by IN 0	epoxide JJ 0	hydrolase NN 0	. . 0	. . 0
DDI-DrugBank.d87.s8	Nevertheless RB B-adv.all	, , 0	the DT 0	possibility NN B-noun.state	of IN 0	additive JJ B-adj.all	negative JJ B-adj.all	inotropic JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	beta_blockers NNS B-noun.person	and CC 0	flecainide NN B-noun.plant	should MD 0	be VB 0	recognized VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d467.s4	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	Targretin NNP B-noun.location	capsules NNS B-noun.artifact	and CC 0	gemfibrozil NN B-noun.body	resulted VBD B-verb.stative	in IN 0	substantial JJ B-adj.all	increases NNS B-noun.event	in IN 0	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	bexarotene NN B-noun.person	, , 0	probably RB B-adv.all	at IN 0	least JJS 0	partially RB B-adv.all	related VBN B-verb.cognition	to TO 0	cytochrome VB B-verb.contact	P450 JJ I-verb.contact	3A4 JJ B-adj.all	inhibition NN B-noun.attribute	by IN 0	gemfibrozil NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d64.s88	Oral JJ B-adj.all	anticoagulants NNS B-noun.object	may MD 0	potentiate VB B-verb.communication	the DT 0	hypoglycemic JJ B-adj.all	action NN B-noun.state	of IN 0	hypoglycemic_agents NNS B-noun.person	, , 0	eg UH 0	, , 0	tolbutamide NN 0	and CC 0	chlorpropamide NN B-noun.artifact	, , 0	by IN 0	inhibiting VBG B-verb.possession	their PRP$ 0	metabolism NN B-noun.attribute	in IN 0	the DT 0	liver NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d396.s2	The DT 0	use NN 0	of IN 0	MAO_inhibitors NNS B-noun.person	or CC 0	tricyclic_antidepressants NNS B-noun.plant	with IN 0	hydrocodone NN 0	preparations NNS B-noun.substance	may MD 0	increase VB B-verb.change	the DT 0	effect NN B-noun.cognition	of IN 0	either CC 0	the DT 0	antidepressant JJ B-adj.all	or CC 0	hydrocodone NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d163.s0	Vitamin_A NN B-noun.artifact	, , 0	Because IN 0	of IN 0	the DT 0	relationship NN B-noun.state	of IN 0	Accutane NNP B-noun.person	to TO 0	vitamin_A NNP B-noun.person	, , 0	patients NNS B-noun.person	should MD 0	be VB 0	advised VBN B-verb.communication	against IN 0	taking VBG 0	vitamin_supplements NNS B-noun.artifact	containing VBG B-verb.stative	vitamin_A NNP I-verb.stative	to TO 0	avoid VB B-verb.social	additive JJ B-adj.all	toxic JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0
DDI-DrugBank.d321.s3	The DT 0	pharmacokinetics NNS B-noun.time	of IN 0	praziquantel NN B-noun.location	were VBD B-verb.stative	unchanged JJ B-adj.all	following JJ 0	coadministration NN B-noun.person	with IN 0	albendazole NN B-noun.person	( ( 0	400 CD 0	mg NN B-noun.quantity	) ) 0	. . 0	. . 0
DDI-MedLine.d14.s2	Comparative JJ B-adj.all	analysis NN B-noun.attribute	of IN 0	the DT 0	effects NNS B-noun.phenomenon	of IN 0	stimulation NN B-noun.artifact	and CC 0	inhibition NN B-noun.attribute	of IN 0	cholino- NN B-noun.food	and CC 0	adrenoreceptors NNS B-noun.person	on IN 0	this DT 0	inhibitory JJ B-adj.all	action NN B-noun.process	of IN 0	angiotensins NNS B-noun.person	suggested VBD B-verb.communication	the DT 0	mediation NN B-noun.act	of IN 0	angiotensin NN B-noun.phenomenon	influence NN B-noun.phenomenon	through IN 0	the DT 0	modulation NN B-noun.time	of IN 0	cholinergic JJ B-adj.all	reactions NNS B-noun.cognition	of IN 0	parietal JJ B-noun.body	cells NNS I-noun.body	in IN 0	the DT 0	stomach NN B-noun.body	. . 0	. . 0
DDI-DrugBank.d139.s1	Cephalosporins NNS B-noun.person	- : 0	Cephalosporins NNS 0	containing VBG B-verb.stative	side NN 0	chains NNS 0	of IN 0	N NNP 0	- : 0	methylthiotetrazole NN B-noun.attribute	( ( 0	cefmenoxime NN B-noun.person	, , 0	cefoperazone NN 0	, , 0	cefotetan NN 0	, , 0	cefamandole NN B-noun.location	, , 0	latamoxef NN B-noun.location	) ) 0	or CC 0	methylthiadiazole NN B-noun.attribute	( ( 0	cefazolin NN 0	) ) 0	can MD 0	cause VB B-verb.creation	vitamin NN 0	K NNP 0	deficiency NN B-noun.attribute	and CC 0	hypoprothrombinemia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d284.s10	In IN 0	a DT 0	12-month JJ 0	controlled JJ B-adj.all	trial NN B-noun.act	that WDT 0	included VBD B-verb.stative	a DT 0	50 CD B-adj.all	mcg NN B-noun.quantity	once RB B-adv.all	daily JJ 0	BROVANA NNP 0	dose NN 0	, , 0	30 CD 0	of IN 0	the DT 0	528 CD 0	BROVANA NNP B-noun.group	-treated VBD 0	subjects NNS B-noun.person	received VBD B-verb.possession	concomitant JJ B-adj.all	theophylline NN 0	at IN 0	study NN B-noun.artifact	entry NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d32.s4	Antacids NNS B-noun.person	or CC 0	H_2_-receptor_antagonists NNS B-noun.person	, , 0	The DT 0	effect NN B-noun.cognition	of IN 0	increased VBN B-verb.change	gastric JJ B-adj.all	pH NN B-noun.attribute	on IN 0	the DT 0	bioavailability NN B-noun.cognition	of IN 0	ceftibuten NN B-noun.person	was VBD 0	evaluated VBN B-verb.change	in IN 0	18 CD B-adj.all	healthy JJ B-adj.all	adult NN B-noun.person	volunteers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d420.s5	Iron_Supplements NNS B-noun.person	and CC 0	Foods NNP B-noun.other	Fortified NNP I-noun.other	With IN I-noun.other	Iron NNP I-noun.other	Concomitant NNP I-noun.other	administration NN B-noun.time	of IN 0	cefdinir NN B-noun.person	with IN 0	a DT 0	therapeutic JJ B-adj.all	iron_supplement NN B-noun.artifact	containing VBG B-verb.stative	60 CD B-adj.all	mg NN B-noun.quantity	of IN 0	elemental JJ B-adj.all	iron NN B-noun.person	( ( 0	as IN 0	FeSO4 NNP 0	) ) 0	or CC 0	vitamins NNS B-noun.person	supplemented VBN B-verb.social	with IN 0	10 CD B-adj.all	mg NN B-noun.quantity	of IN 0	elemental JJ B-adj.all	iron NN B-noun.person	reduced VBD B-verb.change	extent NN B-noun.attribute	of IN 0	absorption NN B-noun.act	by IN 0	80 CD B-adj.all	% NN 0	and CC 0	31 CD 0	% NN 0	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d543.s6	Anticholinergic_drugs NNS B-noun.animal	may MD 0	antagonize VB B-verb.cognition	the DT 0	effects NNS B-noun.phenomenon	of IN 0	the DT 0	drugs NNS B-noun.artifact	that WDT 0	alter VBP B-verb.change	gastrointestinal JJ B-adj.all	motility NN B-noun.motive	, , 0	such JJ 0	as IN 0	metoclopramide NN 0	. . 0	. . 0
DDI-DrugBank.d5.s26	The DT 0	consumption NN B-noun.act	of IN 0	alcohol NN B-noun.artifact	during IN 0	treatment NN B-noun.plant	with IN 0	WELLBUTRIN NNP B-noun.group	should MD 0	be VB 0	minimized VBN B-verb.change	or CC 0	avoided VBN B-verb.social	( ( 0	also RB B-adv.all	see VB B-verb.social	_ RP 0	a DT 0	href= JJ B-adj.all	bupropz_od.htm#CI NNP B-noun.group	CONTRAINDICATIONS NNP I-noun.group	) ) 0	. . 0
DDI-DrugBank.d180.s0	Digitalis NNP B-noun.person	toxicity NN I-noun.person	may MD 0	be VB 0	aggravated VBN B-verb.change	by IN 0	the DT 0	initial JJ B-adj.all	release NN B-noun.state	of IN 0	norepinephrine NN B-noun.person	caused VBN B-verb.communication	by IN 0	Bretylium_Tosylate NNP B-noun.person	Injection NNP I-noun.person	. . 0	. . 0
DDI-DrugBank.d328.s30	Glyburide NNP B-noun.person	, , 0	Glyburide NNP B-noun.person	is VBZ B-verb.stative	a DT 0	CYP NNP B-noun.group	2C9 CD 0	substrate NN B-noun.quantity	. . 0	. . 0
DDI-DrugBank.d132.s7	Furosemide RB 0	, , 0	In IN 0	normal JJ B-adj.all	volunteers NNS B-noun.person	, , 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	diflunisal NN B-noun.state	and CC 0	furosemide NN B-noun.artifact	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	diuretic JJ B-adj.all	activity NN B-noun.state	of IN 0	furosemide NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d509.s3	Potential NNP B-noun.person	for IN 0	Other NNP B-noun.person	Drugs NNP I-noun.person	to TO 0	Affect VB B-verb.change	ABILIFY NNP B-noun.group	Aripiprazole NNP I-noun.group	is VBZ B-verb.stative	not RB I-verb.stative	a DT 0	substrate NN B-noun.person	of IN 0	CYP1A1 NNP B-noun.person	, , 0	CYP1A2 NNP B-noun.person	, , 0	CYP2A6 NNP B-noun.person	, , 0	CYP2B6 NNP B-noun.person	, , 0	CYP2C8 NNP B-noun.person	, , 0	CYP2C9 NNP B-noun.person	, , 0	CYP2C19 NNP B-noun.person	, , 0	or CC 0	CYP2E1 JJ B-noun.body	enzymes NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d334.s5	Non SYM 0	- : 0	steroidal_Anti SYM 0	- : 0	inflammatory_Agents NNS B-noun.person	, , 0	In IN 0	some DT 0	patients NNS B-noun.person	with IN 0	compromised JJ B-adj.all	renal JJ B-adj.all	function NN B-noun.act	who WP 0	are VBP 0	being VBG 0	treated VBN B-verb.change	with IN 0	non NN B-noun.person	- : 0	steroidal_anti SYM 0	- : 0	inflammatory_drugs NNS B-noun.time	, , 0	the DT 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	lisinopril NN B-noun.animal	may MD 0	result VB B-verb.stative	in IN 0	a DT 0	further JJ B-adj.all	deterioration NN B-noun.cognition	of IN 0	renal JJ B-adj.all	function NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d531.s63	Monitoring NN B-noun.person	of IN 0	liver NN B-noun.animal	enzymes VBZ B-verb.motion	is VBZ 0	recommended VBN B-verb.communication	when WRB 0	SUSTIVA NNP 0	is VBZ 0	used VBN B-verb.consumption	in IN 0	combination NN 0	with IN 0	ritonavir NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d107.s8	However RB 0	, , 0	reports NNS B-noun.communication	suggest VBP B-verb.communication	that IN 0	NSAIDs NNP B-noun.person	may MD 0	diminish VB B-verb.change	the DT 0	antihypertensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	ACE_inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d505.s4	Cholinesterase_Inhibitors NNS B-noun.person	, , 0	Dipyridamole NNP B-noun.person	may MD 0	counteract VB B-verb.change	the DT 0	anticholinesterase JJ B-adj.all	effect NN B-noun.cognition	of IN 0	cholinesterase_inhibitors NNS B-noun.person	, , 0	thereby RB B-adv.all	potentially RB B-adv.all	aggravating JJ B-adj.all	myasthenia NN B-noun.person	gravis NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d450.s10	Concomitant JJ B-adj.all	use NN 0	of IN 0	digoxin NN B-noun.person	and CC 0	sympathomimetics NNS B-noun.person	increases VBZ B-verb.change	the DT 0	risk NN 0	of IN 0	cardiac JJ B-noun.phenomenon	arrhythmias NN I-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d68.s1	Digoxin NNP B-noun.person	, , 0	Supraventricular JJ 0	arrhythmias NN 0	may MD 0	mask VB B-verb.cognition	the DT 0	cardiotoxicity NN B-noun.communication	associated VBN B-verb.cognition	with IN 0	excessive JJ B-adj.all	digoxin NN B-noun.state	levels NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d48.s9	Simultaneous JJ B-adj.all	administration NN B-noun.act	of IN 0	SPRYCEL NNP B-noun.group	with IN 0	antacids NNS B-noun.attribute	should MD 0	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d568.s5	Epidemiological JJ B-adj.all	studies NNS B-noun.group	of IN 0	the DT 0	case NN B-noun.communication	- : 0	control NN B-noun.act	and CC 0	cohort NN B-noun.artifact	design NN B-noun.artifact	that WDT 0	have VBP 0	demonstrated VBN B-verb.perception	an DT 0	association NN B-noun.cognition	between IN 0	use NN 0	of IN 0	psychotropic_drugs NNS B-noun.plant	that WDT 0	interfere VBP B-verb.stative	with IN 0	serotonin NN B-noun.person	reuptake NN B-noun.person	and CC 0	the DT 0	occurrence NN B-noun.state	of IN 0	upper JJ B-adj.all	gastrointestinal JJ B-adj.pert	bleeding NN B-noun.act	have VBP 0	also RB B-adv.all	shown VBN B-verb.perception	that DT 0	concurrent JJ B-adj.all	use NN 0	of IN 0	an DT 0	NSAID NNP B-noun.group	or CC 0	aspirin NN B-noun.substance	potentiated VBD B-verb.contact	the DT 0	risk NN 0	of IN 0	bleeding NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d434.s32	Valproate NNP B-noun.person	, , 0	Available JJ B-adj.all	data NNS B-noun.cognition	suggest VBP B-verb.communication	that IN 0	there EX 0	is VBZ B-verb.stative	no DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	of IN 0	valproate NN B-noun.attribute	on IN 0	the DT 0	clearance NN B-noun.act	of IN 0	Felbatol NNP B-noun.person	_ ( 0	at IN 0	steady JJ B-adj.all	state NN B-noun.state	, , 0	Therefore RB 0	, , 0	the DT 0	addition NN B-noun.act	of IN 0	valproate NN B-noun.attribute	is VBZ B-verb.stative	not RB B-adv.all	expected VBN B-verb.cognition	to TO 0	cause VB B-verb.creation	a DT 0	clinically RB B-adv.all	important JJ B-adj.all	effect NN B-noun.cognition	on IN 0	Felbatol NNP B-noun.person	_ . 0	( ( 0	felbamate NN B-noun.animal	) ) 0	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d424.s6	No DT 0	interaction NN 0	trials NNS B-noun.communication	have VBP 0	been VBN 0	conducted VBN B-verb.creation	with IN 0	MEPRON NNP B-noun.person	and CC 0	rifabutin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d320.s0	Chirocaine NN 0	__ WDT 0	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	caution NN B-noun.cognition	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	other JJ B-adj.all	local JJ B-adj.all	anesthetics NNS B-noun.group	or CC 0	agents NNS B-noun.person	structurally RB B-adv.all	related VBN B-verb.cognition	to TO 0	amide VB B-verb.social	- : 0	type JJ B-adj.all	local JJ B-adj.all	anesthetics NNS B-noun.group	since IN 0	the DT 0	toxic JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	these DT 0	drugs NNS B-noun.artifact	could MD 0	be VB B-verb.stative	additive JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d223.s26	Alcohol NNP B-noun.person	, , 0	It PRP 0	should MD 0	be VB 0	borne VBN B-verb.contact	in IN 0	mind NN 0	that IN 0	alcohol NN 0	ingestion NN B-noun.act	may MD 0	increase VB B-verb.change	the DT 0	danger NN B-noun.person	inherent JJ B-noun.person	in IN 0	any DT 0	intentional JJ B-noun.possession	or CC 0	unintentional JJ B-adj.all	SINEQUAN NNP 0	overdosage NN 0	. . 0	. . 0
DDI-DrugBank.d123.s16	Theophylline PRP 0	, , 0	As IN 0	with IN 0	some DT 0	other JJ B-adj.all	quinolones NNS B-noun.communication	, , 0	concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	ciprofloxacin NN B-noun.person	with IN 0	theophylline PRP 0	may MD 0	lead VB B-verb.cognition	to TO 0	elevated JJ B-adj.all	serum NN B-noun.body	concentrations NNS B-noun.attribute	of IN 0	theophylline NN 0	and CC 0	prolongation NN B-noun.act	of IN 0	its PRP$ 0	elimination NN B-noun.artifact	half NN B-noun.person	- : 0	life NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d175.s17	Other JJ 0	nonsteroidal_anti JJ 0	- : 0	inflammatory_agents NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	aspirin NN 0	) ) 0	may MD 0	also RB B-adv.all	have VBP B-verb.possession	this DT 0	effect NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d81.s2	In IN 0	a DT 0	study NN B-noun.artifact	in IN 0	hypertensive JJ B-adj.all	patients NNS B-noun.person	, , 0	addition NN 0	of IN 0	isradipine NN 0	to TO 0	existing VBG B-verb.stative	hydrochlorothiazide NN 0	therapy NN 0	did VBD 0	not RB B-adv.all	result VB B-verb.stative	in IN 0	any DT 0	unexpected JJ B-adj.all	adverse JJ B-adj.all	effects NNS B-noun.phenomenon	, , 0	and CC 0	isradipine NN B-noun.person	had VBD 0	an DT 0	additional JJ B-adj.all	antihypertensive JJ B-adj.all	effect NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d311.s0	Taking VBG 0	a DT 0	rauwolfia_alkaloid JJ B-noun.group	while IN 0	you PRP 0	are VBP 0	taking VBG B-verb.possession	or CC 0	within IN 0	2 CD B-adj.all	weeks NNS B-noun.time	of IN 0	taking VBG B-verb.social	MAO_inhibitors NNS B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	central JJ B-noun.body	nervous JJ I-noun.body	system NN B-noun.substance	depression NN B-noun.state	or CC 0	may MD 0	cause VB B-verb.communication	a DT 0	severe JJ 0	high JJ B-adj.all	blood NN B-noun.phenomenon	pressure NN I-noun.phenomenon	reaction NN B-noun.process	. . 0	. . 0
DDI-DrugBank.d231.s8	Furosemide NN 0	may MD 0	decrease VB B-verb.change	arterial JJ B-adj.all	responsiveness NN B-noun.cognition	to TO 0	norepinephrine VB B-verb.communication	. . 0	. . 0
DDI-DrugBank.d298.s0	Cyclopentolate NNP B-noun.person	may MD 0	interfere VB B-verb.stative	with IN 0	the DT 0	anti NNS B-noun.person	- : 0	glaucoma NN B-noun.phenomenon	action NN B-noun.process	of IN 0	carbachol NN B-noun.state	or CC 0	pilocarpine NN B-noun.communication	, , 0	. . 0
DDI-MedLine.d73.s3	The DT 0	MPTP NNP B-noun.group	- : 0	induced VBN B-verb.creation	neuronal JJ B-adj.all	damage NN B-noun.person	produced VBD B-verb.creation	a DT 0	tolerance NN B-noun.act	to TO 0	the DT 0	disruptive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	amphetamine NN B-noun.person	and CC 0	a DT 0	supersensitivity NN B-noun.person	to TO 0	the DT 0	disruptive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	apomorphine NN B-noun.person	in IN 0	rats NNS B-noun.animal	responding VBG B-verb.stative	in IN 0	a DT 0	schedule NN B-noun.person	controlled VBN B-verb.consumption	paradigm NN I-verb.consumption	. . 0	. . 0
DDI-DrugBank.d174.s2	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	an DT 0	aluminum NN B-noun.person	- : 0	containing VBG B-verb.communication	antacid NN B-noun.person	had VBD 0	no DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	in IN 0	the DT 0	bioavailability NN B-noun.cognition	of IN 0	6MNA NNP B-noun.location	. . 0	. . 0
DDI-DrugBank.d531.s30	No DT 0	dose NN 0	adjustment NN 0	of IN 0	SUSTIVA NNP B-noun.group	is VBZ 0	recommended VBN B-verb.communication	when WRB 0	given VBN B-verb.possession	with IN 0	clarithromycin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d187.s9	Phenytoin NN B-noun.person	, , 0	Isoniazid NNP B-noun.person	may MD 0	increase VB B-verb.body	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	phenytoin NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d185.s1	During IN 0	co SYM 0	- : 0	administration NN B-noun.time	, , 0	systemic JJ B-adj.all	levels NNS B-noun.state	of IN 0	TMP NNP B-noun.group	and CC 0	SMX NNP B-noun.group	were VBD B-verb.stative	essentially RB B-adv.all	unchanged JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d60.s11	In IN 0	clinical JJ B-adj.all	studies NNS B-noun.group	propofol NN B-noun.person	had VBD B-verb.social	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	duration NN 0	of IN 0	action NN B-noun.state	or CC 0	dosing NN B-noun.possession	requirements NNS I-noun.possession	for IN 0	NIMBEX NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d60.s8	Fifteen NNP B-noun.person	to TO 0	30 CD B-adj.all	minutes NNS B-noun.time	of IN 0	exposure NN B-noun.cognition	to TO 0	1.25 CD 0	MAC NNP B-noun.other	isoflurane NN B-verb.change	or CC 0	enflurane NN B-noun.person	had VBD 0	minimal JJ B-adj.pert	effects NNS B-noun.phenomenon	on IN 0	the DT 0	duration NN 0	of IN 0	action NN B-noun.process	of IN 0	initial JJ B-adj.all	doses NNS B-noun.event	of IN 0	NIMBEX NNP B-noun.group	and CC 0	therefore RB B-adv.all	, , 0	no DT 0	adjustment NN B-noun.person	to TO 0	the DT 0	initial JJ B-adj.all	dose NN B-noun.attribute	should MD 0	be VB B-verb.stative	necessary JJ B-adj.all	when WRB 0	NIMBEX NNP B-noun.group	is VBZ 0	administered VBN B-verb.possession	shortly RB B-adv.all	after IN 0	initiation NN B-noun.time	of IN 0	volatile JJ B-adj.all	agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d308.s0	THE DT 0	POTENTIATING NN B-noun.group	ACTION NN B-noun.group	OF IN 0	HYDROXYZINE NN B-noun.group	MUST MD 0	BE VB 0	CONSIDERED VBN B-verb.cognition	WHEN WRB 0	THE DT 0	DRUG NN B-noun.group	IS VBZ 0	USED VBN B-verb.consumption	IN IN 0	CONJUNCTION NN 0	WITH IN 0	CENTRAL_NERVOUS_SYSTEM_DEPRESSANTS NNS B-noun.group	SUCH JJ B-noun.group	AS IN 0	NARCOTICS NNS B-noun.group	, , 0	NON NNP B-noun.person	- : 0	NARCOTIC_ANALGESICS NNS B-noun.group	AND CC 0	BARBITURATES NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d123.s7	Therefore RB 0	, , 0	patients NNS B-noun.person	under IN 0	methotrexate NN B-noun.person	therapy NN B-noun.person	should MD 0	be VB 0	carefully RB B-adv.all	monitored VBN B-verb.perception	when WRB 0	concomitant JJ B-adj.all	ciprofloxacin NN B-noun.person	therapy NN B-noun.person	is VBZ 0	indicated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d353.s9	Consequently RB B-adv.all	, , 0	the DT 0	combination NN B-noun.event	of IN 0	methotrexate NN B-noun.food	with IN 0	acitretin NN B-noun.person	is VBZ B-verb.stative	also RB B-adv.all	contraindicated VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d118.s2	Sirolimus NNP B-noun.person	works VBZ B-verb.social	differently RB B-adv.all	from IN 0	the DT 0	immunosuppressants NNS B-noun.person	currently RB B-adv.all	available JJ B-adj.all	, , 0	and CC 0	except IN 0	for IN 0	increased VBN B-verb.change	lipid NN B-noun.body	levels NNS B-noun.attribute	, , 0	the DT 0	adverse JJ B-adj.all	reaction NN B-noun.process	profile NN B-noun.location	of IN 0	sirolimus NN B-noun.communication	does VBZ 0	not RB B-adv.all	appear VB B-verb.change	to TO 0	overlap VB B-verb.change	to TO 0	any DT 0	great JJ B-adj.all	extent NN B-noun.person	with IN 0	that DT 0	associated VBN B-verb.cognition	with IN 0	cyclosporine NN B-noun.state	or CC 0	tacrolimus NN B-noun.person	. . 0	. . 0
DDI-MedLine.d111.s10	Theophylline PRP 0	decreased VBD B-verb.change	the DT 0	binding NN B-noun.act	of IN 0	acetaminophen NN B-noun.quantity	by IN 0	a DT 0	net JJ B-adj.all	change NN B-noun.act	of IN 0	6.8 CD 0	% NN 0	( ( 0	percentage NN B-noun.person	increase NN B-noun.process	in IN 0	FDF NNP 0	, , 0	8.8 CD 0	% NN 0	) ) 0	at IN 0	277.5 CD 0	micromol NN B-noun.quantity	/ '' 0	L NNP 0	, , 0	. . 0
DDI-DrugBank.d458.s11	Dosage NN 0	adjustment NN 0	may MD 0	be VB 0	required VBN B-verb.communication	if IN 0	cyclosporine NN B-noun.person	, , 0	tacrolimus NN B-noun.person	, , 0	or CC 0	methylprednisolone NN B-noun.attribute	are VBP 0	given VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	NIZORAL NNP B-noun.group	_ POS 0	Tablets NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d568.s32	However RB 0	, , 0	there EX 0	are VBP 0	limited VBN B-verb.change	in IN 0	vivo JJ B-adj.all	data NNS B-noun.cognition	suggesting VBG B-verb.communication	a DT 0	modest JJ B-adj.all	CYP2D6 JJ B-adj.all	inhibitory JJ B-adj.all	effect NN B-noun.cognition	for IN 0	escitalopram NN B-noun.act	, , 0	i.e. FW 0	, , 0	coadministration NN B-noun.person	of IN 0	escitalopram NN B-noun.cognition	( ( 0	20 CD 0	mg RB 0	/ JJ 0	day NN 0	for IN 0	21 CD B-adj.all	days NNS B-noun.act	) ) 0	with IN 0	the DT 0	tricyclic_antidepressant JJ B-adj.all	desipramine NN B-noun.communication	( ( 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	50 CD B-adj.all	mg NN B-noun.quantity	) ) 0	, , 0	a DT 0	substrate NN B-noun.person	for IN 0	CYP2D6 NNP B-noun.person	, , 0	resulted VBD B-verb.stative	in IN 0	a DT 0	40 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	Cmax NNP B-noun.person	and CC 0	a DT 0	100 CD 0	% NN 0	increase NN B-noun.event	in IN 0	AUC NNP 0	of IN 0	desipramine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d404.s3	Since IN 0	blood NN B-noun.act	level NN B-noun.state	of IN 0	calcitriol NN B-noun.communication	/ : 0	ergocalcitriol NN B-noun.animal	will MD 0	be VB 0	reduced VBN B-verb.change	, , 0	higher JJR B-adj.all	doses NNS B-noun.person	of IN 0	Rocaltrol NNP B-noun.location	may MD 0	be VB B-verb.stative	necessary JJ B-adj.all	if IN 0	these DT 0	drugs NNS B-noun.artifact	are VBP 0	administered VBN B-verb.body	simultaneously RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d267.s2	There EX 0	are VBP B-verb.stative	no DT 0	clinical JJ B-adj.all	data NNS B-noun.cognition	on IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	NUROMAX NNP B-noun.group	and CC 0	other JJ 0	nondepolarizing VBG B-verb.communication	neuromuscular_blocking_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d20.s3	Administration NN B-noun.person	of IN 0	eplerenone NN 0	with IN 0	other JJ 0	CYP3A4 JJ B-adj.all	inhibitors NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	erythromycin NN B-noun.communication	500 CD 0	mg IN 0	BID NNP B-noun.group	, , 0	verapamil RB B-adv.all	240 CD 0	mg IN 0	QD NNP 0	, , 0	saquinavir NN 0	1200 CD 0	mg IN 0	TID NNP 0	, , 0	fluconazole JJ B-adj.all	200 CD 0	mg IN 0	QD NNP 0	) ) 0	resulted VBD B-verb.stative	in IN 0	increases NNS B-noun.quantity	in IN 0	Cmax NNP B-noun.location	of IN 0	eplerenone NN 0	ranging VBG B-verb.stative	from IN 0	1.4- CD 0	to TO 0	1.6- CD 0	fold NN B-noun.attribute	and CC 0	AUC NNP B-noun.group	from IN 0	2.0- CD 0	to TO 0	2.9- CD 0	fold NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d175.s21	Cardiac_Glycosides NNS B-noun.artifact	, , 0	In IN 0	a DT 0	study NN B-noun.artifact	of IN 0	young JJ B-adj.all	healthy JJ B-adj.all	male NN B-noun.person	subjects NNS B-noun.person	no DT 0	evidence NN B-noun.attribute	of IN 0	a DT 0	direct JJ B-adj.all	pharmacokinetic JJ B-adj.all	captopril NN B-noun.act	- : 0	digoxin NN B-noun.person	interaction NN B-noun.person	could MD 0	be VB 0	found VBN B-verb.possession	. . 0	. . 0
DDI-DrugBank.d74.s1	FLUOTHANE NNP 0	may MD 0	augment VB B-verb.change	the DT 0	hypotension NN 0	caused VBN B-verb.communication	by IN 0	the DT 0	ganglionic NN B-noun.person	- : 0	blocking VBG B-verb.communication	effect NN B-noun.cognition	of IN 0	tubocurarine NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d466.s1	However RB 0	, , 0	co RB 0	_ JJ 0	administration NN B-noun.time	of IN 0	fexofenadine_hydrochloride JJ 0	with IN 0	either DT 0	ketoconazole NN B-noun.location	or CC 0	erythromycin NN B-noun.person	led VBD B-verb.motion	to TO 0	increased VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	fexofenadine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d568.s31	In IN 0	addition NN 0	, , 0	steady JJ B-adj.all	state NN B-noun.state	levels NNS B-noun.state	of IN 0	racemic JJ B-adj.all	citalopram NN B-noun.person	were VBD B-verb.stative	not RB B-adv.all	significantly RB B-adv.all	different JJ B-adj.all	in IN 0	poor JJ B-adj.all	metabolizers NNS B-noun.person	and CC 0	extensive JJ B-noun.person	CYP2D6 NNP I-noun.person	metabolizers NNS I-noun.person	after IN 0	multiple JJ B-noun.person	- : 0	dose JJ B-adj.all	administration NN B-noun.time	of IN 0	citalopram NN B-noun.location	, , 0	suggesting VBG B-verb.communication	that IN 0	coadministration NN B-noun.person	, , 0	with IN 0	escitalopram NN B-noun.food	, , 0	of IN 0	a DT 0	drug NN B-noun.person	that WDT 0	inhibits VBZ B-verb.stative	CYP2D6 NNP I-verb.stative	, , 0	is VBZ B-verb.stative	unlikely JJ B-adj.all	to TO 0	have VB 0	clinically RB B-adv.all	significant JJ B-adj.all	effects NNS B-noun.phenomenon	on IN 0	escitalopram NN B-noun.artifact	metabolism NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d440.s4	Of IN 0	over IN 0	3500 CD 0	patients NNS B-noun.person	enrolled VBD B-verb.social	in IN 0	the DT 0	Ibandronate NNP B-noun.person	osteoporosis NNP I-noun.person	Treatment NNP I-noun.person	and CC 0	Prevention NNP B-noun.other	Studies NNPS I-noun.other	, , 0	15 CD B-adj.all	% NN 0	used VBN B-verb.consumption	anti NNS I-verb.consumption	- : 0	peptic JJ B-adj.all	agents NNS B-noun.person	( ( 0	primarily RB B-adv.all	H2_blockers NNS B-noun.person	and CC 0	PPIs NNP B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d191.s1	Steroids NNS B-noun.communication	enhance VBP B-verb.change	the DT 0	renal JJ B-adj.all	toxicity NN B-noun.attribute	of IN 0	edetate_calcium_disodium NN B-noun.food	in IN 0	animals NNS B-noun.animal	. . 0	7 CD B-adj.all	Edetate_calcium_disodium NN B-noun.artifact	interferes VBZ B-verb.stative	with IN 0	the DT 0	action NN B-noun.process	of IN 0	zinc_insulin JJ B-adj.all	preparations NNS B-noun.person	by IN 0	chelating VBG B-verb.cognition	the DT 0	zinc NN B-noun.person	. . 0	7 CD B-adj.all	. . 0
DDI-DrugBank.d353.s12	Vitamin_A NN B-noun.artifact	and CC 0	oral JJ B-noun.body	retinoids NNS I-noun.body	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	vitamin_A NNP B-noun.group	and/or CC 0	other JJ B-adj.all	oral JJ B-noun.body	retinoids NNS I-noun.body	with IN 0	acitretin NN B-noun.person	must MD 0	be VB 0	avoided VBN B-verb.social	because IN 0	of IN 0	the DT 0	risk NN 0	of IN 0	hypervitaminosis NN 0	A. NN 0	. . 0
DDI-DrugBank.d97.s35	Dose DT 0	reduction NN B-noun.act	of IN 0	CRIXIVAN NNP B-noun.group	to TO 0	600 CD 0	mg IN 0	every DT 0	8 CD B-adj.all	hours NNS B-noun.time	should MD 0	be VB 0	considered VBN B-verb.cognition	when WRB 0	taking VBG B-verb.cognition	delavirdine JJ 0	400 CD 0	mg IN 0	three CD 0	times NNS B-noun.event	a DT 0	day NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d533.s2	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	irbesartan NN B-noun.person	reduced VBD B-verb.change	aliskiren JJ B-adj.all	Cmax NNP B-noun.person	up IN 0	to TO 0	50 CD B-adj.all	% NN 0	after IN 0	multiple JJ B-adj.all	dosing NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d499.s13	Digoxin NNP B-noun.person	, , 0	In IN 0	a DT 0	study NN B-noun.artifact	in IN 0	12 CD B-adj.all	patients NNS B-noun.person	with IN 0	congestive JJ B-adj.all	heart NN B-noun.person	failure NN B-noun.person	where WRB 0	ketoprofen NN B-noun.person	and CC 0	digoxin NN B-noun.person	were VBD B-verb.stative	concomitantly RB B-adv.all	administered VBN B-verb.possession	, , 0	ketoprofen NN B-noun.person	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	digoxin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d531.s19	When WRB 0	coadministered VBN B-verb.communication	with IN 0	SUSTIVA NNP B-noun.group	in IN 0	treatment NN B-noun.communication	- : 0	naive JJ B-adj.all	patients NNS B-noun.person	, , 0	the DT 0	recommended VBN B-verb.communication	dose NN B-noun.quantity	of IN 0	atazanavir NN B-noun.person	is VBZ B-verb.stative	300 CD 0	mg NN B-noun.quantity	with IN 0	ritonavir NN 0	100 CD 0	mg NN B-noun.quantity	and CC 0	SUSTIVA NNP B-noun.group	600 CD 0	mg NN B-noun.quantity	( ( 0	all DT 0	once RB B-adv.all	daily JJ I-adv.all	) ) 0	. . 0	. . 0
DDI-DrugBank.d212.s18	Coadministration NN B-noun.person	of IN 0	digoxin NN B-noun.person	did VBD 0	not RB B-adv.all	influence VB B-verb.emotion	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	levetiracetam NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d531.s2	In IN B-adj.all	vitro NN I-adj.all	studies NNS B-noun.group	have VBP 0	demonstrated VBN B-verb.cognition	that IN 0	efavirenz NN B-noun.person	inhibits VBZ B-verb.stative	2C9 NNP I-verb.stative	, , 0	2C19 NNP B-noun.person	, , 0	and CC 0	3A4 JJ 0	isozymes NNS B-verb.change	in IN 0	the DT 0	range NN B-noun.location	of IN 0	observed JJ B-adj.all	efavirenz NN B-noun.person	plasma NN B-noun.person	concentrations NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d411.s8	Antidiabetic_Agents NNS B-noun.relation	( ( 0	Insulin NNP B-noun.person	, , 0	Sulfonylureas NNP B-noun.location	) ) 0	, , 0	Requirements NNP B-noun.person	for IN 0	insulin NN B-noun.possession	or CC 0	oral JJ B-adj.all	antidiabetic_agents NNS B-noun.location	may MD 0	be VB 0	reduced VBN B-verb.change	in IN 0	hypothyroid JJ B-adj.all	patients NNS B-noun.person	with IN 0	diabetes NN B-noun.person	mellitus NN B-noun.person	and CC 0	may MD 0	subsequently RB B-adv.all	increase VB B-verb.change	with IN 0	the DT 0	initiation NN B-noun.act	of IN 0	thyroid JJ B-noun.body	hormone NN I-noun.body	replacement NN B-noun.person	therapy NN B-noun.person	. . 0	. . 0
DDI-MedLine.d25.s0	Rhabdomyolysis NNP B-noun.person	secondary JJ I-noun.person	to TO 0	a DT 0	drug NN B-noun.artifact	interaction NN B-noun.act	between IN 0	simvastatin NN B-noun.person	and CC 0	clarithromycin NN B-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d175.s5	Agents NNS B-noun.person	Having VBG I-noun.person	Vasodilator NNP I-noun.person	Activity NNP I-noun.person	, , 0	Data NNP B-noun.person	on IN 0	the DT 0	effect NN B-noun.cognition	of IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	other JJ 0	vasodilators NNS B-noun.person	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.perception	captopril NN I-verb.perception	for IN 0	heart NN 0	failure NN B-noun.person	are VBP B-verb.stative	not RB B-adv.all	available JJ B-adj.all	, , 0	. . 0
DDI-MedLine.d115.s5	Antiretroviral JJ B-adj.all	regimens NNS B-noun.motive	consisted VBD B-verb.stative	of IN I-verb.stative	two CD B-adj.all	reverse_transcriptase_inhibitors NNS B-noun.person	and CC 0	one CD 0	protease_inhibitor NN B-noun.person	. . 0	. . 0
DDI-MedLine.d39.s3	The DT 0	serum NN B-noun.artifact	estrogen NN B-noun.artifact	concentrations NNS B-noun.artifact	of IN 0	estradiol NN B-noun.act	+ : 0	endotoxin NN B-noun.person	- : 0	treated VBN B-verb.communication	rats NNS B-noun.person	decreased VBN B-verb.change	by IN 0	50 CD B-adj.all	% NN 0	, , 0	while IN 0	those DT 0	of IN 0	the DT 0	endotoxin NN B-noun.person	- : 0	treated VBN B-verb.communication	rats NNS B-noun.person	increased VBD B-verb.change	( ( 0	2- UH 0	to TO 0	5-fold JJ 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d247.s7	Epinephrine NN B-noun.person	also RB B-adv.all	should MD 0	be VB 0	used VBN B-verb.consumption	cautiously RB B-adv.all	with IN 0	other JJ 0	drugs NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	digitalis NN B-noun.person	, , 0	glycosides NNS B-noun.body	) ) 0	that WDT 0	sensitize VBP B-verb.perception	the DT 0	myocardium NN B-noun.artifact	to TO 0	the DT 0	actions NNS B-noun.act	of IN 0	sympathomimetic_drugs NNS B-noun.object	. . 0	. . 0
DDI-DrugBank.d176.s14	In IN 0	a DT 0	pharmacokinetic JJ B-adj.all	interaction NN B-noun.act	study NN B-noun.artifact	with IN 0	warfarin NN B-noun.act	, , 0	bioavailability NN B-noun.plant	parameters NNS B-noun.person	, , 0	the DT 0	degree NN B-noun.communication	of IN 0	protein NN B-noun.substance	binding NN B-verb.contact	, , 0	and CC 0	the DT 0	anticoagulant JJ B-adj.all	effect NN B-noun.cognition	( ( 0	measured VBN B-verb.cognition	by IN 0	prothrombin NN B-noun.person	time NN 0	) ) 0	of IN 0	warfarin NN B-noun.act	were VBD B-verb.stative	not RB B-adv.all	significantly RB B-adv.all	changed VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d217.s10	The DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	nitrofurantoin NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	since IN 0	nitrofurantoin NN B-noun.animal	may MD 0	antagonize VB B-verb.cognition	the DT 0	antibacterial JJ B-adj.all	effect NN B-noun.cognition	of IN 0	Norfloxacin NNP B-noun.person	in IN 0	the DT 0	urinary JJ B-adj.all	tract NN B-noun.body	. . 0	. . 0
DDI-DrugBank.d506.s0	If IN 0	phenytoin NN B-noun.person	or CC 0	other JJ 0	hepatic JJ B-adj.all	enzyme NN B-noun.person	inducers NNS I-noun.person	are VBP 0	taken VBN 0	concurrently RB B-adv.all	with IN 0	Norpace NNP B-noun.person	or CC 0	Norpace_CR JJ B-adj.all	, , 0	lower JJR B-adj.all	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	disopyramide NN B-noun.location	may MD 0	occur VB B-verb.stative	. . 0	. . 0
DDI-DrugBank.d99.s2	Poor JJ B-adj.all	metabolizers NNS B-noun.person	have VBP 0	higher JJR 0	than IN 0	expected VBN B-verb.cognition	plasma NN 0	concentrations NNS 0	of IN 0	tricyclic_antidepressants NNS B-noun.person	( ( 0	TCAs NNP B-noun.other	) ) 0	when WRB 0	given VBN B-verb.possession	usual JJ B-adj.all	doses NNS B-noun.act	. . 0	. . 0
DDI-DrugBank.d277.s15	Interaction NN B-noun.act	of IN 0	GABITRIL NNP B-noun.group	with IN 0	Other NNP B-noun.person	Drugs NNP I-noun.person	, , 0	Cimetidine NNP B-noun.person	, , 0	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	cimetidine NN B-noun.phenomenon	( ( 0	800 CD 0	mg RB 0	/ JJ 0	day NN 0	) ) 0	to TO 0	patients NNS B-noun.person	taking VBG B-verb.social	tiagabine NN I-verb.social	chronically RB B-adv.all	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	tiagabine NN 0	pharmacokinetics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d237.s13	Other JJ 0	, , 0	Coadministration NNP B-noun.person	of IN 0	grapefruit NN B-noun.phenomenon	juice NN B-noun.person	with IN 0	cisapride NN B-noun.cognition	increases VBZ B-verb.change	the DT 0	bioavailability NN B-noun.cognition	of IN 0	cisapride NN B-noun.food	and CC 0	concomitant JJ B-adj.all	use NN B-noun.attribute	should MD 0	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d29.s14	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	clarithromycin NN B-noun.person	with IN 0	pimozide NN 0	is VBZ 0	contraindicated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d236.s15	Antihypertensives NNPS B-noun.person	, , 0	Amphetamines NNPS B-noun.person	may MD 0	antagonize VB B-verb.cognition	the DT 0	hypotensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	antihypertensives NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d3.s15	Nondepolarizing_Muscle_Relaxants NNS B-noun.person	, , 0	In IN 0	postmarketing VBG B-verb.communication	experience NN I-verb.communication	there RB 0	have VBP 0	been VBN 0	reports NNS B-noun.communication	of IN 0	a DT 0	possible JJ B-adj.all	interaction NN B-noun.act	between IN 0	TORADOLIV NNP 0	/ ( 0	IM NNP 0	and CC 0	nondepolarizing_muscle_relaxants NNS B-noun.person	that WDT 0	resulted VBD B-verb.stative	in IN 0	apnea NN B-noun.animal	. . 0	. . 0
DDI-DrugBank.d488.s6	Drugs NNP B-noun.person	Decreasing NNP I-noun.person	Heparin NNP I-noun.person	Effect NNP I-noun.person	, , 0	Digitalis NNP B-noun.person	, , 0	tetracyclines NNS B-noun.artifact	, , 0	nicotine NN B-noun.person	, , 0	or CC 0	antihistamines NNS B-noun.animal	may MD 0	partially RB 0	counteract VB B-verb.contact	the DT 0	anticoagulant JJ B-adj.all	action NN B-noun.state	of IN 0	heparin_sodium NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d328.s32	Coadministration NN B-noun.person	of IN 0	valdecoxib NN B-noun.attribute	( ( 0	40 CD 0	mg IN 0	BID NNP 0	( ( 0	day NN 0	1 CD 0	) ) 0	and CC 0	40 CD B-adj.all	mg NN B-noun.quantity	QD NNP 0	( ( 0	days NNS 0	2 CD 0	- : 0	7 CD 0	) ) 0	) ) 0	with IN 0	glyburide NN 0	( ( 0	5 CD 0	mg IN 0	QD NNP 0	) ) 0	did VBD 0	not RB B-adv.all	affect VB B-verb.change	either CC 0	the DT 0	pharmacokinetics NNS B-noun.person	( ( 0	exposure NN B-noun.cognition	) ) 0	or CC 0	the DT 0	pharmacodynamics NNS B-noun.person	( ( 0	blood NN B-noun.act	glucose NN I-noun.act	and CC 0	insulin NN B-noun.body	levels NNS B-noun.attribute	) ) 0	of IN 0	glyburide NN 0	. . 0	. . 0
DDI-DrugBank.d412.s6	Synergism NN B-noun.group	has VBZ 0	been VBN 0	shown VBN B-verb.creation	between IN 0	halothane NN B-noun.person	anesthesia NN B-noun.person	and CC 0	intravenously RB B-adv.all	administered VBN B-verb.possession	labetalol_HCl NN I-verb.possession	. . 0	. . 0
DDI-MedLine.d69.s5	Flavoridin NNP B-noun.person	alone RB I-noun.person	was VBD 0	found VBN B-verb.cognition	to TO 0	have VB B-verb.social	no DT 0	effect NN B-noun.cognition	on IN 0	CAS NNP 0	, , 0	but CC 0	can MD 0	completely RB B-adv.all	block VB B-verb.change	contortrostatin NN B-noun.food	- : 0	induced VBN B-verb.creation	phosphorylation NN B-noun.process	of IN 0	this DT 0	protein NN B-noun.communication	in IN 0	MDA NNP 0	- : 0	MB-435 NN B-noun.plant	cells NNS B-noun.body	. . 0	. . 0
DDI-DrugBank.d443.s6	Phenobarbital JJ B-adj.all	, , 0	Decreases VBZ B-verb.cognition	aspirin NN I-verb.cognition	effectiveness NN B-noun.cognition	by IN 0	enzyme JJ B-adj.all	induction NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d480.s28	In IN 0	addition NN 0	, , 0	certain JJ B-adj.all	drugs NNS B-noun.artifact	that WDT 0	are VBP 0	metabolized VBN B-verb.cognition	by IN 0	this DT 0	isozyme NN B-noun.attribute	, , 0	including VBG B-verb.change	many JJ 0	antidepressants NNS B-noun.person	( ( 0	clozapine NN B-noun.person	, , 0	selective_serotonin_reuptake_inhibitors NNS B-noun.person	, , 0	and CC 0	others NNS 0	) ) 0	, , 0	may MD 0	inhibit VB B-verb.change	the DT 0	activity NN B-noun.process	of IN 0	this DT 0	isozyme NN B-noun.attribute	, , 0	and CC 0	thus RB 0	may MD 0	make VB B-verb.change	normal JJ B-adj.all	metabolizers NNS B-noun.person	resemble VBP B-verb.social	poor JJ B-adj.all	metabolizers NNS B-noun.person	with IN 0	regard NN B-noun.act	to TO 0	concomitant VB B-verb.communication	therapy NN I-verb.communication	with IN 0	other JJ 0	drugs NNS B-noun.person	metabolized VBN B-verb.social	by IN 0	this DT 0	enzyme NN B-noun.cognition	system NN I-noun.cognition	, , 0	leading VBG B-verb.motion	to TO 0	drug NN 0	interaction NN 0	. . 0	. . 0
DDI-DrugBank.d345.s17	Bile_acid_binding_resins NNS B-noun.possession	may MD 0	also RB 0	interfere VB B-verb.stative	with IN 0	the DT 0	absorption NN B-noun.artifact	of IN 0	oral JJ B-adj.all	phosphate NN B-noun.artifact	supplements NNS B-noun.artifact	and CC 0	hydrocortisone NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d123.s19	Warfarin NNP B-noun.person	, , 0	Quinolones NNPS 0	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	enhance VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	the DT 0	oral JJ B-adj.all	anticoagulant JJ B-adj.all	warfarin NN B-noun.communication	or CC 0	its PRP$ 0	derivatives NNS B-noun.time	. . 0	. . 0
DDI-DrugBank.d305.s7	Administration NN B-noun.person	of IN 0	dantrolene NN B-noun.person	may MD 0	potentiate VB B-verb.cognition	vecuronium NN B-noun.person	- : 0	induced VBN B-verb.creation	neuromuscular JJ B-adj.all	block NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d237.s9	A DT 0	study NN B-noun.artifact	in IN 0	14 CD B-adj.all	normal JJ B-adj.all	male NN B-noun.person	and CC 0	female JJ B-adj.all	volunteers NNS B-noun.person	suggests VBZ B-verb.communication	that DT 0	coadministration NN B-noun.person	of IN 0	cisapride NN B-noun.food	and CC 0	ketoconazole NN B-noun.person	can MD 0	result VB B-verb.stative	in IN 0	prolongation NN 0	of IN 0	the DT 0	QT NNP 0	interval NN 0	on IN 0	the DT 0	ECG NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d334.s4	Studies NNS B-noun.person	with IN 0	ACE_inhibitors NNS B-noun.person	in IN 0	combination NN 0	with IN 0	diuretics NNS B-noun.person	indicate VBP B-verb.communication	that IN 0	the DT 0	dose NN B-noun.quantity	of IN 0	the DT 0	ACE_inhibitor NN B-noun.other	can MD 0	be VB 0	reduced VBN B-verb.change	when WRB 0	it PRP 0	is VBZ 0	given VBN B-verb.possession	with IN 0	a DT 0	diuretic JJ B-noun.person	. . 0	. . 0
DDI-DrugBank.d19.s7	Patients NNS B-noun.person	taking VBG B-verb.social	isoniazid NN I-verb.social	when WRB 0	disulfiram NN B-noun.person	is VBZ 0	given VBN B-verb.possession	should MD 0	be VB 0	observed VBN B-verb.perception	for IN 0	the DT 0	appearance NN B-noun.act	of IN 0	unsteady JJ B-adj.all	gait NN B-noun.attribute	or CC 0	marked VBN B-verb.cognition	changes NNS B-noun.artifact	in IN 0	mental JJ B-adj.all	status NN B-noun.state	, , 0	. . 0
DDI-DrugBank.d88.s3	Coumarin_Anticoagulants NNS B-noun.artifact	Altered VBN B-verb.change	coagulation NN B-noun.artifact	parameters NNS I-noun.artifact	and/or CC 0	bleeding NN B-verb.body	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	capecitabine NN B-noun.person	concomitantly RB B-adv.all	with IN 0	coumarin NN B-noun.person	- : 0	derivative_anticoagulants NNS B-noun.group	such JJ 0	as IN 0	warfarin NN B-noun.act	and CC 0	phenprocoumon NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d210.s10	Cimetidine NNP B-noun.person	, , 0	Co SYM 0	- : 0	administration NN B-noun.time	with IN 0	high JJ B-adj.all	doses NNS B-noun.attribute	of IN 0	cimetidine NN B-noun.location	[ $ 0	800 CD 0	mg NN B-noun.quantity	twice RB 0	daily RB 0	] CC 0	increased VBD B-verb.change	the DT 0	Cmax NNP B-noun.person	of IN 0	rofecoxib NN B-noun.act	by IN 0	21 CD B-adj.all	% NN 0	, , 0	the DT 0	AUC0 NN B-noun.group	- : 0	120hr JJ 0	by IN 0	23 CD B-adj.all	% NN 0	and CC 0	the DT 0	t1/2 NNP B-noun.person	by IN 0	15 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-MedLine.d51.s1	We PRP 0	investigated VBD B-verb.communication	the DT 0	effects NNS B-noun.phenomenon	of IN 0	adenosine JJ B-adj.all	receptor NN B-noun.person	antagonists NNS B-noun.person	, , 0	caffeine NN B-noun.person	, , 0	theophylline PRP 0	, , 0	8-phenyltheophylline JJ 0	, , 0	and CC 0	8-cyclopentyl-1,3-dipropylxanthine JJ 0	( ( 0	DPCPX NNP B-noun.group	) ) 0	, , 0	in IN 0	a DT 0	light NN B-noun.attribute	/ : 0	dark JJ B-adj.all	test NN B-noun.person	in IN 0	mice NNS B-noun.animal	. . 0	. . 0
DDI-DrugBank.d237.s8	Human JJ B-adj.all	pharmacokinetic JJ B-adj.all	data NNS B-noun.cognition	indicate VBP B-verb.communication	that IN 0	oral JJ B-adj.all	ketoconazole NN B-noun.person	markedly RB B-adv.all	inhibits VBZ B-verb.stative	the DT 0	metabolism NN B-noun.attribute	of IN 0	cisapride NN B-noun.location	, , 0	resulting VBG B-verb.stative	in IN 0	a DT 0	mean JJ B-adj.all	eight CD 0	- : 0	fold JJ B-adj.all	increase NN B-noun.act	in IN 0	AUC NNP 0	of IN 0	cisapride NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d21.s1	These DT 0	results NNS B-noun.communication	would MD 0	seem VB B-verb.perception	to TO 0	dictate VB B-verb.social	against IN 0	the DT 0	clinical JJ B-adj.all	use NN B-noun.process	of IN 0	methotrexate NN B-noun.food	with IN 0	ELSPAR NNP B-noun.group	, , 0	or CC 0	during IN 0	the DT 0	period NN B-noun.time	following VBG 0	ELSPAR NNP B-noun.group	therapy NN 0	when WRB 0	plasma NN B-verb.creation	asparagine NN 0	levels NNS B-noun.attribute	are VBP B-verb.stative	below IN 0	normal JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d531.s72	Anticoagulants NNS B-noun.person	, , 0	Warfarin NNP B-noun.location	. . 0
DDI-DrugBank.d69.s1	Cerubidine NN 0	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	in IN 0	patients NNS B-noun.person	who WP 0	have VBP 0	previously RB B-adv.all	received VBD B-verb.possession	the DT 0	recommended VBN B-verb.communication	maximum JJ B-adj.all	cumulative JJ B-adj.all	doses NNS B-noun.event	of IN 0	doxorubicin NN B-noun.communication	or CC 0	Cerubidine NNP B-noun.location	. . 0	. . 0
DDI-DrugBank.d60.s1	The DT 0	time NN B-noun.time	to TO 0	onset VB B-verb.communication	of IN 0	maximum NN 0	block NN 0	following VBG 0	NIMBEX NNP B-noun.group	is VBZ B-verb.stative	approximately RB B-adv.all	2 CD B-adj.all	minutes NNS B-noun.time	faster RBR B-adj.all	with IN 0	prior JJ B-adj.all	administration NN B-noun.time	of IN 0	succinylcholine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d179.s23	- : 0	Valproic_acid NN B-noun.attribute	( ( 0	e.g. UH 0	, , 0	Depakene NNP B-noun.person	) ) 0	Use NNP 0	of IN 0	sulfapyridine NN 0	with IN 0	these DT 0	medicines NNS B-noun.artifact	may MD 0	increase VB B-verb.change	the DT 0	chance NN B-noun.act	of IN 0	side JJ B-adj.all	effects NNS B-noun.phenomenon	affecting VBG B-verb.change	the DT 0	liver NN B-noun.person	. . 0
DDI-DrugBank.d413.s15	Although IN 0	a DT 0	causal NN B-noun.artifact	mechanism NN B-noun.artifact	and CC 0	a DT 0	cause NN B-noun.act	- : 0	and CC 0	- : 0	effect NN B-noun.person	relationship NN I-noun.person	have VBP 0	not RB 0	been VBN 0	established VBN B-verb.creation	, , 0	current JJ B-adj.all	evidence NN B-noun.communication	suggests VBZ B-verb.communication	that IN 0	renal JJ B-adj.all	function NN B-noun.act	should MD 0	be VB 0	monitored VBN B-verb.perception	in IN 0	patients NNS B-noun.person	on IN 0	thiazide_diuretics NNS B-noun.artifact	and CC 0	allopurinol VB B-verb.motion	even RB B-adv.all	in IN 0	the DT 0	absence NN B-noun.act	of IN 0	renal JJ B-adj.all	failure NN B-noun.person	, , 0	and CC 0	dosage NN B-noun.body	levels NNS B-noun.attribute	should MD 0	be VB B-verb.stative	even RB B-adv.all	more RBR B-adv.all	conservatively RB B-adv.all	adjusted VBN B-verb.change	in IN 0	those DT 0	patients NNS B-noun.person	on IN 0	such JJ 0	combined VBN B-verb.change	therapy NN I-verb.change	if IN 0	diminished VBN B-verb.change	renal JJ B-adj.all	function NN B-noun.act	is VBZ 0	detected VBN B-verb.perception	.. . 0	. . 0
DDI-DrugBank.d328.s39	Coadministration NN B-noun.person	with IN 0	valdecoxib NN B-noun.attribute	increased VBN B-verb.change	exposure NN B-noun.state	of IN 0	omeprazole NN B-noun.attribute	( ( 0	AUC NNP 0	) ) 0	by IN 0	46 CD 0	% NN 0	. . 0	. . 0
DDI-DrugBank.d198.s30	With IN 0	simultaneous JJ B-adj.all	dosing NN B-noun.act	of IN 0	Vardenafil NNP B-noun.communication	20 CD B-adj.all	mg NN B-noun.quantity	and CC 0	terazosin NN B-noun.communication	10 CD B-adj.all	mg NN B-noun.quantity	, , 0	2 CD 0	of IN 0	9 CD B-adj.all	subjects NNS B-noun.person	experienced VBD B-verb.perception	a DT 0	standing VBG B-verb.stative	systolic JJ B-adj.all	blood NN B-noun.act	pressure NN B-noun.act	of IN 0	less JJR B-noun.quantity	than IN 0	85 CD 0	mm NN B-noun.quantity	Hg NNP 0	. . 0	. . 0
DDI-DrugBank.d482.s14	Tell VB B-verb.communication	your PRP$ 0	doctor NN B-noun.person	if IN 0	you PRP 0	are VBP 0	taking VBG B-verb.cognition	any DT 0	of IN 0	the DT 0	following VBG 0	drugs NNS B-noun.person	, , 0	blood_thinners NNS B-noun.person	( ( 0	Coumadin NNP B-noun.location	) ) 0	other JJ 0	antidepressants NNS B-noun.person	metoprolol NN B-noun.person	antihistamines NNS I-noun.person	carbamazepine VBP B-verb.social	( ( 0	Tegretol NNP 0	) ) 0	cimetidine NN 0	( ( 0	Tagamet NNP B-noun.location	) ) 0	estrogens VBZ B-verb.social	fluoxetine NN I-verb.social	( ( 0	Prozac NNP B-noun.person	) ) 0	intraconazole NN B-noun.quantity	( ( 0	Sporanox NNP B-noun.location	) ) 0	ketoconazole NN B-noun.quantity	( ( 0	Nizoral NNP B-noun.person	) ) 0	levodopa NN B-noun.quantity	lithium NN B-noun.artifact	muscle_relaxants NNS B-noun.artifact	birth NN 0	control NN B-noun.act	pills NNS B-noun.artifact	sleeping VBG B-verb.contact	pills NNS B-noun.artifact	thyroid VBP B-verb.possession	medications NNS I-verb.possession	. . 0
DDI-DrugBank.d12.s9	Therefore RB 0	, , 0	the DT 0	combined VBN B-adj.all	use NN B-noun.process	of IN 0	lovastatin NN B-noun.feeling	with IN 0	fibrates NNS B-noun.substance	should MD 0	generally RB B-adv.all	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d340.s7	Drugs NNS B-noun.artifact	Which WDT 0	Require VBP B-verb.stative	a DT 0	Dose NNP B-noun.other	Reduction NNP I-noun.other	When NNP I-noun.other	Coadminstered NNP I-noun.other	With IN I-noun.other	VIRACEPT NNP I-noun.other	Antimycobacterial_agents NNS B-noun.event	, , 0	rifabutin NN B-noun.person	. . 0
DDI-DrugBank.d277.s24	Oral NNP B-noun.group	Contraceptives NNPS I-noun.group	, , 0	Multiple JJ 0	dose NN 0	administration NN 0	of IN 0	tiagabine NN 0	( ( 0	8 CD B-adj.all	mg NN B-noun.quantity	/ : 0	day NN B-noun.person	monotherapy NN B-noun.group	) ) 0	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	oral JJ B-adj.all	contraceptives NNS B-noun.person	in IN 0	healthy JJ B-adj.all	women NNS B-noun.person	of IN 0	childbearing VBG B-verb.competition	age NN I-verb.competition	. . 0	. . 0
DDI-DrugBank.d314.s0	Aminoglutethimide NNP B-noun.person	, , 0	Aminoglutethimide NNP B-noun.person	may MD 0	diminish VB B-verb.change	adrenal JJ B-adj.all	suppression NN B-noun.act	by IN 0	corticosteroids NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d212.s16	Coadministration NN B-noun.person	of IN 0	this DT 0	oral JJ B-adj.all	contraceptive NN B-noun.person	did VBD 0	not RB B-adv.all	influence VB B-verb.emotion	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	levetiracetam NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d222.s0	When WRB 0	atropine NN B-noun.person	and CC 0	pralidoxime NN B-noun.person	are VBP 0	used VBN B-verb.consumption	together RB B-adv.all	, , 0	the DT 0	signs NNS B-noun.communication	of IN 0	atropinization NN B-noun.act	( ( 0	flushing NN B-noun.substance	, , 0	mydriasis NN B-noun.person	, , 0	tachycardia NN B-noun.person	, , 0	dryness NN 0	of IN 0	the DT 0	mouth NN B-noun.object	and CC 0	nose NN 0	) ) 0	may MD 0	occur VB B-verb.stative	earlier JJR B-adj.all	than IN 0	might MD 0	be VB 0	expected VBN B-verb.cognition	than IN 0	when WRB 0	atropine NN B-noun.person	is VBZ 0	used VBN B-verb.consumption	alone RB 0	because IN 0	pralidoxime NN B-noun.time	may MD 0	potentiate VB B-verb.communication	the DT 0	effect NN B-noun.cognition	of IN 0	atropine NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d462.s5	Probenecid NNP B-noun.person	, , 0	The DT 0	oral JJ B-adj.all	combination NN B-noun.event	of IN 0	probenecid NN B-noun.act	before IN 0	intramuscular JJ B-adj.all	injection NN B-noun.act	of IN 0	PIPRACIL NNP B-noun.group	produces VBZ B-verb.social	an DT 0	increase NN B-noun.act	in IN 0	piperacillin NN B-noun.substance	peak NN B-noun.food	serum NN B-adj.all	level NN B-noun.attribute	of IN 0	about IN 0	30 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-MedLine.d82.s1	The DT 0	intestinal JJ B-adj.all	absorption NN B-noun.act	of IN 0	arsenate(As(V NN B-noun.location	) ) 0	) ) 0	has VBZ 0	been VBN 0	investigated VBN B-verb.communication	in IN 0	the DT 0	chick NN B-noun.food	by IN 0	means NNS B-noun.person	of IN 0	the DT 0	in IN 0	situ NN B-noun.location	ligated VBD B-verb.stative	duodenal JJ B-adj.all	loop NN 0	technique NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d434.s31	Carbamazepine NNP B-noun.person	, , 0	Carbamazepine NNP B-noun.person	causes VBZ B-verb.communication	an DT 0	approximate JJ B-noun.communication	50 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	the DT 0	clearance NN B-noun.act	of IN 0	Felbatol NNP B-noun.person	_ ( 0	at IN 0	steady JJ B-adj.all	state NN B-noun.state	and CC 0	, , 0	therefore RB B-adv.all	, , 0	the DT 0	addition NN B-noun.act	of IN 0	carbamazepine NN B-noun.phenomenon	results NNS B-noun.event	in IN 0	an DT 0	approximate JJ B-adj.all	40 CD B-adj.all	% NN 0	decrease NN B-noun.act	in IN 0	the DT 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	trough NN B-noun.act	concentrations NNS B-noun.attribute	of IN 0	Felbatol NNP B-noun.person	_ ( 0	as IN 0	compared VBN 0	to TO 0	the DT 0	same JJ B-adj.all	dose NN B-noun.quantity	of IN 0	Felbatol NNP B-noun.person	_ : 0	given VBN B-verb.possession	as IN 0	monotherapy NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d17.s21	( ( 0	Concurrent JJ 0	use NN 0	with IN 0	thiazide_diuretics NNS B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	, , 0	as IN 0	they PRP 0	may MD 0	provoke VB B-verb.creation	lithium NN B-noun.phenomenon	toxicity NN B-noun.attribute	because IN 0	of IN 0	reduced VBN B-verb.change	renal JJ B-adj.all	clearance NN B-noun.act	. . 0	) ) 0	. . 0
DDI-DrugBank.d219.s20	Although IN 0	in IN 0	vivo JJ B-adj.all	studies NNS B-noun.group	have VBP 0	not RB 0	been VBN 0	done VBN B-verb.social	to TO 0	see VB B-verb.communication	if IN 0	etodolac JJ B-adj.all	clearance NN B-noun.person	is VBZ 0	changed VBN B-verb.change	by IN 0	coadministration NN B-noun.person	of IN 0	phenylbutazone NN B-noun.person	, , 0	it PRP 0	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	that IN 0	they PRP 0	be VB 0	coadministered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d429.s7	Therefore RB 0	, , 0	close JJ B-adj.all	monitoring NN B-noun.person	of IN 0	serum NN B-noun.phenomenon	cyclosporin NN B-noun.phenomenon	level NN B-noun.attribute	is VBZ 0	recommended VBN B-verb.communication	and CC 0	, , 0	if IN 0	necessary JJ B-adj.all	, , 0	chloroquine NN 0	should MD 0	be VB 0	discontinued VBN B-verb.stative	. . 0	. . 0
DDI-DrugBank.d568.s23	Although IN 0	trough JJ B-adj.all	citalopram NN B-noun.person	plasma NN B-noun.plant	levels NNS B-noun.state	were VBD B-verb.stative	unaffected JJ B-adj.all	, , 0	given VBN B-verb.possession	the DT 0	enzyme NN B-noun.person	- : 0	inducing VBG B-verb.communication	properties NNS B-noun.attribute	of IN 0	carbamazepine NN B-noun.communication	, , 0	the DT 0	possibility NN B-noun.state	that WDT 0	carbamazepine VBP 0	might MD 0	increase VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	escitalopram NN B-noun.animal	should MD 0	be VB 0	considered VBN B-verb.cognition	if IN 0	the DT 0	two CD 0	drugs NNS B-noun.artifact	are VBP 0	coadministered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d249.s19	Benzylpenicillin NNP B-noun.person	, , 0	ampicillin NN B-noun.person	, , 0	oxacillin NN B-noun.person	, , 0	chlortetracycline NN 0	, , 0	doxycycline NN B-noun.person	, , 0	cephalothin NN 0	, , 0	erythromycin NN B-noun.person	, , 0	and CC 0	sulfamethoxazole NN B-noun.artifact	have VBP 0	no DT 0	influence NN B-noun.cognition	in IN 0	vitro NN B-noun.animal	on IN 0	the DT 0	protein NN B-noun.substance	binding NN B-verb.contact	of IN 0	diclofenac NN B-noun.food	in IN 0	human JJ B-adj.all	serum NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d219.s7	Cyclosporine NNP B-noun.person	, , 0	Digoxin NNP B-noun.person	, , 0	Methotrexate NNP B-noun.location	Lodine NNP I-noun.location	, , 0	like IN 0	other JJ 0	NSAIDs NNP B-noun.person	, , 0	through IN 0	effects NNS B-noun.phenomenon	on IN 0	renal JJ B-adj.all	prostaglandins NNS B-noun.person	, , 0	may MD 0	cause VB B-verb.communication	changes NNS B-noun.phenomenon	in IN 0	the DT 0	elimination NN B-noun.act	of IN 0	these DT 0	drugs NNS B-noun.artifact	leading VBG B-verb.stative	to TO 0	elevated JJ B-adj.all	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	cyclosporine NN B-noun.person	, , 0	digoxin NN B-noun.person	, , 0	methotrexate NN B-noun.person	, , 0	and CC 0	increased VBD B-verb.change	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d132.s8	Diflunisal NNP B-noun.person	decreased VBD B-verb.communication	the DT 0	hyperuricemic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	furosemide NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d79.s0	The DT 0	absorption NN B-noun.act	of IN 0	lymecycline NN B-noun.location	may MD 0	be VB 0	affected VBN B-verb.change	by IN 0	the DT 0	simultaneous JJ B-adj.all	administration NN B-noun.act	of IN 0	indigestion NN B-noun.act	remedies NNS B-noun.person	, , 0	iron NN B-noun.person	or CC 0	zinc NN B-noun.artifact	supplements NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d154.s11	In IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	Nalfon NNP B-noun.person	and CC 0	a DT 0	steroid NN B-noun.person	concomitantly RB B-adv.all	, , 0	any DT 0	reduction NN B-noun.act	in IN 0	steroid JJ B-adj.all	dosage NN B-noun.attribute	should MD 0	be VB B-verb.stative	gradual JJ B-adj.all	in IN 0	order NN 0	to TO 0	avoid VB B-verb.social	the DT 0	possible JJ B-adj.all	complications NNS B-noun.person	of IN 0	sudden JJ B-adj.all	steroid JJ B-adj.all	withdrawal NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d76.s1	In IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.perception	another DT 0	serotonin_reuptake_inhibitor_drug NN B-noun.person	in IN 0	combination NN 0	with IN 0	monoamine_oxidase_inhibitors NNS B-noun.person	( ( 0	MAOI NNP B-noun.group	) ) 0	, , 0	there EX 0	have VBP 0	been VBN 0	reports NNS B-noun.communication	of IN 0	serious JJ B-adj.all	, , 0	sometimes RB B-adv.all	fatal JJ B-adj.all	, , 0	reactions NNS B-noun.person	including VBG B-verb.social	hyperthermia NN I-verb.social	, , 0	rigidity NN B-noun.attribute	, , 0	myoclonus NN B-noun.person	, , 0	autonomic JJ B-adj.all	instability NN B-noun.feeling	with IN 0	possible JJ B-adj.all	rapid JJ B-noun.body	fluctuations NNS I-noun.body	of IN 0	vital JJ B-adj.all	signs NNS B-noun.communication	, , 0	and CC 0	mental JJ B-noun.body	status NN I-noun.body	changes NNS B-noun.phenomenon	that WDT 0	include VBP B-verb.stative	extreme JJ B-adj.all	agitation NN B-noun.person	progressing VBG B-verb.communication	to TO 0	delirium NN B-noun.person	and CC 0	coma NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d237.s4	Anticoagulants NNS B-noun.person	( ( 0	Oral NNP B-noun.location	) ) 0	, , 0	In IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	oral JJ B-adj.all	anticoagulants NNS B-noun.person	, , 0	the DT 0	coagulation NN B-noun.phenomenon	times NNS B-noun.event	were VBD 0	increased VBN B-verb.change	in IN 0	some DT 0	cases NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d143.s62	In IN 0	addition NN 0	to TO 0	the DT 0	interactions NNS B-noun.person	noted VBD B-verb.communication	above IN 0	, , 0	chronic NN B-noun.cognition	( ( 0	_ $ 0	2 CD B-adj.all	weeks NNS B-noun.time	) ) 0	oral JJ B-noun.group	Cordarone NNP I-noun.group	administration NN I-noun.group	impairs VBZ B-verb.change	metabolism NN B-noun.attribute	of IN 0	phenytoin NN B-noun.food	, , 0	dextromethorphan NN B-noun.person	, , 0	and CC 0	methotrexate NN B-noun.person	. . 0	. . 0
DDI-MedLine.d62.s4	Using VBG B-verb.consumption	in IN 0	situ NN 0	hybridization NN 0	, , 0	we PRP 0	observed VBD B-verb.perception	that IN 0	METH NNP B-noun.person	caused VBD B-verb.creation	a DT 0	rapid JJ B-adj.all	and CC 0	transient NN B-noun.person	dose NN B-noun.person	- : 0	dependent JJ B-adj.all	increase NN B-noun.event	in IN 0	arc PRP$ 0	mRNA JJ B-noun.attribute	level NN I-noun.attribute	in IN 0	the DT 0	striatum NN B-noun.artifact	and CC 0	cortex NN B-noun.plant	that WDT 0	was VBD 0	abolished VBN B-verb.contact	by IN 0	pretreatment NN B-noun.person	with IN 0	the DT 0	specific JJ B-adj.all	dopamine NN B-noun.attribute	D1 : 0	receptor NN B-noun.person	antagonist NN B-noun.person	SCH-23390 NN B-noun.person	but CC 0	not RB B-adv.all	by IN 0	an DT 0	atypical_neuroleptic JJ B-adj.all	clozapine NN B-noun.phenomenon	. . 0	. . 0
DDI-MedLine.d34.s8	The DT 0	lower JJR B-adj.all	rate NN B-noun.time	of IN 0	absorption NN B-noun.act	in IN 0	the DT 0	groups NNS B-noun.group	receiving VBG B-verb.competition	446 CD 0	mg NN 0	Fe NNP 0	instead RB 0	of IN 0	48 CD 0	mg NN B-noun.quantity	of IN 0	Fe NNP 0	per IN 0	kg NN 0	diet NN 0	resulted VBD B-verb.stative	in IN 0	a DT 0	decreased VBN B-verb.change	renal JJ B-adj.all	excretion NN B-noun.act	of IN 0	cobalt NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d143.s18	Amiodarone NNP B-noun.person	may MD 0	suppress VB B-verb.cognition	certain JJ B-noun.person	CYP450 JJ I-noun.person	enzymes NNS I-noun.person	, , 0	including VBG B-verb.change	CYP1A2 NNP I-verb.change	, , 0	CYP2C9 NNP B-noun.person	, , 0	CYP2D6 NNP B-noun.person	, , 0	and CC 0	CYP3A4 NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d210.s5	Patients NNS B-noun.person	taking VBG B-verb.social	low JJ I-verb.social	- : 0	dose NN B-noun.person	aspirin NN B-noun.person	plus CC 0	ibuprofen NNS B-noun.person	were VBD B-verb.stative	not RB B-adv.all	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d219.s26	However RB 0	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	exercised VBN B-verb.body	because IN 0	there EX 0	have VBP 0	been VBN B-verb.stative	a DT B-adj.all	few JJ I-adj.all	spontaneous JJ B-adj.all	reports NNS B-noun.communication	of IN 0	prolonged JJ B-adj.all	prothrombin NN B-noun.person	times NNS B-noun.event	, , 0	with IN 0	or CC 0	without IN 0	bleeding NN B-noun.act	, , 0	in IN 0	etodolac NN B-noun.act	- : 0	treated VBN B-verb.communication	patients NNS B-noun.person	receiving VBG B-verb.change	concomitant JJ B-adj.all	warfarin NN B-noun.act	therapy NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d503.s1	In IN 0	order NN 0	to TO 0	avoid VB B-verb.social	lithium NN B-noun.substance	intoxication NN I-noun.substance	, , 0	lithium NN 0	plasma NN 0	levels NNS B-noun.attribute	should MD 0	be VB 0	monitored VBN B-verb.perception	closely RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d148.s4	However RB 0	, , 0	the DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	Argatroban NNP B-noun.person	and CC 0	warfarin NN B-noun.act	( ( 0	5 CD 0	- : 0	7.5 CD 0	mg PRP$ 0	initial JJ B-adj.all	oral JJ B-adj.all	dose NN 0	followed VBN B-verb.stative	by IN 0	2.5 CD 0	- : 0	6 CD 0	mg RB 0	/ JJ 0	day NN 0	orally RB 0	for IN 0	6 CD B-adj.all	- : 0	10 CD B-adj.all	days NNS B-noun.time	) ) 0	results NNS B-noun.communication	in IN 0	prolongation NN 0	of IN 0	the DT 0	prothrombin NN B-adj.all	time NN B-noun.time	( ( 0	PT NNP 0	) ) 0	and CC 0	International NNP B-noun.other	Normalized NNP I-noun.other	Ratio NNP I-noun.other	( ( 0	INR NNP 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d335.s3	The DT 0	actions NNS B-noun.act	of IN 0	the DT 0	benzodiazepines NNS B-noun.object	may MD 0	be VB 0	potentiated VBN B-verb.communication	by IN 0	barbiturates NNS B-noun.person	, , 0	narcotics NNS B-noun.person	, , 0	phenothiazines NNS B-noun.body	, , 0	monoamine_oxidase_inhibitors NNS B-noun.person	or CC 0	other JJ 0	antidepressants NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d102.s0	Influence NN B-noun.cognition	of IN 0	estradiol NN B-noun.act	and CC 0	progesterone NN B-noun.person	on IN 0	the DT 0	sensitivity NN B-noun.time	of IN 0	rat JJ 0	thoracic JJ 0	aorta NN 0	to TO 0	noradrenaline VB B-verb.communication	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d333.s2	Effect NN 0	of IN 0	Other NNP B-noun.person	Drugs NNP I-noun.person	on IN 0	the DT 0	Pharmacokinetics NNP B-noun.person	of IN 0	Clonazepam NNP B-noun.other	, , 0	Literature NNP B-noun.person	reports NNS I-noun.person	suggest VBP B-verb.communication	that IN 0	ranitidine NN B-noun.state	, , 0	an DT 0	agent NN B-noun.person	that WDT 0	decreases VBZ B-verb.cognition	stomach NN I-verb.cognition	acidity NN B-noun.person	, , 0	does VBZ 0	not RB B-adv.all	greatly RB B-adv.all	alter VB B-verb.change	clonazepam NN B-noun.person	pharmacokinetics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d132.s25	Aspirin NNP B-noun.person	, , 0	In IN 0	normal JJ B-adj.all	volunteers NNS B-noun.person	, , 0	a DT 0	small JJ B-noun.artifact	decrease NN I-noun.artifact	in IN 0	diflunisal JJ B-adj.all	levels NNS B-noun.state	was VBD 0	observed VBN B-verb.perception	when WRB 0	multiple JJ B-adj.all	doses NNS B-noun.event	of IN 0	diflunisal NN B-noun.state	and CC 0	aspirin NN B-noun.person	were VBD 0	administered VBN B-verb.perception	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d501.s4	In IN 0	patients NNS B-noun.person	using VBG B-verb.consumption	cardiac_glycosides NNS B-noun.group	( ( 0	digoxin NN B-noun.person	and CC 0	others NNS 0	) ) 0	, , 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	calcium NN B-noun.artifact	, , 0	potassium NN B-noun.person	and CC 0	magnesium NN B-noun.person	must MD 0	be VB 0	carefully RB B-adv.all	monitored VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d77.s19	Concomitant JJ B-adj.all	use NN 0	of IN 0	tricyclic_antidepressants NNS B-noun.plant	with IN 0	drugs NNS B-noun.artifact	that WDT 0	can MD 0	inhibit VB B-verb.possession	cytochrome JJ B-noun.person	P450 NN I-noun.person	2D6 WDT 0	may MD 0	require VB B-verb.stative	lower JJR B-adj.all	doses NNS B-noun.person	than IN 0	usually RB B-adv.all	prescribed VBN B-verb.communication	for IN 0	either CC 0	the DT 0	tricyclic_antidepressant JJ B-adj.all	or CC 0	the DT 0	other JJ B-adj.all	drug NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d530.s3	Neuroleptic_Drugs NNS B-noun.artifact	; : 0	L SYM 0	- : 0	phenylalanine NN B-noun.person	may MD 0	potentiate VB B-verb.communication	the DT 0	tardive JJ B-adj.all	dyskinesia NN B-noun.object	side NN B-noun.location	reactions NNS B-noun.process	of IN 0	neuroleptic_drugs NNS B-noun.artifact	if IN 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	them PRP 0	. . 0	. . 0
DDI-DrugBank.d530.s0	Non SYM 0	- : 0	selective_monoamine_oxidase_(MAO)_inhibitors NNS B-noun.person	; : 0	including VBG B-verb.social	phenelzine_sulfate JJ I-verb.social	, , 0	tranylcypromine_sulfate NNP B-noun.person	and CC 0	pargyline NN B-noun.artifact	HC1 NN I-noun.artifact	. . 0	. . 0
DDI-DrugBank.d75.s4	An DT 0	in IN 0	vivo JJ B-adj.all	interaction NN B-noun.act	study NN B-noun.artifact	in IN 0	humans NNS B-noun.person	demonstrated VBD B-verb.cognition	that IN 0	a DT 0	single JJ B-adj.all	1 CD B-adj.all	mg NN B-noun.quantity	dose NN B-noun.quantity	of IN 0	anagrelide NN 0	administered VBN B-verb.body	concomitantly RB B-adv.all	with IN 0	a DT 0	single JJ 0	900 CD 0	mg NN B-noun.quantity	dose NN B-noun.quantity	of IN 0	aspirin NN B-noun.person	was VBD 0	generally RB B-adv.all	well RB 0	tolerated VBN 0	. . 0	. . 0
DDI-DrugBank.d228.s0	Oral JJ B-adj.all	doses NNS B-noun.event	of IN 0	Antizol NNP B-noun.person	( ( 0	10 CD B-adj.all	- : 0	20 CD 0	mg PRP 0	/ : 0	kg LS 0	) ) 0	, , 0	via IN 0	alcohol NN 0	dehydrogenase NN 0	inhibition NN 0	, , 0	significantly RB B-adv.all	reduced VBD B-verb.change	the DT 0	rate NN B-noun.time	of IN 0	elimination NN B-noun.act	of IN 0	ethanol NN 0	( ( 0	by IN 0	approximately RB B-noun.communication	40 CD B-adj.all	% NN 0	) ) 0	given VBN B-verb.possession	to TO 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	in IN 0	moderate JJ B-adj.all	doses NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d368.s3	By IN 0	decreasing VBG B-verb.change	the DT 0	gastrointestinal JJ B-adj.all	absorption NN B-noun.act	of IN 0	primidone NN B-noun.person	, , 0	DIAMOX NNP B-noun.group	may MD 0	decrease VB B-verb.cognition	serum NN B-noun.body	concentrations NNS B-noun.attribute	of IN 0	primidone NN B-noun.person	and CC 0	its PRP$ 0	metabolites NNS B-noun.time	, , 0	with IN 0	a DT 0	consequent JJ B-adj.all	possible JJ B-adj.all	decrease NN B-noun.state	in IN 0	anticonvulsant JJ B-adj.all	effect NN B-noun.cognition	. . 0	. . 0
DDI-MedLine.d119.s1	Fluvastatin NNP B-noun.person	is VBZ B-verb.stative	the DT 0	first JJ B-adj.all	synthetic_3-hydroxy-3-methylglutaryl_coenzyme_A_(HMGCoA)_reductase_inhibitor NN 0	to TO 0	be VB 0	approved VBN B-verb.communication	for IN 0	clinical JJ B-adj.all	use NN 0	, , 0	and CC 0	has VBZ 0	been VBN 0	studied VBN B-verb.cognition	extensively RB B-adv.all	in IN 0	humans NNS B-noun.person	since IN 0	1986 CD 0	. . 0	. . 0
DDI-DrugBank.d238.s18	The DT 0	extent NN B-noun.attribute	to TO 0	which WDT 0	SSRI NNP B-noun.group	- : 0	TCAinteractions NNS B-noun.group	may MD 0	pose VB B-verb.possession	clinical JJ B-adj.all	problems NNS B-noun.communication	will MD 0	depend VB B-verb.cognition	on IN 0	the DT 0	degree NN B-noun.communication	of IN 0	inhibition NN B-noun.attribute	and CC 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	the DT 0	SSRI NNP B-noun.group	involved VBD B-verb.stative	. . 0	. . 0
DDI-DrugBank.d307.s45	Calcium_Antagonists NNS B-noun.person	, , 0	After IN 0	repeated VBN B-verb.communication	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	Trileptal NNP B-noun.location	, , 0	the DT 0	AUC NNP B-noun.group	of IN 0	felodipine NN B-noun.person	was VBD 0	lowered VBN B-verb.change	by IN 0	28 CD B-adj.all	% NN 0	[ '' 0	90 CD B-adj.all	% NN 0	CI NNP 0	, , 0	20 CD B-adj.all	- : 0	33 CD 0	] CD 0	. . 0	. . 0
DDI-DrugBank.d140.s5	However RB 0	, , 0	LDL NNP B-noun.group	- : 0	C SYM 0	reduction NN B-noun.body	was VBD B-verb.stative	greater JJR B-adj.all	when WRB 0	atorvastatin NN B-noun.animal	and CC 0	colestipol NN B-noun.person	were VBD 0	coadministered VBN B-verb.communication	than IN 0	when WRB 0	either DT 0	drug NN B-noun.person	was VBD 0	given VBN B-verb.possession	alone RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d567.s11	Danazol NNP B-noun.person	, , 0	The DT 0	risk NN 0	of IN 0	myopathy JJ B-adj.all	/ CD 0	rhabdomyolysis NN B-noun.quantity	is VBZ 0	increased VBN B-verb.change	by IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	danazol NN B-noun.person	particularly RB B-adv.all	with IN 0	higher JJR B-adj.all	doses NNS B-noun.person	of IN 0	lovastatin NN B-noun.substance	( ( 0	see VB B-verb.social	WARNINGS NNS B-noun.act	, , 0	Myopathy NNP B-noun.person	/ NNP I-noun.person	Rhabdomyolysis NNP I-noun.person	) ) 0	. . 0	. . 0
DDI-DrugBank.d340.s5	Based VBN B-verb.cognition	on IN 0	known VBN B-verb.cognition	metabolic JJ B-adj.all	profiles NNS B-noun.artifact	, , 0	clinically RB B-adv.all	significant JJ B-adj.all	drug NN B-noun.person	interactions NNS I-noun.person	are VBP 0	not RB B-adv.all	expected VBN B-verb.cognition	between IN 0	VIRACEPT NNP B-noun.person	and CC 0	dapsone NN B-noun.person	, , 0	trimethoprim VBP B-verb.change	/ : 0	sulfamethoxazole NN B-noun.quantity	, , 0	clarithromycin NN B-noun.person	, , 0	erythromycin NN B-noun.person	, , 0	itraconazole NN B-noun.artifact	or CC 0	fluconazole NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d176.s15	Drug NN 0	/ '' 0	Laboratory NNP B-noun.group	Test NNP I-noun.group	Interaction NNP I-noun.group	Fosinopril NNP I-noun.group	may MD 0	cause VB B-verb.communication	a DT 0	false JJ B-adj.all	low JJ B-adj.all	measurement NN B-noun.attribute	of IN 0	serum NN B-noun.body	digoxin NN I-noun.body	levels NNS B-noun.state	with IN 0	the DT 0	Digi- NNP B-noun.person	Tab NNP I-noun.person	_ NNP I-noun.person	RIA NNP I-noun.person	Kit NNP I-noun.person	for IN 0	Digoxin NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d357.s1	Antihypertensive_Medications NNS B-noun.artifact	and CC 0	Vasodilators NNP B-noun.person	, , 0	The DT 0	following VBG 0	adverse JJ 0	events NNS 0	were VBD 0	experienced VBN B-verb.perception	more RBR B-adv.all	commonly RB B-adv.all	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	concomitant JJ B-adj.all	antihypertensive_medications NNS B-noun.attribute	or CC 0	vasodilators NNS B-noun.person	( ( 0	n UH 0	= $ 0	94 CD 0	) ) 0	compared VBN B-verb.cognition	to TO 0	patients NNS B-noun.person	not RB 0	receiving VBG B-verb.communication	these DT 0	concomitant JJ B-adj.all	drugs NNS B-noun.artifact	( ( 0	n UH 0	= $ 0	456 CD 0	) ) 0	, , 0	hypotension NN B-noun.communication	10 CD B-adj.all	% NN 0	vs NN 0	4 CD B-adj.all	% NN 0	, , 0	myocardial JJ B-adj.all	infarction NN B-noun.communication	3 CD B-adj.all	% NN 0	vs IN 0	1 CD B-adj.all	% NN 0	, , 0	serious JJ B-adj.all	pneumonia NN B-noun.communication	5 CD B-adj.all	% NN 0	vs NN B-noun.communication	3 CD B-adj.all	% NN 0	, , 0	serious JJ B-noun.body	falls VBZ B-verb.stative	9 CD B-adj.all	% NN 0	vs NN B-noun.communication	3 CD B-adj.all	% NN 0	, , 0	and CC 0	bone NN 0	and CC 0	joint JJ B-adj.all	injuries NNS B-noun.communication	6 CD B-adj.all	% NN 0	vs NN 0	2 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d565.s1	Pharmacologic JJ B-adj.pert	studies NNS B-noun.group	indicate VBP B-verb.cognition	that IN 0	there EX 0	may MD 0	be VB B-verb.stative	additive JJ B-adj.all	effects NNS B-noun.phenomenon	in IN 0	prolonging VBG B-verb.communication	AV NNP 0	conduction NN 0	when WRB 0	using VBG B-verb.consumption	beta JJ I-verb.consumption	- : 0	blockers NNS B-noun.person	or CC 0	digitalis NNS B-noun.person	concomitantly RB B-adv.all	with IN 0	Tiazac NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d562.s7	Also RB B-adv.all	, , 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	quinolones NNS B-noun.communication	with IN 0	products NNS B-noun.artifact	containing VBG B-verb.stative	iron NN B-noun.person	, , 0	multivitamins NNS B-noun.person	containing VBG B-verb.stative	zinc NN I-verb.stative	, , 0	or CC 0	Videx NNP B-noun.person	( ( 0	didanosine NN 0	) ) 0	chewable NN B-noun.communication	/ : 0	buffered VBN B-verb.creation	tablets NNS B-noun.artifact	or CC 0	the DT 0	pediatric JJ B-adj.pert	powder NN B-noun.state	for IN 0	oral JJ B-adj.all	solution NN B-noun.cognition	may MD 0	result VB B-verb.stative	in IN 0	low JJ B-adj.all	urine NN B-noun.body	levels NNS B-noun.attribute	. . 0	. . 0
DDI-MedLine.d116.s2	Rifampin NNP B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	increase VB B-verb.change	the DT 0	warfarin NN B-noun.location	requirements NNS B-noun.person	in IN 0	human JJ B-adj.all	subjects NNS B-noun.person	ingesting VBG B-verb.communication	these DT 0	agents NNS B-noun.person	simultaneously RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d525.s4	Eprosartan NNP B-noun.person	( ( 0	up IN 0	to TO 0	400 CD 0	mg IN 0	b.i.d NNP B-noun.person	. . 0	or CC 0	800 CD 0	mg IN 0	q.d NNP 0	. . 0	) ) 0	doses NNS B-noun.quantity	have VBP 0	been VBN 0	safely RB B-adv.all	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	a DT 0	thiazide_diuretic JJ 0	( ( 0	hydrochlorothiazide NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d509.s27	Alcohol NNP B-noun.person	, , 0	There EX 0	was VBD B-verb.stative	no DT 0	significant JJ B-adj.all	difference NN B-noun.cognition	between IN 0	aripiprazole NN B-noun.communication	coadministered VBN B-verb.communication	with IN 0	ethanol NN B-noun.person	and CC 0	placebo NN B-noun.plant	coadministered VBN B-verb.contact	with IN 0	ethanol NN B-noun.person	on IN 0	performance NN B-noun.act	of IN 0	gross JJ B-adj.all	motor NN B-noun.cognition	skills NNS I-noun.cognition	or CC 0	stimulus JJ B-adj.all	response NN B-noun.communication	in IN 0	healthy JJ B-adj.all	subjects NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d129.s3	n SYM 0	- : 0	dodecyl_gallate NN B-noun.group	showed VBD B-verb.communication	the DT 0	most RBS 0	potent JJ B-adj.all	inhibition NN B-noun.attribute	( ( 0	66 CD 0	% NN 0	inhibition NN B-noun.attribute	at IN 0	10 CD B-adj.all	microM NN B-noun.quantity	) ) 0	, , 0	which WDT 0	was VBD B-verb.stative	far RB B-adv.all	more RBR B-adv.all	potent JJ B-adj.all	than IN 0	that DT 0	of IN 0	crude NN 0	tannic_acid NN 0	. . 0	. . 0
DDI-DrugBank.d48.s11	H2_Blockers NNS 0	/ POS 0	Proton_Pump_Inhibitors NNS B-noun.person	, , 0	Long RB 0	- DT 0	term NN B-noun.time	suppression NN 0	of IN 0	gastric JJ B-adj.all	acid NN B-noun.act	secretion NN B-noun.act	by IN 0	H2_blockers NNS B-noun.person	or CC 0	proton_pump_inhibitors NNS B-noun.person	( ( 0	eg UH 0	, , 0	famotidine NN B-noun.person	and CC 0	omeprazole NN B-noun.attribute	) ) 0	is VBZ B-verb.stative	likely JJ B-adj.all	to TO 0	reduce VB B-verb.change	dasatinib NN B-noun.person	exposure NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d400.s13	Warfarin NNP B-noun.person	, , 0	The DT 0	effects NNS B-noun.phenomenon	of IN 0	warfarin NN B-noun.act	and CC 0	NSAIDs NNP B-noun.person	on IN 0	GI NNP 0	bleeding NN B-verb.body	are VBP B-verb.stative	synergistic JJ B-adj.all	, , 0	such JJ 0	that IN 0	users NNS B-noun.person	of IN 0	both DT 0	drugs NNS B-noun.artifact	together RB B-adv.all	have VBP 0	a DT 0	risk NN 0	of IN 0	serious JJ B-adj.all	GI NNP 0	bleeding VBG B-verb.body	higher JJR B-adj.all	than IN 0	users NNS B-noun.person	of IN 0	either DT 0	drug NN B-noun.state	alone RB 0	. . 0	. . 0
DDI-DrugBank.d382.s39	Coadministration NN B-noun.person	of IN 0	Aprepitant NNP B-noun.person	with IN 0	drugs NNS B-noun.artifact	that WDT 0	induce VBP B-verb.cognition	CYP3A4 JJ B-noun.phenomenon	activity NN B-noun.process	may MD 0	result VB B-verb.stative	in IN 0	reduced VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	and CC 0	decreased VBD B-verb.change	efficacy NN B-noun.person	of IN 0	Aprepitant NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d237.s12	Protease_Inhibitors NNS B-noun.person	, , 0	In IN 0	vitro NN B-noun.animal	data NNS I-noun.animal	indicate VBP B-verb.communication	that IN 0	indinavir NN B-noun.person	and CC 0	ritonavir NN B-noun.person	markedly RB B-adv.all	inhibit VBP B-verb.stative	the DT 0	metabolism NN B-noun.attribute	of IN 0	cisapride NN B-noun.act	which WDT 0	can MD 0	result VB B-verb.stative	in IN 0	an DT 0	increase NN B-noun.act	in IN 0	plasma NN B-noun.substance	cisapride NN 0	levels NNS B-noun.state	and CC 0	prolongation NN B-noun.act	of IN 0	the DT 0	QT NNP 0	interval NN 0	on IN 0	the DT 0	ECG NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d477.s5	Urinary_acidifying VBG B-verb.communication	agents NNS B-noun.person	decrease VB B-verb.communication	blood NN B-noun.state	levels NNS B-noun.state	and CC 0	increase VB B-verb.change	excretion NN B-noun.act	of IN 0	amphetamines NNS B-noun.animal	. . 0	. . 0
DDI-MedLine.d83.s1	Olanzapine NNP B-noun.person	, , 0	a DT 0	thienobenzodiazepine_derivative JJ 0	, , 0	is VBZ B-verb.stative	a DT 0	second_generation_(atypical)_antipsychotic_agent NN B-noun.act	which WDT 0	has VBZ 0	proven VBN B-verb.cognition	efficacy NN 0	against IN 0	the DT 0	positive JJ B-adj.all	and CC 0	negative JJ B-adj.all	symptoms NNS B-noun.relation	of IN 0	schizophrenia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d328.s33	Coadministration NN B-noun.person	of IN 0	valdecoxib NN B-noun.attribute	( ( 0	40 CD 0	mg IN 0	BID NNP 0	( ( 0	day NN 0	1 CD 0	) ) 0	and CC 0	40 CD B-adj.all	mg NN B-noun.quantity	QD NNP 0	( ( 0	days NNS 0	2 CD 0	- : 0	7 CD 0	) ) 0	) ) 0	with IN 0	glyburide NN 0	( ( 0	10 CD B-adj.all	mg NN B-noun.quantity	glyburide IN 0	BID NNP B-noun.group	) ) 0	resulted VBD B-verb.stative	in IN 0	21 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	glyburide JJ B-adj.all	AUC0 NN B-noun.group	- : 0	12 CD B-adj.all	and CC 0	a DT 0	16 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	glyburide JJ B-adj.all	Cmax NNP B-noun.person	leading VBG B-verb.motion	to TO 0	a DT 0	16 CD B-adj.all	% NN 0	decrease NN B-noun.act	in IN 0	glucose DT 0	AUC0 NN B-noun.group	- : 0	24 CD B-adj.all	. . 0	. . 0
DDI-DrugBank.d113.s0	Warfarin NNP B-noun.person	, , 0	Meclofenamate_sodium NN B-noun.person	enhances VBZ B-verb.stative	the DT 0	effect NN B-noun.cognition	of IN 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d97.s64	Calcium_Channel_Blockers NNS B-noun.person	, , 0	Dihydropyridine NNP B-noun.person	, , 0	e.g. NNP B-noun.person	, , 0	felodipine NN B-noun.person	, , 0	nifedipine NN B-noun.person	, , 0	nicardipine NN B-noun.person	. . 0
DDI-DrugBank.d143.s10	A DT 0	case NN B-noun.state	report NN B-noun.communication	of IN 0	one CD 0	patient NN B-noun.person	taking VBG B-verb.social	amiodarone JJ 0	200 CD 0	mg NN B-noun.quantity	and CC 0	indinavir NN B-noun.communication	800 CD 0	mg IN 0	three CD 0	times NNS B-noun.event	a DT 0	day NN B-noun.person	resulted VBD B-verb.communication	in IN 0	increases NNS B-noun.quantity	in IN 0	amiodarone JJ B-adj.all	concentrations NNS B-noun.person	from IN 0	0.9 CD 0	mg PRP 0	/ ( 0	L NNP 0	to TO 0	1.3 CD 0	mg IN 0	/ NNP B-noun.person	L. NNP I-noun.person	. . 0
DDI-DrugBank.d561.s1	The DT 0	possibility NN B-noun.state	of IN 0	hypotensive JJ B-adj.all	effects NNS B-noun.phenomenon	with IN 0	Lotensin NNP B-noun.person	can MD 0	be VB 0	minimized VBN B-verb.change	by IN 0	either DT 0	discontinuing VBG B-verb.communication	the DT 0	diuretic JJ B-adj.all	or CC 0	increasing VBG B-verb.change	the DT 0	salt NN 0	intake NN 0	prior RB 0	to TO 0	initiation NN B-noun.act	of IN 0	treatment NN B-noun.plant	with IN 0	Lotensin NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d72.s4	Because IN 0	busulfan NN B-noun.person	is VBZ 0	eliminated VBN B-verb.cognition	from IN 0	the DT 0	body NN B-noun.object	via IN 0	conjugation NN B-noun.person	with IN 0	glutathione NN 0	, , 0	use NN 0	of IN 0	acetaminophen NN B-noun.person	prior RB 0	to TO 0	( ( 0	72 CD 0	hours NNS 0	) ) 0	or CC 0	concurrent JJ B-adj.all	with IN 0	BUSULFEX NNP B-noun.group	may MD 0	result VB B-verb.stative	in IN 0	reduced VBN B-verb.change	busulfan JJ B-adj.all	clearance NN B-noun.person	based VBN B-verb.cognition	upon IN 0	the DT 0	known VBN B-adj.all	property NN B-noun.possession	of IN 0	acetaminophen NN B-noun.person	to TO 0	decrease VB B-verb.cognition	glutathione NN 0	levels NNS B-noun.attribute	in IN 0	the DT 0	blood NN B-noun.act	and CC 0	tissues NNS B-noun.body	. . 0	. . 0
DDI-DrugBank.d463.s0	It PRP 0	is VBZ 0	recommended VBN B-verb.communication	that IN 0	buspirone_hydrochloride NN 0	not RB B-adv.all	be VB 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	MAO_inhibitors NNS 0	Because IN 0	the DT 0	effects NNS B-noun.phenomenon	of IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	buspirone_HCl NNP B-noun.person	with IN 0	most JJS 0	other JJ 0	psychotropic_drugs NNS B-noun.artifact	have VBP 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	, , 0	the DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	buspirone_HCl NNP B-noun.person	with IN 0	other JJ 0	CNS NNP B-noun.group	- : 0	active JJ B-adj.all	drugs NNS B-noun.group	should MD 0	be VB 0	approached VBN B-verb.communication	with IN 0	caution NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d325.s8	Cyclopropane NNP B-noun.person	or CC 0	halogenated_hydrocarbon_anesthetics NNS B-noun.person	increase VBP B-verb.change	cardiac JJ 0	autonomic JJ B-adj.all	irritability NN B-noun.attribute	and CC 0	may MD 0	sensitize VB B-verb.perception	the DT 0	myocardium NN B-noun.artifact	to TO 0	the DT 0	action NN B-noun.process	of IN 0	certain JJ 0	intravenously RB B-adv.all	administered VBN B-verb.possession	catecholamines NNS B-noun.artifact	, , 0	such JJ 0	as IN 0	dopamine NN 0	. . 0	. . 0
DDI-DrugBank.d143.s20	Reported VBN B-verb.communication	examples NNS B-noun.cognition	of IN 0	this DT 0	interaction NN B-noun.act	include VBP B-verb.change	the DT 0	following NN 0	, , 0	Immunosuppressives NNP B-noun.person	, , 0	Cyclosporine NNP B-noun.person	( ( 0	CYP3A4 JJ B-adv.all	substrate NN I-adv.all	) ) 0	administered VBN B-verb.possession	in IN 0	combination NN 0	with IN 0	oral JJ B-adj.all	amiodarone NN 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	produce VB B-verb.contact	persistently RB B-adv.all	elevated VBN B-verb.social	plasma NN B-noun.person	concentrations NNS I-noun.person	of IN 0	cyclosporine NN 0	resulting VBG B-verb.stative	in IN 0	elevated JJ B-adj.all	creatinine NN B-noun.person	, , 0	despite IN 0	reduction NN B-noun.process	in IN 0	dose NN 0	of IN 0	cyclosporine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d531.s32	Other JJ 0	macrolide_antibiotics NNS B-noun.person	, , 0	such JJ 0	as IN 0	erythromycin NN B-noun.person	, , 0	have VBP 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	in IN 0	combination NN 0	with IN 0	SUSTIVA NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d511.s1	Concomitant JJ B-adj.all	treatment NN B-noun.communication	of IN 0	four CD 0	patients NNS B-noun.person	in IN 0	the DT 0	United NNP B-noun.other	Kingdom NNP I-noun.other	with IN 0	FOSCAVIR NNP B-noun.group	and CC 0	intravenous JJ B-adj.all	pentamidine NN B-noun.location	may MD 0	have VB 0	caused VBN B-verb.consumption	hypocalcemia NN I-verb.consumption	, , 0	. . 0
DDI-DrugBank.d54.s15	Tricyclic_Antidepressants NNS B-noun.person	, , 0	Use NNP B-noun.person	of IN 0	thyroid_products NNS B-noun.body	with IN 0	imipramine NN B-noun.act	and CC 0	other JJ B-adj.all	tricyclic_antidepressants NNS B-noun.group	may MD 0	increase VB B-verb.cognition	receptor NN B-noun.person	sensitivity NN B-noun.person	and CC 0	enhance VB B-verb.change	antidepressant JJ B-adj.all	activity NN B-noun.process	transient NN B-noun.artifact	cardiac JJ B-noun.artifact	arrhythmias NNS I-noun.artifact	have VBP 0	been VBN 0	observed VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d500.s2	Absorption NNP B-noun.person	of IN 0	tetracyclines NNS B-noun.phenomenon	is VBZ 0	impaired VBN B-verb.change	by IN 0	antacids NNS B-noun.substance	containing VBG B-verb.stative	aluminum NN I-verb.stative	, , 0	calcium NN B-noun.person	, , 0	or CC 0	magnesium NN B-noun.person	, , 0	and CC 0	iron NN B-noun.person	- : 0	containing VBG B-verb.stative	preparations NNS B-noun.substance	. . 0	. . 0
DDI-DrugBank.d291.s0	When WRB 0	Bezalip NNP B-noun.person	or CC 0	Bezalip_retard NN B-noun.substance	is VBZ 0	used VBN B-verb.consumption	at IN 0	the DT 0	same JJ B-adj.all	time NN B-noun.group	as IN 0	other JJ 0	medicines NNS B-noun.substance	or CC 0	substances NNS B-noun.substance	the DT 0	following JJ B-adj.all	interactions NNS B-noun.person	must MD 0	be VB 0	taken VBN B-verb.social	into IN 0	account NN 0	, , 0	; : 0	Bezalip NNP B-noun.person	and CC 0	Bezalip_retard NNP B-noun.person	may MD 0	enhance VB B-verb.change	the DT 0	action NN B-noun.process	of IN 0	anticoagulants_of_the_coumarin_type NNP B-noun.person	. . 0	. . 0
DDI-MedLine.d83.s18	CONCLUSIONS NNS B-noun.artifact	, , 0	Olanzapine NNP B-noun.person	demonstrated VBD B-verb.cognition	superior JJ B-adj.all	antipsychotic JJ B-adj.all	efficacy NN B-noun.phenomenon	compared VBN B-verb.cognition	with IN 0	haloperidol NN B-noun.person	in IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	acute JJ B-adj.all	phase NN B-noun.person	schizophrenia NN B-noun.person	, , 0	and CC 0	in IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	some DT 0	patients NNS B-noun.person	with IN 0	first JJ B-noun.person	- : 0	episode NN B-noun.communication	or CC 0	treatment NN B-noun.communication	- : 0	resistant JJ B-adj.all	schizophrenia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d238.s3	Close JJ B-adj.all	supervision NN B-noun.artifact	and CC 0	careful JJ B-adj.all	adjustment NN B-noun.act	of IN 0	dosage NN B-noun.act	are VBP 0	required VBN B-verb.stative	when WRB 0	Anafranil NNP B-noun.person	is VBZ 0	administered VBN B-verb.possession	with IN 0	anticholinergic JJ B-adj.all	or CC 0	sympathomimetic_drugs NNS B-noun.body	. . 0	. . 0
DDI-DrugBank.d236.s17	Ethosuximide NNP B-noun.person	, , 0	Amphetamines NNPS B-noun.person	may MD 0	delay VB B-verb.stative	intestinal JJ B-adj.all	absorption NN B-noun.act	of IN 0	ethosuximide NN 0	. . 0	. . 0
DDI-DrugBank.d76.s8	Increased VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	terfenadine NN B-noun.artifact	, , 0	astemizole NN B-noun.location	, , 0	and CC 0	cisapride JJ B-adj.all	cause NN B-noun.act	QT NNP 0	prolongation NN 0	and CC 0	have VBP 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	torsades NNS B-noun.person	de IN 0	pointes NNS B-noun.time	- : 0	type NN B-noun.person	ventricular JJ B-adj.all	tachycardia NN B-noun.location	, , 0	sometimes RB B-adv.all	fatal JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d179.s18	- : 0	Naltrexone NN B-noun.person	( ( 0	e.g. UH 0	, , 0	Trexan NNP B-noun.location	) ) 0	( ( 0	with IN 0	long JJ B-noun.body	- : 0	term NN B-noun.time	, , 0	high JJ B-noun.group	- : 0	dose NN 0	use NN 0	) ) 0	or CC 0	. . 0
DDI-DrugBank.d211.s5	Probenecid NNP B-noun.person	, , 0	May MD 0	decrease VB B-verb.change	renal JJ B-adj.all	tubular JJ B-adj.all	secretion NN B-noun.act	of IN 0	ampicillin NN B-noun.substance	resulting VBG B-verb.stative	in IN 0	increased VBN B-verb.change	blood NN B-noun.body	levels NNS B-noun.state	and/or CC 0	ampicillin JJ B-adj.all	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d187.s13	Valproate NNP B-noun.person	, , 0	A DT 0	recent JJ B-noun.artifact	case NN I-noun.artifact	study NN B-noun.artifact	has VBZ 0	shown VBN B-verb.perception	a DT 0	possible JJ B-adj.all	increase NN B-noun.act	in IN 0	the DT 0	plasma NN B-noun.plant	level NN B-noun.state	of IN 0	valproate NN B-noun.attribute	when WRB 0	co RB 0	administered VBN B-verb.possession	with IN 0	isoniazid NN B-noun.feeling	. . 0	. . 0
DDI-DrugBank.d5.s21	Administration NN B-noun.person	of IN 0	WELLBUTRIN NNP B-noun.person	Tablets NNS I-noun.person	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.communication	either DT 0	levodopa NN B-noun.state	or CC 0	amantadine VB B-verb.social	concurrently RB B-adv.all	should MD 0	be VB 0	undertaken VBN B-verb.cognition	with IN 0	caution NN B-noun.cognition	, , 0	using VBG B-verb.consumption	small JJ B-adj.all	initial JJ B-adj.all	doses NNS B-noun.possession	and CC 0	small JJ B-adj.all	gradual JJ B-adj.all	dose NN B-noun.act	increases NNS B-noun.event	. . 0	. . 0
DDI-MedLine.d125.s2	Rat NNP B-noun.person	kidney NN I-noun.person	homogenates NNS B-noun.person	supplemented VBN B-verb.social	with IN 0	coenzyme NN B-noun.person	A NNP 0	, , 0	ATP NNP 0	, , 0	oxaloacetate NN B-noun.person	, , 0	and CC 0	Mg2 : 0	+ PRP 0	converted VBD B-verb.change	1,3-difluoroacetone JJ 0	to TO 0	( ( 0	-)-erythro UH 0	- : 0	fluorocitrate NN B-noun.person	in IN 0	vitro NN B-noun.animal	. . 0	. . 0
DDI-DrugBank.d260.s0	Probenecid NNP B-noun.person	, , 0	Probenecid NNP B-noun.person	is VBZ 0	known VBN B-verb.cognition	to TO 0	interact VB B-verb.contact	with IN 0	the DT 0	metabolism NN B-noun.artifact	or CC 0	renal JJ B-adj.all	tubular JJ B-adj.all	excretion NN B-noun.act	of IN 0	many JJ 0	drugs NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	acetaminophen NN B-noun.person	, , 0	acyclovir NN B-noun.person	, , 0	angiotensin NN B-noun.person	- : 0	converting_enzyme_inhibitors NNS B-noun.person	, , 0	aminosalicylic_acid JJ 0	, , 0	barbiturates NNS B-noun.person	, , 0	benzodiazepines NNS B-noun.person	, , 0	bumetanide NN 0	, , 0	clofibrate NN B-noun.person	, , 0	methotrexate NN B-noun.person	, , 0	famotidine NN 0	, , 0	furosemide RB 0	, , 0	nonsteroidal_anti JJ 0	- : 0	inflammatory JJ B-adj.all	agents NNS B-noun.person	, , 0	theophylline PRP 0	, , 0	and CC 0	zidovudine NN B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d225.s0	Immediate NNP B-noun.person	and CC 0	Extended NNP B-noun.other	Release NNP I-noun.other	Tablets NNPS I-noun.other	The DT 0	hypoglycemic JJ B-adj.all	action NN B-noun.state	of IN 0	sulfonylureas NNS B-noun.location	may MD 0	be VB 0	potentiated VBN B-verb.communication	by IN 0	certain JJ B-adj.all	drugs NNS B-noun.artifact	including VBG B-verb.stative	nonsteroidal_anti JJ I-verb.stative	- : 0	inflammatory_agents NNS B-noun.person	, , 0	some DT 0	azoles NNS B-noun.artifact	and CC 0	other JJ B-adj.all	drugs NNS B-noun.artifact	that WDT 0	are VBP B-verb.stative	highly RB B-adv.all	protein VBP 0	bound VBN B-verb.contact	, , 0	salicylates NNS B-noun.person	, , 0	sulfonamides VBZ B-verb.motion	, , 0	chloramphenicol NN B-noun.person	, , 0	probenecid NN B-noun.person	, , 0	coumarins NNS B-noun.person	, , 0	monoamine_oxidase_inhibitors NNS B-noun.person	, , 0	and CC 0	beta_adrenergic_blocking_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d362.s5	Therefore RB 0	, , 0	ketoconazole NN B-noun.group	should MD 0	be VB 0	administered VBN B-verb.possession	with IN 0	caution NN B-noun.feeling	with IN 0	intranasal JJ B-adj.all	ciclesonide NN B-noun.location	. . 0	. . 0
DDI-MedLine.d61.s3	The DT 0	pharmacokinetic JJ B-adj.all	variables NNS B-noun.cognition	for IN 0	digoxin NN B-noun.person	were VBD 0	determined VBN B-verb.communication	after IN 0	a DT 0	1.0 CD 0	mg DT 0	intravenous JJ B-adj.all	dose NN B-noun.event	of IN 0	digoxin NN B-noun.food	in IN 0	each DT 0	subject NN B-noun.artifact	, , 0	before RB 0	and CC 0	after IN 0	oral JJ B-adj.all	amiodarone NN 0	, , 0	400 CD 0	mg NN B-noun.quantity	daily RB B-adv.all	for IN 0	3 CD B-adj.all	weeks NNS B-noun.time	. . 0	. . 0
DDI-DrugBank.d31.s2	Profound JJ B-adj.all	hypotensive JJ B-adj.all	episodes NNS B-noun.communication	may MD 0	occur VB B-verb.cognition	when WRB 0	diazoxide NN B-noun.animal	infection NN I-noun.animal	and CC 0	hydralazine NN B-noun.person	are VBP 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d488.s0	Drug NN B-noun.person	Interactions NNS I-noun.person	, , 0	a. NN 0	Drugs NNP B-noun.person	Enhancing NNP I-noun.person	Heparin NNP I-noun.person	Effect NNP I-noun.person	, , 0	Oral JJ B-noun.body	anticoagulants NNS I-noun.body	, , 0	Heparin_sodium NNP B-noun.person	may MD 0	prolong VB B-verb.stative	the DT 0	one CD 0	- : 0	stage NN 0	prothrombin NN 0	time NN 0	. . 0	. . 0
DDI-DrugBank.d231.s4	Furosemide RB 0	has VBZ B-verb.possession	a DT 0	tendency NN B-noun.attribute	to TO 0	antagonize VB B-verb.cognition	the DT 0	skeletal JJ B-adj.pert	muscle NN B-noun.body	relaxing VBG B-verb.stative	effect NN 0	of IN 0	tubocurarine NN B-noun.act	and CC 0	may MD 0	potentiate VB B-verb.communication	the DT 0	action NN B-noun.process	of IN 0	succinylcholine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d79.s0	If IN 0	taken VBN B-verb.consumption	1 CD 0	hour NN 0	before IN 0	indinavir NN B-noun.time	( ( 0	IDV NNP 0	) ) 0	, , 0	didanosine NN B-noun.person	does VBZ 0	not RB B-adv.all	affect VB B-verb.change	IDV NNP 0	exposure NN B-noun.communication	, , 0	despite IN 0	persistent JJ B-noun.possession	buffering NN I-noun.possession	effects NNS B-noun.phenomenon	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d434.s27	The DT 0	ratios NNS B-noun.time	of IN 0	the DT 0	AUCs NNP B-noun.group	of IN 0	unbound JJ B-adj.all	valproate NN B-noun.attribute	to TO 0	the DT 0	AUCs NNP B-noun.group	of IN 0	the DT 0	total JJ B-adj.all	valproate NN B-noun.possession	were VBD B-verb.stative	11.1 CD 0	% NN 0	, , 0	13.0 CD 0	% NN 0	, , 0	and CC 0	11.5 CD 0	% NN 0	, , 0	with IN 0	coadministration NN B-noun.person	of IN 0	0 CD B-noun.quantity	, , 0	1200 CD 0	, , 0	and CC 0	2400 CD 0	mg RB 0	/ JJ 0	day NN 0	of IN 0	Felbatol NNP B-noun.person	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d387.s1	Antihistamines NNS B-noun.animal	may MD 0	partially RB 0	counteract VB B-verb.contact	the DT 0	anticoagulation NN B-noun.location	effects NNS B-noun.phenomenon	of IN 0	heparin NN B-noun.state	or CC 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-MedLine.d106.s9	It PRP 0	is VBZ 0	concluded VBN B-verb.cognition	that IN 0	chloral_hydrate NNP B-noun.person	and CC 0	methaqualone NN B-noun.person	may MD 0	be VB 0	administered VBN B-verb.possession	safely RB B-adv.all	without IN 0	additional JJ B-adj.all	caution NN B-noun.cognition	in IN 0	prothrombin NN 0	test NN 0	monitoring NN B-verb.perception	during IN 0	oral JJ B-adj.all	anticoagulant JJ B-adj.all	therapy NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d175.s20	If IN 0	a DT 0	diuretic JJ B-noun.person	is VBZ B-verb.stative	also RB B-adv.all	used VBN B-verb.consumption	, , 0	it PRP 0	may MD 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	lithium NN B-noun.phenomenon	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d412.s16	Labetalol_HCl NN B-noun.group	has VBZ 0	also RB B-adv.all	been VBN 0	reported VBN B-verb.communication	to TO 0	produce VB B-verb.creation	a DT 0	false JJ B-adj.all	positive JJ B-adj.all	test NN B-noun.communication	for IN 0	amphetamine NN B-noun.person	when WRB 0	screening VBG B-verb.perception	urine NN I-verb.perception	for IN 0	the DT 0	presence NN B-noun.person	of IN 0	drugs NNS B-noun.animal	using VBG B-verb.consumption	the DT 0	commercially RB B-adj.all	available JJ B-adj.all	assay NN B-noun.person	methods NNS B-noun.person	Toxi NNP B-noun.person	- : 0	Lab NNP B-noun.person	A NNP I-noun.person	_ , 0	( ( 0	thin JJ 0	- : 0	layer NN B-verb.creation	chromatographic JJ B-adj.all	assay NN B-noun.cognition	) ) 0	and CC 0	Emit NNP B-noun.person	- : 0	d.a.u JJ 0	. . 0	_ : 0	( ( 0	radioenzymatic JJ B-adj.all	assay NN B-noun.cognition	) ) 0	. . 0	. . 0
DDI-DrugBank.d345.s6	However RB 0	, , 0	in IN 0	a DT 0	follow NN B-noun.person	- : 0	up IN 0	study NN B-noun.act	in IN 0	normal JJ B-adj.all	subjects NNS B-noun.person	, , 0	single JJ B-adj.all	- : 0	dose JJ B-adj.all	administration NN B-noun.time	of IN 0	colestipol_hydrochloride JJ 0	and CC 0	propranolol NN B-noun.person	and CC 0	twice RB B-adv.all	- : 0	a SYM 0	- : 0	day NN B-noun.person	administration NN B-noun.person	for IN 0	5 CD B-adj.all	days NNS B-noun.act	of IN 0	both DT 0	agents NNS B-noun.person	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	extent NN B-noun.attribute	of IN 0	propranolol NN B-noun.substance	absorption NN B-noun.artifact	, , 0	but CC 0	had VBD 0	a DT 0	small JJ 0	yet RB 0	statistically RB B-adv.all	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	its PRP$ 0	rate NN B-noun.time	of IN 0	absorption NN B-noun.artifact	, , 0	. . 0
DDI-DrugBank.d284.s0	If IN 0	additional JJ B-adj.all	adrenergic_drugs NNS B-noun.act	are VBP B-verb.stative	to TO 0	be VB 0	administered VBN B-verb.possession	by IN 0	any DT 0	route NN B-noun.location	, , 0	they PRP 0	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	caution NN B-noun.act	because IN 0	the DT 0	pharmacologically RB B-adv.all	predictable JJ B-adj.all	sympathetic JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	BROVANA NNP B-noun.group	may MD 0	be VB 0	potentiated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d493.s0	Methotrexate NNP B-noun.person	, , 0	HUMIRA NNP B-noun.group	has VBZ 0	been VBN 0	studied VBN B-verb.cognition	in IN 0	rheumatoid JJ B-adj.all	arthritis NN B-noun.group	patients NNS B-noun.person	taking VBG B-verb.social	concomitant JJ B-adj.all	MTX NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d328.s0	The DT 0	drug NN B-noun.artifact	interaction NN B-noun.act	studies NNS B-noun.artifact	with IN 0	valdecoxib NN B-noun.attribute	were VBD 0	performed VBN B-verb.consumption	both DT 0	with IN 0	valdecoxib NN B-noun.attribute	and CC 0	a DT 0	rapidly RB B-adv.all	hydrolyzed VBD B-verb.communication	intravenous JJ B-adj.all	prodrug NN B-noun.communication	form NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d373.s13	The DT 0	effect NN B-noun.cognition	may MD 0	be VB 0	mediated VBN B-verb.cognition	by IN 0	the DT 0	known VBN B-adj.all	inhibition NN B-noun.attribute	of IN 0	cimetidine NN B-noun.person	on IN 0	hepatic JJ B-adj.all	cytochrome NN B-noun.person	P-450 NN I-noun.person	, , 0	the DT 0	enzyme NN B-noun.cognition	system NN I-noun.cognition	probably RB B-adv.all	responsible JJ B-adj.all	for IN 0	the DT 0	first JJ B-noun.person	- : 0	pass NN B-noun.time	metabolism NN B-noun.attribute	of IN 0	nifedipine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d195.s2	Anastrozole NNP B-noun.person	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	antipyrine NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d31.s6	Acebutolol NNP B-noun.person	, , 0	atenolol NN B-noun.person	, , 0	and CC 0	nadolol NN B-noun.person	( ( 0	low JJ 0	hepatic JJ B-adj.all	clearance NN B-noun.attribute	or CC 0	no DT 0	first JJ B-noun.person	- : 0	pass NN B-noun.person	metabolism NN B-noun.artifact	) ) 0	are VBP B-verb.stative	unlikely JJ B-adj.all	to TO 0	be VB 0	affected VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d269.s14	Inducers NNS B-noun.person	and CC 0	Inhibitors NNP B-noun.person	of IN 0	Hepatic NNP B-noun.person	Metabolism NNP I-noun.person	, , 0	Rifampin NNP B-noun.person	reduced VBD B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	carvedilol NN B-noun.act	by IN 0	about RB 0	70 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-MedLine.d29.s4	No DT 0	significant JJ B-adj.all	difference NN B-noun.cognition	was VBD 0	found VBN B-verb.possession	between IN 0	the DT 0	mean JJ B-adj.all	values NNS B-noun.attribute	of IN 0	the DT 0	volume NN B-noun.artifact	of IN 0	distribution NN B-noun.act	of IN 0	cloxacillin NN B-noun.food	with IN 0	and CC 0	without IN 0	probenecid NN B-noun.time	( ( 0	13.0 CD 0	and CC 0	12.6 CD 0	liters NNS B-noun.quantity	, , 0	respectively RB B-adv.all	) ) 0	. . 0	. . 0
DDI-DrugBank.d563.s0	Special JJ B-adj.all	consideration NN B-noun.attribute	should MD 0	be VB 0	given VBN B-verb.possession	to TO 0	the DT 0	administration NN B-noun.time	of IN 0	ETHYOL NNP B-noun.group	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	antihypertensive_medications NNS B-noun.attribute	or CC 0	other JJ B-adj.all	drugs NNS B-noun.artifact	that WDT 0	could MD 0	cause VB B-verb.communication	or CC 0	potentiate JJ B-adj.all	hypotension NN B-noun.person	. . 0	. . 0
DDI-MedLine.d18.s2	Aerosol NNP B-noun.person	particles NNS I-noun.person	of IN 0	budesonide NN B-noun.food	were VBD 0	generated VBN B-verb.communication	from IN 0	an DT 0	ethanol NN B-noun.person	solution NN B-noun.person	, , 0	dried VBD B-verb.change	, , 0	and CC 0	collected VBN B-verb.possession	by IN 0	a DT 0	cascade NN B-noun.person	impactor NN B-noun.person	for IN 0	characterization NN B-noun.act	or CC 0	by IN 0	a DT 0	liquid JJ B-adj.all	impinger NN B-noun.state	for IN 0	dissolution NN B-noun.act	experiments NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d198.s10	HIV_Protease_Inhibitors NNS B-noun.person	, , 0	Indinavir NNP B-noun.person	( ( 0	800 CD 0	mg IN 0	t.i.d NNP B-noun.person	. . 0	) ) 0	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	Vardenafil NNP B-noun.communication	10 CD B-adj.all	mg NN B-noun.quantity	resulted VBD B-verb.stative	in IN 0	a DT 0	16-fold JJ B-noun.artifact	increase NN I-noun.artifact	in IN 0	vardenafil NN 0	AUC NNP 0	, , 0	a DT 0	7-fold JJ B-adj.all	increase NN B-noun.event	in IN 0	vardenafil NNP B-noun.person	Cmax NNP I-noun.person	and CC 0	a DT 0	2-fold JJ B-adj.all	increase NN B-noun.event	in IN 0	vardenafil NN B-noun.artifact	half NN B-noun.person	- : 0	life NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d350.s6	For IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	both DT 0	therapies NNS B-noun.person	, , 0	standard JJ B-adj.all	monitoring NN B-noun.person	of IN 0	tacrolimus NN B-noun.phenomenon	blood NN B-noun.location	concentrations NNS B-noun.person	and CC 0	appropriate JJ B-adj.all	tacrolimus NN B-noun.state	dosage NN I-noun.state	adjustments NNS B-noun.person	are VBP 0	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d431.s6	Lansoprazole NNP B-noun.person	has VBZ 0	also RB B-adv.all	been VBN 0	shown VBN B-verb.perception	to TO 0	have VB B-verb.social	no DT 0	clinically RB B-adv.all	significant JJ B-adj.all	interaction NN B-noun.person	with IN 0	amoxicillin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d33.s0	Although IN 0	the DT 0	occurrence NN B-noun.state	has VBZ 0	not RB 0	been VBN 0	reported VBN B-verb.communication	with IN 0	Cefizox NNP B-noun.person	, , 0	nephrotoxicity NN B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	following VBG B-verb.stative	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	other JJ 0	cephalosporins NNS B-noun.person	and CC 0	aminoglycosides NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d42.s4	In IN 0	patients NNS B-noun.person	taking VBG B-verb.social	furosemide RB I-verb.social	, , 0	nifedipine NN B-noun.person	, , 0	diltiazem NN B-noun.person	, , 0	ACE_inhibitors NNS B-noun.person	, , 0	verapamil RB B-adv.all	, , 0	glyburide NN 0	, , 0	propranolol NN B-noun.person	, , 0	and CC 0	various JJ B-adj.all	chemotherapy NN B-noun.location	agents NNS B-noun.person	, , 0	no DT 0	effect NN B-noun.phenomenon	was VBD 0	shown VBN B-verb.perception	on IN 0	the DT 0	clearance NN B-noun.act	of IN 0	hydrodolasetron NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d395.s22	Theophylline PRP 0	- : 0	related JJ B-adj.all	adverse JJ B-adj.all	effects NNS B-noun.phenomenon	have VBP 0	occurred VBN B-verb.cognition	in IN 0	patients NNS B-noun.artifact	when WRB 0	theophylline NN 0	and CC 0	enoxacin NN B-noun.person	were VBD 0	coadministered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d565.s9	In IN 0	vitro NN B-noun.animal	, , 0	propranolol NN B-noun.person	appears VBZ B-verb.social	to TO 0	be VB 0	displaced VBN B-verb.creation	from IN 0	its PRP$ 0	binding JJ B-adj.pert	sites NNS B-noun.location	by IN 0	diltiazem NN B-noun.person	. . 0	. . 0
DDI-MedLine.d19.s4	Numerous JJ B-adj.all	drug NN B-noun.person	interactions NNS I-noun.person	are VBP B-verb.stative	possible JJ B-adj.all	with IN 0	some DT 0	anticonvulsant_agents NNS B-noun.location	, , 0	such JJ 0	as IN 0	phenobarbitone NN B-noun.person	and CC 0	phenytoin NN B-noun.person	, , 0	which WDT 0	affect VBP B-verb.change	hepatic JJ B-adj.all	microsomal JJ B-adj.all	enzyme NN B-noun.plant	systems NNS B-noun.body	. . 0	. . 0
DDI-DrugBank.d400.s1	Methotrexate NNP B-noun.person	, , 0	NSAIDs NNP B-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	competitively RB B-adv.all	inhibit VB B-verb.stative	methotrexate JJ B-adj.all	accumulation NN B-noun.person	in IN 0	rabbit NN B-noun.act	kidney NN I-noun.act	slices NNS B-noun.act	. . 0	. . 0
DDI-DrugBank.d382.s34	therefore RB B-adv.all	, , 0	coadministration NN B-noun.person	of IN 0	Aprepitant NNP B-noun.person	with IN 0	drugs NNS B-noun.artifact	that WDT 0	strongly RB B-adv.all	induce VB B-verb.cognition	CYP3A4 JJ B-noun.phenomenon	activity NN B-noun.process	( ( 0	e.g. UH 0	, , 0	rifampin NN B-noun.person	, , 0	carbamazepine NN 0	, , 0	phenytoin NN B-noun.body	) ) 0	may MD 0	result VB B-verb.stative	in IN 0	reduced VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	aprepitant NN B-noun.time	that WDT 0	may MD 0	result VB B-verb.stative	in IN 0	decreased VBN B-verb.change	efficacy NN 0	of IN 0	Aprepitant NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d380.s4	There EX 0	have VBP 0	been VBN B-verb.stative	a DT 0	number NN B-noun.quantity	of IN 0	reports NNS B-noun.artifact	in IN 0	the DT 0	post NN B-noun.act	- : 0	marketing NN B-verb.communication	experience NN B-noun.cognition	of IN 0	coma NN B-noun.person	and CC 0	death NN 0	associated VBN B-verb.cognition	with IN 0	the DT 0	concomitant JJ B-adj.all	intravenous JJ B-adj.all	misuse NN B-noun.act	of IN 0	buprenorphine NN B-noun.person	and CC 0	benzodiazepines NNS B-noun.person	by IN 0	addicts NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d272.s3	Concomitant JJ B-adj.all	use NN 0	of IN 0	bromocriptine_mesylate JJ 0	with IN 0	other JJ B-adj.all	ergot_alkaloids NNS B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d165.s20	Although IN 0	no DT 0	studies NNS B-noun.group	have VBP 0	been VBN 0	conducted VBN B-verb.communication	, , 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	Itraconazole NNP B-noun.person	and CC 0	phenytoin NN B-noun.person	may MD 0	alter VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	phenytoin NN B-noun.food	, , 0	. . 0
DDI-MedLine.d85.s14	We PRP 0	propose VBP B-verb.cognition	these DT 0	pharmacokinetic JJ B-adj.all	changes NNS B-noun.relation	to TO 0	be VB B-verb.stative	the DT 0	underlying VBG 0	mechanism NN B-noun.food	for IN 0	the DT 0	reduction NN B-noun.act	of IN 0	oral JJ B-adj.all	CCNU NNP B-noun.group	cytotoxicity NN B-noun.state	by IN 0	misonidazole NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d340.s33	VIRACEPT NNP B-noun.group	and CC 0	rifampin NN B-noun.plant	should MD 0	not RB 0	be VB 0	coadministered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d138.s3	Tricyclic_antidepressants NNS B-noun.artifact	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	blunt VB B-verb.communication	the DT 0	hypotensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	systemic JJ B-adj.all	clonidine NN B-noun.phenomenon	. . 0	It PRP 0	is VBZ B-verb.stative	not RB B-adv.all	known VBN B-verb.cognition	whether IN 0	the DT 0	concurrent JJ B-adj.all	use NN 0	of IN 0	these DT 0	agents NNS B-noun.person	with IN 0	ALPHAGAN_P NNP B-noun.person	in IN 0	humans NNS B-noun.animal	can MD 0	lead VB B-verb.cognition	to TO 0	resulting VBG B-verb.stative	interference NN 0	with IN 0	the DT 0	IOP NNP 0	lowering VBG B-verb.motion	effect NN 0	. . 0	. . 0
DDI-DrugBank.d456.s13	Patients NNS B-noun.person	taking VBG B-verb.social	warfarin NN B-noun.act	or CC 0	other JJ 0	coumarin NN B-noun.person	- : 0	derivative_anticoagulants NNS B-noun.group	should MD 0	be VB 0	monitored VBN B-verb.perception	regularly RB B-adv.all	for IN 0	changes NNS B-noun.relation	in IN 0	prothrombin NN B-adj.all	time NN B-noun.time	or CC 0	INR NNP B-noun.group	. . 0
DDI-DrugBank.d531.s40	Lopinavir NNP B-noun.person	/ POS 0	ritonavir NN B-noun.person	. . 0
DDI-DrugBank.d374.s0	Auranofin NNP B-noun.person	should MD 0	be VB 0	avoided VBN B-verb.social	by IN 0	patients NNS B-noun.person	with IN 0	a DT 0	history NN B-noun.cognition	of IN 0	serious JJ B-adj.all	reaction NN B-noun.motive	to TO 0	any DT 0	gold_medication NN B-noun.act	, , 0	including VBG B-verb.social	Solganal NNP B-noun.person	and CC 0	Myochrysine NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d198.s29	With IN 0	simultaneous JJ B-adj.all	dosing NN B-noun.act	of IN 0	Vardenafil NNP B-noun.communication	10 CD B-adj.all	mg NN B-noun.quantity	and CC 0	terazosin NN B-noun.communication	10 CD B-adj.all	mg NN B-noun.quantity	, , 0	6 CD 0	of IN 0	8 CD B-adj.all	subjects NNS B-noun.person	experienced VBD B-verb.perception	a DT 0	standing VBG B-verb.stative	systolic JJ B-adj.all	blood NN B-noun.act	pressure NN B-noun.act	of IN 0	less JJR B-noun.quantity	than IN 0	85 CD 0	mm NN B-noun.quantity	Hg NNP 0	. . 0	. . 0
DDI-DrugBank.d124.s26	Although IN 0	specific JJ B-adj.all	studies NNS B-noun.group	have VBP 0	not RB 0	been VBN 0	performed VBN B-verb.social	, , 0	coadministration NN B-noun.person	with IN 0	drugs NNS B-noun.artifact	that WDT 0	are VBP B-verb.stative	mainly RB B-adv.all	metabolized VBN B-verb.cognition	by IN 0	CYP3A4 NNP B-noun.person	( ( 0	eg UH 0	, , 0	calcium_channel_blockers NNS B-noun.person	, , 0	dapsone NN 0	, , 0	disopyramide NN 0	, , 0	quinine NN B-noun.location	, , 0	amiodarone NN 0	, , 0	quinidine NN B-noun.location	, , 0	warfarin NN B-noun.location	, , 0	tacrolimus NN B-noun.person	, , 0	cyclosporine NN B-noun.person	, , 0	ergot_derivatives NNS B-noun.person	, , 0	pimozide NN 0	, , 0	carbamazepine NN 0	, , 0	fentanyl NN B-noun.person	, , 0	alfentanyl NN B-noun.person	, , 0	alprazolam NN B-noun.person	, , 0	and CC 0	triazolam NN B-noun.act	) ) 0	may MD 0	have VB 0	elevated VBN B-verb.social	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	when WRB 0	coadministered VBN B-verb.communication	with IN 0	saquinavir NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d404.s7	Digitalis NNP B-noun.person	, , 0	Vitamin_D JJ B-adj.all	dosage NN B-noun.artifact	must MD 0	be VB 0	determined VBN B-verb.communication	with IN 0	care NN B-noun.food	in IN 0	patients NNS B-noun.person	undergoing VBG B-verb.communication	treatment NN I-verb.communication	with IN 0	digitalis NNS B-noun.food	, , 0	as IN 0	hypercalcemia NN B-noun.person	in IN 0	such JJ B-adj.all	patients NNS B-noun.person	may MD 0	precipitate VB B-verb.stative	cardiac JJ B-adj.all	arrhythmias NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d122.s3	Chloramphenicol NN 0	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	be VB B-verb.stative	antagonistic JJ B-adj.all	to TO 0	beta JJ 0	- : 0	lactam_antibiotics NNS B-noun.person	, , 0	including VBG B-verb.social	ceftazidime NN I-verb.social	, , 0	based VBN B-verb.cognition	on IN 0	in IN 0	vitro NN B-noun.animal	studies NNS I-noun.animal	and CC 0	time NN 0	kill VB B-verb.contact	curves NNS B-noun.person	with IN 0	enteric JJ B-adj.all	gram NN B-noun.person	- : 0	negative JJ B-adj.all	bacilli NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d11.s0	Drug NN B-noun.person	- : 0	Drug NN B-noun.group	Interactions NNP I-noun.group	Albuterol NNP I-noun.group	; : 0	STRATTERA NNP B-noun.group	should MD 0	be VB 0	administered VBN B-verb.possession	with IN 0	caution NN B-noun.cognition	to TO 0	patients NNS B-noun.person	being VBG 0	treated VBN B-verb.change	with IN 0	systemically RB B-adv.all	- : 0	administered VBN B-verb.communication	( ( 0	oral JJ B-adv.all	or CC 0	intravenous JJ B-adj.all	) ) 0	albuterol NN B-noun.quantity	( ( 0	or CC 0	other JJ B-adj.all	beta2_agonists NNS B-noun.location	) ) 0	because IN 0	the DT 0	action NN B-noun.process	of IN 0	albuterol NN B-noun.person	on IN 0	the DT 0	cardiovascular JJ B-adj.all	system NN B-noun.substance	can MD 0	be VB 0	potentiated VBN B-verb.change	resulting VBG B-verb.stative	in IN 0	increases NNS B-noun.quantity	in IN 0	heart NN 0	rate NN B-noun.time	and CC 0	blood NN B-noun.act	pressure NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d249.s4	Ingestion NN 0	of IN 0	diclofenac NN B-noun.person	may MD 0	increase VB B-verb.body	serum NN B-noun.body	concentrations NNS B-noun.attribute	of IN 0	digoxin NN B-noun.person	and CC 0	methotrexate NN B-noun.person	and CC 0	increase VB B-verb.change	cyclosporine VB I-verb.change	s PRP 0	nephrotoxicity NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d412.s4	Cimetidine NNP B-noun.person	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	increase VB B-verb.change	the DT 0	bioavailability NN B-noun.cognition	of IN 0	labetalol_HCl NN B-noun.group	. . 0	. . 0
DDI-DrugBank.d20.s4	ACE_Inhibitors NNS B-noun.person	and CC 0	Angiotensin_II_Receptor_Antagonists NNPS B-noun.person	( ( 0	Congestive NNP B-noun.other	Heart NNP I-noun.other	Failure NNP I-noun.other	Post NNP I-noun.other	- : 0	Myocardial JJ B-noun.other	Infarction)- NN I-noun.other	In IN I-noun.other	EPHESUS NNP I-noun.other	, , 0	3020 CD 0	( ( 0	91 CD 0	% NN 0	) ) 0	patients NNS B-noun.person	receiving VBG B-verb.change	INSPRA NNP B-noun.group	25 CD 0	to TO 0	50 CD B-adj.all	mg NN B-noun.quantity	also RB B-adv.all	received VBD B-verb.possession	ACE_inhibitors NNS B-noun.person	or CC 0	angiotensin_II_receptor_antagonists NNS B-noun.person	( ( 0	ACEI NNP B-noun.group	/ POS I-noun.group	ARB NNP I-noun.group	) ) 0	. . 0	. . 0
DDI-DrugBank.d129.s3	In IN 0	diabetic JJ B-adj.all	patients NNS B-noun.person	, , 0	the DT 0	metabolic JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	androgens NNS B-noun.animal	may MD 0	decrease VB B-verb.cognition	blood NN B-noun.act	glucose NN I-noun.act	and CC 0	therefore RB B-adv.all	, , 0	insulin NN B-noun.substance	requirements NNS B-noun.object	. . 0	. . 0
DDI-DrugBank.d373.s7	Since IN 0	there EX 0	have VBP 0	been VBN 0	isolated VBN B-verb.change	reports NNS B-noun.artifact	of IN 0	patients NNS B-noun.person	with IN 0	elevated JJ B-adj.all	digoxin NN B-noun.person	levels NNS B-noun.state	, , 0	it PRP 0	is VBZ 0	recommended VBN B-verb.communication	that IN 0	digoxin NN B-noun.state	levels NNS B-noun.state	be VB 0	monitored VBN B-verb.perception	when WRB 0	initiating VBG B-verb.communication	, , 0	adjusting NN B-verb.change	, , 0	and CC 0	discontinuing VBG B-verb.communication	nifedipine NN B-noun.person	to TO 0	avoid VB B-verb.social	possible JJ B-adj.all	over- JJ B-noun.other	or CC 0	under IN 0	- : 0	digitalization NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d485.s22	Example NN B-noun.person	inducers NNS B-noun.person	include VBP B-verb.change	aminoglutethimide IN 0	, , 0	carbamazepine NN 0	, , 0	nafcillin NN B-noun.person	, , 0	nevirapine NN B-noun.person	, , 0	phenobarbital JJ B-adj.all	, , 0	phenytoin NN B-noun.person	, , 0	and CC 0	rifamycins NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d533.s3	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	atorvastatin NN B-noun.substance	resulted VBD B-verb.stative	in IN 0	about IN 0	a DT 0	50 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	aliskiren JJ B-adj.all	Cmax NNP B-noun.person	and CC 0	AUC NNP B-noun.group	after IN 0	multiple JJ B-adj.all	dosing NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d494.s1	Using VBG B-verb.consumption	calcium_acetate JJ B-adj.all	with IN 0	digitalis_glycosides NNS B-noun.person	( ( 0	heart NN 0	medicine NN 0	) ) 0	may MD 0	cause VB B-verb.communication	hypercalcemia NN B-noun.person	( ( 0	too RB B-adv.all	much JJ B-adj.all	calcium NN B-noun.communication	in IN 0	the DT 0	blood NN B-noun.location	) ) 0	, , 0	which WDT 0	could MD 0	increase VB B-verb.change	the DT 0	chance NN B-noun.act	of IN 0	developing VBG B-verb.communication	an DT 0	irregular JJ B-adj.all	heartbeat NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d157.s1	( ( 0	See VB 0	CLINICAL NNP B-noun.group	PHARMACOLOGY NNP I-noun.group	) ) 0	Coadministration NN 0	of IN 0	Femara NNP B-noun.person	and CC 0	tamoxifen JJ B-verb.consumption	20 CD B-adj.all	mg NN B-noun.quantity	daily RB 0	resulted VBD B-verb.stative	in IN 0	a DT 0	reduction NN B-noun.act	of IN 0	letrozole NN B-noun.communication	plasma NN B-noun.plant	levels NNS B-noun.state	by IN 0	38 CD 0	% NN 0	on IN 0	average NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d527.s5	In IN 0	addition NN 0	, , 0	under IN 0	the DT 0	influence NN B-noun.cognition	of IN 0	sympatholytic JJ B-adj.all	medicinal JJ B-adj.all	products NNS B-noun.cognition	such JJ 0	as IN 0	beta NNS B-noun.person	- : 0	blockers NNS B-noun.person	, , 0	clonidine NN B-noun.person	, , 0	guanethidine NN B-noun.person	, , 0	and CC 0	reserpine NN B-noun.act	, , 0	the DT 0	signs NNS B-noun.communication	of IN 0	hypoglycemia NN B-noun.animal	may MD 0	be VB 0	reduced VBN B-verb.change	or CC 0	absent JJ B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d261.s0	Tetracycline NNP B-noun.person	, , 0	a DT 0	bacteriostatic_antibiotic JJ B-noun.other	, , 0	may MD 0	antagonize VB B-verb.cognition	the DT 0	bactericidal JJ B-adj.all	effect NN B-noun.cognition	of IN 0	penicillin NN B-noun.food	and CC 0	concurrent JJ B-adj.all	use NN 0	of IN 0	these DT 0	drugs NNS B-noun.artifact	should MD 0	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d212.s9	Valproate NNP B-noun.communication	500 CD 0	mg NN B-noun.quantity	twice RB 0	daily RB 0	did VBD 0	not RB B-adv.all	modify VB B-verb.change	the DT 0	rate NN B-noun.time	or CC 0	extent NN B-noun.attribute	of IN 0	levetiracetam NN B-noun.phenomenon	absorption NN I-noun.phenomenon	or CC 0	its PRP$ 0	plasma NN B-noun.attribute	clearance NN I-noun.attribute	or CC 0	urinary JJ B-adj.all	excretion NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d465.s0	The DT 0	vasodilating VBG B-verb.change	effects NNS B-noun.phenomenon	of IN 0	isosorbide_dinitrate NNP B-noun.other	may MD 0	be VB B-verb.stative	additive JJ B-adj.all	with IN 0	those DT 0	of IN 0	other JJ 0	vasodilators NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d190.s1	However RB 0	, , 0	since IN 0	there EX 0	is VBZ B-verb.stative	an DT 0	increased VBN B-verb.change	risk NN 0	of IN 0	bleeding VBG B-verb.body	with IN 0	Xigris NNP B-noun.person	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	employed VBN B-verb.consumption	when WRB 0	Xigris NNP B-noun.person	is VBZ 0	used VBN B-verb.consumption	with IN 0	other JJ 0	drugs NNS B-noun.artifact	that WDT 0	affect VBP B-verb.possession	hemostasis NN I-verb.possession	. . 0	. . 0
DDI-DrugBank.d565.s33	Studies NNS B-noun.person	showed VBD B-verb.communication	that IN 0	diltiazem NN B-noun.person	increased VBD B-verb.change	the DT 0	AUC NNP B-noun.group	of IN 0	midazolam NN B-noun.food	and CC 0	triazolam NN B-noun.act	by IN 0	3 CD B-adj.all	- : 0	4 CD B-adj.all	fold NN B-noun.person	and CC 0	the DT 0	Cmax NNP B-noun.person	by IN 0	2-fold JJ B-noun.artifact	, , 0	compared VBN B-verb.cognition	to TO 0	placebo VB B-verb.cognition	. . 0	. . 0
DDI-MedLine.d51.s4	However RB 0	, , 0	the DT 0	antagonism NN B-noun.attribute	of IN 0	the DT 0	theophylline NN B-noun.person	- : 0	induced VBN B-verb.creation	anxiogenic JJ B-adj.pert	effects NNS B-noun.phenomenon	by IN 0	CGS21680 NN B-noun.person	was VBD B-verb.stative	only RB B-adv.all	observed VBN B-verb.perception	in IN 0	the DT 0	time NN B-noun.time	spent VBN B-verb.stative	in IN 0	the DT 0	light JJ B-adj.all	zone NN B-noun.artifact	, , 0	and CC 0	DPCPX NNP B-noun.group	- : 0	induced VBN B-verb.creation	anxiogenic JJ B-adj.pert	effects NNS B-noun.phenomenon	were VBD B-verb.stative	neither RB 0	reversed VBN B-verb.communication	by IN 0	CGS_21680 NNP B-noun.person	nor CC 0	by IN 0	CPA NNP 0	. . 0	. . 0
DDI-DrugBank.d198.s11	It PRP 0	is VBZ 0	recommended VBN B-verb.communication	not RB B-adv.all	to TO 0	exceed VB B-verb.stative	a DT 0	single JJ B-adj.all	2.5 CD 0	mg IN 0	Vardenafil NNP B-noun.person	dose NN I-noun.person	in IN 0	a DT 0	24-hour JJ 0	period NN B-noun.time	when WRB 0	used VBN B-verb.consumption	in IN 0	combination NN 0	with IN 0	indinavir NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d216.s3	Olanzapine NNP B-noun.person	, , 0	Coadministration NNP B-noun.person	of IN 0	eszopiclone NN B-noun.communication	3 CD B-adj.all	mg NN B-noun.quantity	and CC 0	olanzapine JJ B-noun.communication	10 CD B-adj.all	mg PRP 0	produced VBD B-verb.creation	a DT 0	decrease NN B-noun.event	in IN 0	DSST NNP 0	scores NNS B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d395.s8	If IN 0	signs NNS B-noun.communication	and CC 0	symptoms NNS B-noun.communication	suggestive VBP B-verb.communication	of IN 0	digoxin NN B-noun.substance	toxicity NN B-noun.phenomenon	occur NN B-noun.event	when WRB 0	enoxacin NN B-noun.person	and CC 0	digoxin NN B-noun.person	are VBP 0	given VBN B-verb.possession	concomitantly RB B-adv.all	, , 0	physicians NNS B-noun.person	are VBP 0	advised VBN B-verb.communication	to TO 0	obtain VB B-verb.possession	serum NN B-noun.body	digoxin NN I-noun.body	levels NNS B-noun.state	and CC 0	adjust VBP B-verb.possession	digoxin NN B-noun.person	doses VBZ B-verb.body	appropriately RB B-adv.all	. . 0	. . 0
DDI-MedLine.d53.s5	Combined VBN B-verb.change	treatment NN B-noun.feeling	with IN 0	1,25(OH)2D3 JJ 0	and CC 0	TAM NNP B-noun.other	enhances VBZ B-verb.communication	the DT 0	degree NN B-noun.communication	of IN 0	apoptosis NN B-noun.person	assessed VBN B-verb.cognition	using VBG B-verb.consumption	morphological JJ B-adj.all	markers NNS B-noun.person	that WDT 0	identify VBP B-verb.cognition	chromatin NN B-noun.cognition	and CC 0	nuclear JJ B-adj.pert	matrix NN B-noun.phenomenon	protein NN I-noun.phenomenon	condensation NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d320.s2	Thus RB 0	agents NNS B-noun.person	likely JJ B-adj.all	to TO 0	be VB B-verb.stative	concomitantly RB B-adv.all	administered VBN B-verb.possession	with IN 0	Chirocaine NNP B-noun.person	that WDT 0	are VBP 0	metabolized VBN B-verb.cognition	by IN 0	this DT 0	isoenzyme JJ B-adj.all	family NN B-noun.group	may MD 0	potentially RB B-verb.possession	interact JJ B-adj.all	with IN 0	Chirocaine NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d404.s2	Phenytoin NN 0	/ '' 0	Phenobarbital NNP B-noun.other	, , 0	The DT 0	coadministration NN B-noun.person	of IN 0	phenytoin NN B-noun.substance	or CC 0	phenobarbital NN B-noun.artifact	will MD 0	not RB B-adv.all	affect VB B-verb.change	plasma NN B-verb.creation	concentrations NNS B-noun.attribute	of IN 0	vitamin_D NNP B-noun.location	, , 0	but CC 0	may MD 0	reduce VB B-verb.change	endogenous JJ B-adj.all	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	calcitriol NN B-noun.communication	/ : 0	ergocalcitriol NN B-noun.act	by IN 0	accelerating VBG B-verb.change	metabolism NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d449.s1	Nafazodone NNP B-noun.person	, , 0	fluvoxamine NN B-noun.person	, , 0	cimetidine NN B-noun.person	( ( 0	consider VB B-verb.communication	Xanax NNP B-noun.person	dose NN B-noun.event	reduction NN B-noun.process	) ) 0	. . 0	. . 0
DDI-DrugBank.d324.s3	zaleplon NN B-noun.artifact	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	ethanol NN 0	. . 0	. . 0
DDI-DrugBank.d146.s3	Response NN B-noun.communication	to TO 0	sympathomimetic_agents NNS B-noun.location	may MD 0	be VB 0	enhanced VBN B-verb.change	by IN 0	colchicine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d568.s24	Triazolam NNP B-noun.person	; : 0	Combined VBN B-verb.cognition	administration NN B-noun.person	of IN 0	racemic JJ B-adj.all	citalopram NN B-noun.cognition	( ( 0	titrated VBN 0	to TO 0	40 CD 0	mg RB 0	/ JJ 0	day NN 0	for IN 0	28 CD B-adj.all	days NNS B-noun.act	) ) 0	and CC 0	the DT 0	CYP3A4 JJ B-adj.all	substrate NN B-noun.person	triazolam NN B-noun.person	( ( 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	0.25 CD 0	mg NN B-noun.quantity	) ) 0	did VBD 0	not RB B-adv.all	significantly RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	either DT 0	citalopram NN B-noun.location	or CC 0	triazolam NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d47.s7	Although IN 0	metoclopramide NN 0	may MD 0	increase VB B-verb.change	the DT 0	bioavailability NN B-noun.cognition	of IN 0	levodopa NN B-noun.state	by IN 0	increasing VBG B-verb.change	gastric JJ B-adj.pert	emptying NN B-verb.change	, , 0	metoclopramide NN 0	may MD 0	also RB B-adv.all	adversely RB B-adv.all	affect VB B-verb.change	disease JJ B-adj.all	control NN B-noun.act	by IN 0	its PRP$ 0	dopamine NN B-noun.act	receptor NN B-noun.artifact	antagonistic JJ B-adj.all	properties NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d345.s9	Therefore RB 0	, , 0	patients NNS B-noun.person	on IN 0	propranolol NN B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	when WRB 0	COLESTID NNP B-noun.person	Tablets NNPS I-noun.person	are VBP B-verb.stative	either RB 0	added VBD B-verb.communication	or CC 0	deleted VBN B-verb.possession	from IN 0	a DT 0	therapeutic JJ B-adj.all	regimen NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d544.s5	The DT 0	following JJ B-adj.all	medications NNS B-noun.communication	have VBP 0	been VBN 0	administered VBN B-verb.possession	in IN 0	clinical JJ B-adj.all	trials NNS B-noun.person	with IN 0	Simulect NNP B-noun.person	with IN 0	no DT 0	increase NN B-noun.act	in IN 0	adverse JJ B-adj.all	reactions NNS B-noun.person	, , 0	ATG NNP 0	/ POS 0	ALG NNP B-noun.other	, , 0	azathioprine NN B-noun.person	, , 0	corticosteroids NNS B-noun.person	, , 0	cyclosporine NN B-noun.person	, , 0	mycophenolate_mofetil NNP B-noun.person	, , 0	and CC 0	muromonab NN B-noun.act	- : 0	CD3 NN 0	. . 0	. . 0
DDI-DrugBank.d179.s29	- : 0	Procainamide NN B-noun.other	( ( 0	e.g. UH 0	, , 0	Pronestyl NNP B-noun.location	) ) 0	or CC 0	. . 0
DDI-DrugBank.d285.s1	A DT 0	similar JJ B-adj.all	association NN B-noun.state	, , 0	though IN 0	less RBR B-adv.all	marked JJ B-adj.all	, , 0	has VBZ 0	been VBN 0	suggested VBN B-verb.communication	with IN 0	barbiturates NNS B-noun.artifact	, , 0	phenyl NN B-noun.person	- : 0	butazone NN 0	, , 0	phenytoin_sodium NN B-noun.artifact	, , 0	carbamazepine NN B-noun.person	and CC 0	possibly RB 0	with IN 0	griseofulvin NN B-noun.food	, , 0	ampicillin NN B-noun.person	, , 0	and CC 0	tetracyclines NNS B-noun.communication	( ( 0	72 CD 0	) ) 0	. . 0
DDI-DrugBank.d516.s4	Sucralfate NNP B-noun.person	administered VBD B-verb.possession	2 CD B-adj.all	hours NNS B-noun.artifact	before IN 0	lomefloxacin NN B-noun.person	resulted VBD B-verb.contact	in IN 0	a DT 0	slower JJR B-adj.all	absorption NN B-noun.person	( ( 0	mean VB B-verb.stative	C NNP 0	max NN 0	decreased VBN B-verb.change	by IN 0	30 CD B-adj.all	% NN 0	and CC 0	mean VB B-verb.stative	T NNP 0	max NN 0	increased VBN B-verb.change	by IN 0	1 CD B-adj.all	hour NN 0	) ) 0	and CC 0	a DT 0	lesser JJR B-adj.all	extent NN B-noun.person	of IN 0	absorption NN B-noun.process	( ( 0	mean VB B-verb.stative	AUC NNP 0	decreased VBD B-verb.change	by IN 0	approximately RB B-noun.time	25 CD B-adj.all	% NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d219.s15	Lithium NNP B-noun.person	, , 0	NSAIDs NNP B-noun.person	have VBP 0	produced VBN B-verb.creation	an DT 0	elevation NN B-noun.act	of IN 0	plasma NN B-noun.plant	lithium NN B-noun.body	levels NNS B-noun.attribute	and CC 0	a DT 0	reduction NN B-noun.act	in IN 0	renal JJ B-adj.all	lithium NN B-noun.phenomenon	clearance NN B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d562.s13	Physicians NNS B-noun.person	are VBP 0	provided VBN B-verb.communication	this DT 0	information NN B-noun.cognition	to TO 0	increase VB B-verb.change	awareness NN B-noun.cognition	of IN 0	the DT 0	potential NN B-noun.person	for IN 0	serious JJ B-adj.all	interactions NNS B-noun.motive	when WRB 0	cinoxacin NN B-noun.person	and CC 0	certain JJ B-adj.all	nonsteroidal_anti NNS B-noun.person	- : 0	inflammatory_agents NNS B-noun.person	are VBP 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d480.s20	After IN 0	14 CD B-adj.all	days NNS B-noun.time	of IN 0	co SYM 0	- : 0	administration NN B-noun.time	, , 0	mean VB B-verb.stative	trough JJ B-adj.all	concentrations NNS B-noun.attribute	of IN 0	clozapine NN B-noun.act	and CC 0	its PRP$ 0	metabolites NNS B-noun.time	, , 0	N NNP 0	- : 0	desmethylclozapine NN B-noun.person	and CC 0	clozapine_N JJ B-noun.other	- : 0	oxide NN 0	, , 0	were VBD 0	elevated VBN B-verb.social	with IN 0	fluvoxamine NN B-noun.person	by IN 0	about IN 0	three CD 0	- : 0	fold NN B-noun.person	compared VBN B-verb.change	to TO 0	baseline VB B-verb.cognition	concentrations NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d123.s5	Methotrexate NNP B-noun.person	Renal NNP I-noun.person	tubular JJ B-adj.all	transport NN B-noun.process	of IN 0	methotrexate NN B-noun.object	may MD 0	be VB 0	inhibited VBN B-verb.change	by IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	ciprofloxacin NN B-noun.person	, , 0	potentially RB B-adv.all	leading VBG B-verb.stative	to TO 0	increased VBN B-verb.change	plasma NN B-noun.substance	levels NNS B-noun.state	of IN 0	methotrexate NN B-noun.food	. . 0	. . 0
DDI-MedLine.d135.s1	Phencyclidine NN B-noun.person	( ( 0	PCP NNP 0	) ) 0	produces VBZ B-verb.creation	psychotomimetic JJ B-adj.all	effects NNS B-noun.phenomenon	in IN 0	humans NNS B-noun.animal	that IN 0	resemble JJ B-adj.all	schizophrenia NN B-noun.plant	symptoms NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d269.s3	Catecholamine SYM 0	- : 0	depleting VBG B-verb.communication	Agents NNS B-noun.person	, , 0	Patients NNPS B-noun.person	taking VBG B-verb.social	both DT 0	agents_with_b SYM 0	- : 0	blocking_properties NNS B-noun.group	and CC 0	a DT 0	drug NN B-noun.person	that WDT 0	can MD 0	deplete VB B-verb.creation	catecholamines NNS B-noun.animal	( ( 0	e.g. UH 0	, , 0	reserpine NN B-noun.person	and CC 0	monoamine_oxidase_inhibitors NNS B-noun.person	) ) 0	should MD 0	be VB 0	observed VBN B-verb.perception	closely RB B-adj.all	for IN 0	signs NNS B-noun.communication	of IN 0	hypotension NN B-noun.act	and/or CC 0	severe JJ B-adj.all	bradycardia NN B-noun.group	. . 0	. . 0
DDI-DrugBank.d270.s54	Physicians NNS B-noun.person	needing VBG 0	to TO 0	treatpatients NNS B-noun.plant	co SYM 0	- : 0	infected VBN B-verb.communication	with IN 0	tuberculosis NN B-noun.person	andusing VBG B-verb.communication	a DT 0	nevirapine NN B-noun.artifact	containing VBG B-verb.stative	regimen JJ B-adj.all	mayuse NN 0	rifabutin NN 0	instead RB 0	. . 0	. . 0
DDI-DrugBank.d350.s5	CANCIDAS NNP B-noun.group	reduced VBD B-verb.change	the DT 0	blood NN B-noun.location	AUC0 NN B-noun.person	- : 0	12 CD B-noun.quantity	of IN 0	tacrolimus NN B-noun.phenomenon	by IN 0	approximately RB B-noun.time	20 CD B-adj.all	% NN 0	, , 0	peak JJ B-adj.all	blood NN B-noun.act	concentration NN B-noun.cognition	( ( 0	Cmax NNP B-noun.person	) ) 0	by IN 0	16 CD B-adj.all	% NN 0	, , 0	and CC 0	12-hour JJ 0	blood NN B-adj.all	concentration NN B-noun.cognition	( ( 0	C12hr NNP 0	) ) 0	by IN 0	26 CD B-adj.all	% NN 0	in IN 0	healthy JJ B-adj.all	subjects NNS B-noun.person	when WRB 0	tacrolimus NN B-noun.animal	( ( 0	2 CD B-adj.all	doses NNS B-noun.quantity	of IN 0	0.1 CD 0	mg PRP 0	/ ( 0	kg RB 0	12 CD 0	hours NNS 0	apart RB 0	) ) 0	was VBD 0	administered VBN B-verb.possession	on IN 0	the DT 0	10th JJ B-adj.all	day NN B-noun.person	of IN 0	CANCIDAS NNP B-noun.communication	70 CD B-adj.all	mg NN B-noun.quantity	daily RB B-adv.all	, , 0	as IN 0	compared VBN 0	to TO 0	results NNS B-verb.weather	from IN 0	a DT 0	control NN B-noun.act	period NN B-noun.person	in IN 0	which WDT 0	tacrolimus NN B-noun.person	was VBD 0	administered VBN B-verb.perception	alone RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d247.s5	Administration NN B-noun.person	of IN 0	epinephrine NN B-noun.person	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.communication	cyclopropane NN B-noun.state	or CC 0	halogenated_hydrocarbon_general_anesthetics NNS B-noun.substance	such JJ 0	as IN 0	halothane NN 0	which WDT 0	sensitize VBP B-verb.change	the DT 0	myocardium NN B-noun.artifact	, , 0	may MD 0	induce VB B-verb.cognition	cardiac JJ B-adj.all	arrhythmia NN B-noun.person	.. . 0	. . 0
DDI-DrugBank.d236.s10	MAO_inhibitors NNS B-noun.person	, , 0	MAOI_antidepressants NNS B-noun.person	, , 0	as RB 0	well RB 0	as IN 0	a DT 0	metabolite NN B-noun.attribute	of IN 0	furazolidone NN B-noun.artifact	, , 0	slow JJ B-adj.all	amphetamine JJ B-adj.all	metabolism NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d410.s6	Vasospastic JJ B-adj.all	reactions NNS B-noun.motive	have VBP 0	been VBN 0	reported VBN B-verb.communication	with IN 0	therapeutic JJ B-adj.all	doses NNS B-noun.event	of IN 0	ergotamine NN B-noun.person	- : 0	containing VBG B-verb.communication	drugs NNS B-noun.artifact	when WRB 0	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	these DT 0	antibiotics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d318.s10	Other JJ 0	nephrotoxic JJ B-adj.all	medications NNS B-noun.artifact	, , 0	agents NNS B-noun.person	such JJ 0	as IN 0	aminoglycosides NNS B-noun.person	, , 0	cyclosporine NN B-noun.person	, , 0	and CC 0	pentamidine NN B-noun.act	may MD 0	enhance VB B-verb.change	the DT 0	potential NN B-noun.person	for IN 0	drug NN B-noun.person	- : 0	induced VBN B-verb.creation	renal JJ B-adj.all	toxicity NN B-noun.attribute	, , 0	and CC 0	should MD 0	be VB 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	only RB B-adv.all	with IN 0	great JJ B-adj.all	caution NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d360.s2	A DT 0	possible JJ B-adj.all	interaction NN B-noun.act	has VBZ 0	been VBN 0	suggested VBN B-verb.communication	with IN 0	hormonal_contraceptives NNS B-noun.artifact	and CC 0	the DT 0	herbal JJ B-adj.pert	supplement NN B-noun.feeling	St. NNP B-noun.group	Johns NNP I-noun.group	Wort NNP I-noun.group	based VBN B-verb.cognition	on IN 0	some DT 0	reports NNS B-noun.artifact	of IN 0	oral JJ B-adj.all	contraceptive NN B-noun.person	users NNS B-noun.person	experiencing VBG B-verb.communication	breakthrough NN B-noun.person	bleeding VBG B-verb.body	shortly RB B-adv.all	after IN 0	starting VBG B-verb.change	St. NNP B-noun.group	Johns NNP I-noun.group	Wort NNP I-noun.group	. . 0	. . 0
DDI-DrugBank.d364.s2	In IN 0	a DT 0	pharmacokinetic JJ B-adj.all	study NN B-noun.artifact	, , 0	40 CD B-adj.all	healthy JJ B-adj.all	female JJ B-noun.person	subjects NNS B-noun.person	received VBD B-verb.possession	fluvoxamine NN B-noun.person	in IN 0	escalating VBG B-verb.communication	doses NNS B-noun.person	from IN 0	50 CD B-adj.all	to TO 0	200 CD 0	mg NN B-noun.quantity	per IN 0	day NN B-noun.person	for IN 0	16 CD B-adj.all	days NNS B-noun.time	, , 0	with IN 0	coadministration NN B-noun.person	of IN 0	alosetron RB B-noun.communication	1 CD B-adj.all	mg NN B-noun.quantity	on IN 0	the DT 0	last JJ B-adj.all	day NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d20.s7	In IN 0	a DT 0	study NN B-noun.artifact	in IN 0	diabetics NNS B-noun.person	with IN 0	microalbuminuria NNS B-noun.group	INSPRA NNP B-noun.group	200 CD 0	mg NN B-noun.quantity	combined VBN B-verb.change	with IN 0	the DT 0	ACE_inhibitor NN B-noun.quantity	enalapril VBP B-verb.stative	10 CD B-adj.all	mg PRP 0	increased VBD B-verb.change	the DT 0	frequency NN B-noun.person	of IN 0	hyperkalemia NN 0	( ( 0	serum NN B-noun.person	potassium NN B-noun.person	_ $ 0	5.5 CD 0	mEq CD 0	/ IN 0	L NNP 0	) ) 0	from IN 0	17 CD B-adj.all	% NN 0	on IN 0	enalapril NN B-noun.artifact	alone RB 0	to TO 0	38 CD 0	% NN 0	. . 0	. . 0
DDI-DrugBank.d19.s9	In IN 0	rats NNS B-noun.animal	, , 0	simultaneous JJ B-adj.all	ingestion NN B-noun.act	of IN 0	disulfiram NN B-noun.food	and CC 0	nitrite NN B-noun.person	in IN 0	the DT 0	diet NN B-noun.person	for IN 0	78 CD B-adj.all	weeks NNS B-noun.time	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	cause VB B-verb.communication	tumors NNS B-noun.person	, , 0	and CC 0	it PRP 0	has VBZ 0	been VBN 0	suggested VBN B-verb.communication	that DT 0	disulfiram NN B-noun.person	may MD 0	react VB B-verb.emotion	with IN 0	nitrites NNS B-noun.person	in IN 0	the DT 0	rat NN 0	stomach NN 0	to TO 0	form VB B-verb.creation	a DT 0	nitrosamine NN B-noun.person	, , 0	which WDT 0	is VBZ B-verb.stative	tumorigenic JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d352.s0	Antidiabetic_drug JJ B-adj.all	requirements NNS B-noun.object	( ( 0	i.e. FW B-adv.all	, , 0	insulin NN B-noun.body	) ) 0	may MD 0	be VB 0	altered VBN B-verb.change	. . 0	. . 0
DDI-MedLine.d124.s1	Previous JJ B-adj.all	studies NNS B-noun.group	have VBP 0	demonstrated VBN B-verb.perception	a DT 0	significant JJ B-adj.all	reduction NN B-noun.cognition	in IN 0	the DT 0	oral JJ B-adj.all	bioavailability NN B-noun.cognition	of IN 0	trovafloxacin NN B-noun.state	and CC 0	ciprofloxacin NN B-noun.person	when WRB 0	administered VBN B-verb.communication	concomitantly RB B-adv.all	with IN 0	an DT 0	intravenous JJ B-adj.all	opiate NN B-noun.state	such JJ 0	as IN 0	morphine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d0.s1	Pharmacokinetic JJ B-adj.all	studies NNS B-noun.group	indicate VBP B-verb.cognition	that IN 0	administration NN B-noun.time	of IN 0	disulfiram NN B-noun.food	or CC 0	diazepam NN B-noun.person	does VBZ 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	acamprosate NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d270.s53	Nevirapine NNP B-noun.person	and CC 0	rifampin NN B-noun.plant	should MD 0	not RB B-adv.all	beadministered VBN B-verb.body	concomitantly RB B-adv.all	becausedecreases VBZ B-verb.stative	in IN 0	nevirapine JJ B-adj.all	plasmaconcentrations NNS B-noun.artifact	may MD 0	reduce VB B-verb.change	the DT 0	efficacy NN B-noun.phenomenon	ofthe RB 0	drug NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d40.s14	- : 0	Drugs NNS B-noun.person	that WDT 0	may MD 0	either RB 0	increase VB B-verb.change	or CC 0	decrease VB B-verb.cognition	plasma NN B-noun.phenomenon	phenytoin NN B-noun.event	concentrations NNS B-noun.person	include VBP B-verb.change	, , 0	phenobarbital JJ B-adj.all	, , 0	vaiproic JJ B-adj.all	acid NN B-noun.person	, , 0	and CC 0	sodium_valproate NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d443.s5	Urinary NNP B-noun.person	Alkalinizers NNP I-noun.person	, , 0	Decrease NNP B-noun.person	aspirin NN I-noun.person	effectiveness NN B-noun.cognition	by IN 0	increasing VBG B-verb.change	the DT 0	rate NN B-noun.time	of IN 0	salicylate JJ B-adj.all	renal JJ B-adj.all	excretion NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d113.s7	Antacids NNP B-noun.person	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	aluminum NN B-noun.person	and CC 0	magnesium_hydroxides NNS B-noun.group	does VBZ 0	not RB B-adv.all	interfere VB B-verb.stative	with IN 0	absorption NN B-noun.act	of IN 0	meclofenamate_sodium NN B-noun.person	. . 0	. . 0
DDI-MedLine.d103.s15	Lastly RB B-adv.all	local JJ B-adj.all	use NN 0	of IN 0	the DT 0	mucocutaneous JJ B-adj.all	and CC 0	cytoprotective JJ B-adj.all	properties NNS B-noun.attribute	of IN 0	magnesium NN B-noun.person	is VBZ B-verb.stative	still RB B-adv.all	valid JJ B-adj.all	, , 0	in IN 0	cardioplegic_solutions NNS B-noun.artifact	and CC 0	for IN 0	preservation NN B-noun.act	of IN 0	transplants NNS B-noun.person	particularly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d428.s10	Cimetidine NNP B-noun.person	increased VBD B-verb.change	the DT 0	AUC NNP B-noun.group	of IN 0	epirubicin NN B-noun.communication	by IN 0	50 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d215.s0	Caution NN B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	when WRB 0	anileridine NN 0	is VBZ 0	coadministered VBN B-verb.contact	with IN 0	other JJ 0	opioids NNS B-noun.person	, , 0	sedatives NNS B-noun.person	, , 0	phenothiazines NNS B-noun.body	, , 0	or CC 0	anesthetics NNS B-noun.person	, , 0	as IN 0	these DT 0	agents NNS B-noun.person	may MD 0	increase VB B-verb.cognition	respiratory NN B-noun.person	and CC 0	circulatory JJ B-adj.all	depression NN B-noun.act	. . 0	. . 0
DDI-MedLine.d36.s0	Carbamazepine NNP 0	overdose RB 0	recognized VBN B-verb.cognition	by IN 0	a DT 0	tricyclic_antidepressant JJ B-adj.all	assay NN B-noun.cognition	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d552.s0	Nabilone NNP B-noun.person	should MD 0	be VB 0	administered VBN B-verb.possession	with IN 0	caution NN B-noun.cognition	to TO 0	patients NNS B-noun.person	who WP 0	are VBP 0	taking VBG B-verb.social	other JJ B-adj.all	psychoactive_drugs NNS B-noun.plant	or CC 0	CNS_depressants NNS B-noun.artifact	, , 0	including VBG B-verb.emotion	alcohol NN I-verb.emotion	, , 0	barbiturates NNS B-noun.artifact	and CC 0	narcotic_analgesics NNS B-noun.person	, , 0	or CC 0	to TO 0	those DT 0	with IN 0	a DT 0	history NN B-noun.cognition	of IN 0	psychiatric JJ B-adj.pert	disorder NN B-noun.person	( ( 0	including VBG B-verb.change	manic JJ B-adj.pert	- : 0	depressive JJ B-adj.all	illness NN B-noun.feeling	and CC 0	schizophrenia NN B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d289.s16	Caution NN B-noun.person	should MD 0	be VB 0	exercised VBN B-verb.communication	if IN 0	tacrolimus NN B-noun.person	and CC 0	bosentan NN 0	are VBP 0	used VBN B-verb.consumption	together RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d427.s9	sucralfate NN B-noun.state	or CC 0	divalent NN B-noun.communication	or CC 0	trivalent JJ B-adj.all	cations NNS B-noun.state	such JJ 0	as IN 0	iron NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d307.s40	Hormonal NNP B-noun.person	contraceptives VBZ B-verb.communication	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	Trileptal NNP B-noun.person	with IN 0	an DT 0	oral JJ B-adj.all	contraceptive NN B-noun.cognition	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	influence VB B-verb.communication	the DT 0	plasma NN B-noun.plant	concentrations NNS B-noun.attribute	of IN 0	the DT 0	two CD 0	hormonal JJ B-adj.all	components NNS B-noun.person	, , 0	ethinylestradiol NN 0	( ( 0	EE NNP 0	) ) 0	and CC 0	levonorgestrel NN B-noun.attribute	( ( 0	LNG NNP 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d422.s1	Patients NNS B-noun.person	treated VBD B-verb.communication	concurrently RB B-adv.all	with IN 0	BREVIBLOC NNP B-noun.person	( ( I-noun.person	esmolol_HCl NNP I-noun.person	) ) 0	and CC 0	a DT 0	catecholamine NN B-noun.person	depletor NN B-noun.person	should MD 0	therefore RB 0	be VB B-verb.stative	closely RB B-adv.all	observed VBN B-verb.perception	for IN 0	evidence NN B-noun.time	of IN 0	hypotension NN B-noun.act	or CC 0	marked VBN B-verb.contact	bradycardia NNS B-noun.person	, , 0	which WDT 0	may MD 0	result VB B-verb.stative	in IN 0	vertigo RB B-adv.all	, , 0	syncope NN B-noun.person	, , 0	or CC 0	postural JJ B-adj.all	hypotension NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d234.s6	The DT 0	effects NNS B-noun.phenomenon	of IN 0	nonbenzodiazepine JJ B-adj.all	agonists NNS B-noun.person	at IN 0	benzodiazepine NN B-noun.location	receptors NNS B-noun.person	, , 0	such JJ 0	as IN 0	zopiclone NN 0	, , 0	triazolopyridazines NNS B-noun.communication	and CC 0	others NNS 0	, , 0	are VBP 0	also RB B-adv.all	blocked VBN B-verb.contact	by IN 0	ROMAZICON NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d132.s16	Methotrexate NNP B-noun.person	, , 0	Caution NN B-noun.location	should MD 0	be VB 0	used VBN B-verb.consumption	if IN 0	diflunisal NN B-noun.person	is VBZ 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	methotrexate NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d135.s5	Drugs NNS B-noun.artifact	that IN 0	Inhibit NNP B-noun.person	or CC 0	Induce NNP B-noun.group	Cytochrome NNP I-noun.group	P450 NNP I-noun.group	3A4 NNP I-noun.group	Enzymes NNP I-noun.group	Lapatinib NNP I-noun.group	undergoes VBZ B-verb.creation	extensive JJ B-adj.all	metabolism NN B-noun.attribute	by IN 0	CYP3A4 NNP B-noun.person	, , 0	and CC 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	strong JJ B-adj.all	inhibitors NNS B-noun.person	or CC 0	inducers NNS B-noun.person	of IN 0	CYP3A4 JJ B-noun.phenomenon	alter NN I-noun.phenomenon	lapatinib NN B-noun.animal	concentrations NNS I-noun.animal	significantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d48.s8	Antacids NNP B-noun.person	, , 0	Nonclinical JJ B-noun.person	data NNS I-noun.person	demonstrate VBP B-verb.communication	that IN 0	the DT 0	solubility NN B-noun.cognition	of IN 0	dasatinib NN B-noun.person	is VBZ B-verb.stative	pH JJ B-adj.all	dependent NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d11.s3	Dosage NN 0	adjustment NN 0	of IN 0	STRATTERA NNP B-noun.group	may MD 0	be VB B-verb.stative	necessary JJ B-adj.all	when WRB 0	coadministered VBN B-verb.communication	with IN 0	CYP2D6 JJ B-adj.all	inhibitors NNS B-noun.person	, , 0	e.g. NNP B-noun.person	, , 0	paroxetine NN B-noun.person	, , 0	fluoxetine NN B-noun.person	, , 0	and CC 0	quinidine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d307.s47	Other JJ 0	drug NN B-noun.person	interactions NNS I-noun.person	Cimetidine NNP I-noun.person	, , 0	erythromycin NN B-noun.person	and CC 0	dextropropoxyphene NN B-noun.person	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	MHD NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d533.s7	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	aliskiren NNS B-noun.person	did VBD 0	not RB B-adv.all	significantly RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	lovastatin NN B-noun.feeling	, , 0	digoxin NN B-noun.person	, , 0	valsartan NN B-noun.attribute	, , 0	amlodipine NN B-noun.person	, , 0	metformin NN B-noun.person	, , 0	celecoxib NN B-noun.body	, , 0	atenolol NN B-noun.person	, , 0	atorvastatin NN B-noun.person	, , 0	ramipril NN B-noun.artifact	or CC 0	hydrochlorothiazide NN 0	. . 0	. . 0
DDI-DrugBank.d510.s0	The DT 0	concurrent JJ B-adj.all	use NN 0	of IN 0	Robinul NNP B-noun.other	Injection NNP I-noun.other	with IN 0	other JJ 0	anticholinergics NNS B-noun.attribute	or CC 0	medications NNS B-noun.artifact	with IN 0	anticholinergic JJ B-adj.all	activity NN B-noun.state	, , 0	such JJ 0	as IN 0	phenothiazines NNS B-noun.artifact	, , 0	antiparkinson_drugs NNS B-noun.object	, , 0	or CC 0	tricyclic_antidepressants NNS B-noun.plant	, , 0	may MD 0	intensify VB B-verb.cognition	the DT 0	antimuscarinic JJ B-adj.pert	effects NNS B-noun.phenomenon	and CC 0	may MD 0	result VB B-verb.stative	in IN 0	an DT 0	increase NN B-noun.act	in IN 0	anticholinergic JJ B-adj.all	side NN B-noun.body	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d528.s0	Acetaminophen NNP B-noun.person	and CC 0	methotrexate NN B-noun.attribute	; : 0	L SYM 0	- : 0	methionine NN B-noun.person	may MD 0	decrease VB B-verb.change	hepatic JJ B-adj.all	toxicity NN B-noun.attribute	in IN 0	those DT 0	with IN 0	acetaminophen JJ B-adj.all	overdosage NN B-noun.state	or CC 0	in IN 0	those DT 0	taking VBG 0	methotrexate NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d501.s5	Insulin NNP B-noun.person	, , 0	A DT 0	clinical JJ B-adj.all	study NN B-noun.artifact	in IN 0	6 CD B-adj.all	insulin NN B-noun.person	- : 0	dependent JJ B-adj.all	diabetic NN B-noun.person	patients NNS B-noun.person	demonstrated VBD B-verb.perception	no DT 0	effect NN B-noun.cognition	of IN 0	EXTRANEAL NNP B-noun.other	on IN 0	insulin NN B-noun.substance	absorption NN B-noun.artifact	from IN 0	the DT 0	peritoneal JJ B-adj.all	cavity NN B-noun.state	or CC 0	on IN 0	insulins NNS B-noun.artifact	ability NN 0	to TO 0	control VB B-verb.social	blood NN B-noun.act	glucose NN I-noun.act	when WRB 0	insulin NN B-noun.person	was VBD 0	administered VBN B-verb.possession	intraperitoneally RB B-adv.all	with IN 0	EXTRANEAL NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d289.s10	Specific JJ B-adj.all	interaction NN B-noun.act	studies NNS B-noun.artifact	have VBP 0	demonstrated VBN B-verb.perception	the DT 0	following NN 0	, , 0	Cyclosporine_A NNP B-noun.person	, , 0	During IN 0	the DT 0	first JJ B-adj.all	day NN B-noun.person	of IN 0	concomitant JJ B-adj.all	administration NN B-noun.person	, , 0	trough JJ B-noun.body	concentrations NNS I-noun.body	of IN 0	bosentan NN B-noun.food	were VBD 0	increased VBN B-verb.change	by IN 0	about IN 0	30-fold JJ 0	. . 0	. . 0
DDI-MedLine.d62.s1	As IN 0	immediate JJ B-adj.all	- : 0	early JJ B-adj.all	genes NNS B-noun.time	( ( 0	IEGs NNP B-noun.person	) ) 0	are VBP 0	thought VBN B-verb.cognition	to TO 0	play VB B-verb.creation	a DT 0	critical JJ B-adj.all	role NN B-noun.attribute	in IN 0	mediating VBG B-verb.communication	stimulus NN B-noun.cognition	- : 0	induced VBN B-verb.creation	neural JJ B-adj.all	plasticity NN B-noun.state	, , 0	IEG NNP 0	response NN B-noun.communication	induced VBN B-verb.creation	by IN 0	methamphetamine NN B-noun.person	( ( 0	METH NNP 0	) ) 0	has VBZ 0	been VBN 0	characterized VBN B-verb.communication	to TO 0	define VB B-verb.stative	the DT 0	changes NNS B-noun.artifact	in IN 0	gene NN 0	expression NN B-noun.communication	that WDT 0	may MD 0	underlie VB B-verb.cognition	its PRP$ 0	long JJ B-noun.body	- : 0	lasting JJ B-verb.contact	behavioral JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d331.s5	This DT 0	antagonistic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	probenecid NN B-noun.person	on IN 0	bumetanide NN 0	natriuresis NN B-noun.group	is VBZ 0	not RB 0	due JJ 0	to TO 0	a DT 0	direct JJ 0	action NN 0	on IN 0	sodium NN B-noun.artifact	excretion NN B-noun.act	but CC 0	is VBZ B-verb.stative	probably RB B-adv.all	secondary JJ B-adj.all	to TO 0	its PRP$ 0	inhibitory JJ B-adj.all	effect NN B-noun.cognition	on IN 0	renal JJ B-adj.all	tubular JJ B-adj.all	secretion NN B-noun.act	of IN 0	bumetanide NN 0	. . 0	. . 0
DDI-DrugBank.d94.s18	Because IN 0	of IN 0	its PRP$ 0	primary JJ B-adj.all	CNS NNP 0	effect NN 0	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	used VBN B-verb.consumption	when WRB 0	EQUETROTM NNP B-noun.person	is VBZ 0	taken VBN B-verb.possession	with IN 0	other JJ B-adj.all	centrally_acting_drugs NNS B-noun.location	and CC 0	alcohol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d82.s25	( ( 0	Indomethacin NNP 0	) ) 0	diuretics NNS B-noun.person	are VBP 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	, , 0	the DT 0	patient NN B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	closely RB B-adv.all	to TO 0	determine VB B-verb.communication	if IN 0	the DT 0	desired VBN B-verb.emotion	effect NN 0	of IN 0	the DT 0	diuretic NN B-noun.person	is VBZ 0	obtained VBN B-verb.possession	. . 0	. . 0
DDI-DrugBank.d232.s2	Results NNS B-noun.location	of IN 0	studies NNS B-noun.food	in IN 0	multiple JJ B-adj.all	sclerosis NN B-noun.location	patients NNS B-noun.person	taking VBG B-verb.change	TYSABRI NNP B-noun.group	_ : 0	and CC 0	concomitant JJ B-noun.person	interferon_beta-1a NNP I-noun.person	( ( 0	AVONEX NNP B-noun.group	_ $ 0	30 CD B-adj.all	mcg NN 0	IM NNP 0	once RB B-adv.all	weekly JJ I-adv.all	) ) 0	or CC 0	glatiramer_acetate JJ B-adj.all	were VBD B-verb.stative	inconclusive JJ B-adj.all	with IN 0	regard NN B-noun.act	to TO 0	the DT 0	need NN B-noun.object	for IN 0	dose NN B-noun.act	adjustment NN B-noun.act	of IN 0	the DT 0	beta NN B-noun.body	- : 0	interferon NN B-noun.person	or CC 0	glatiramer_acetate NN B-noun.quantity	. . 0	. . 0
DDI-MedLine.d73.s4	Methamphetamine NN B-noun.person	, , 0	like IN 0	MPTP NNP B-noun.group	, , 0	produced VBD B-verb.creation	depletions NNS B-noun.process	of IN 0	striatal JJ B-adj.all	dopamine NN B-noun.act	but CC 0	these DT 0	actions NNS B-noun.act	were VBD 0	potentiated VBN B-verb.communication	by IN 0	pargyline NN B-noun.person	pretreatment NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d5.s0	Few JJ 0	systemic JJ B-adj.all	data NNS B-noun.cognition	have VBP 0	been VBN 0	collected VBN B-verb.contact	on IN 0	the DT 0	metabolism NN B-noun.attribute	of IN 0	WELLBUTRIN NNP 0	following VBG B-verb.stative	concomitant JJ B-adj.all	administration NN B-noun.person	with IN 0	other JJ 0	drugs NNS B-noun.artifact	or CC 0	, , 0	alternatively RB B-adv.all	, , 0	the DT 0	effect NN B-noun.cognition	of IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	WELLBUTRIN NNP 0	on IN 0	the DT 0	metabolism NN B-noun.attribute	of IN 0	other JJ 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d313.s7	A DT 0	clinical JJ B-adj.all	study NN B-noun.artifact	in IN 0	healthy JJ B-adj.all	male NN B-noun.person	volunteers NNS B-noun.person	( ( 0	n=24 NNP 0	) ) 0	demonstrated VBD B-verb.cognition	that IN 0	mixing VBG B-verb.change	NovoLog NNP B-noun.person	with IN 0	NPH_human_insulin NNP B-noun.person	immediately RB I-noun.person	before IN 0	injection NN B-noun.person	produced VBD B-verb.creation	some DT 0	attenuation NN B-noun.act	in IN 0	the DT 0	peak JJ B-adj.all	concentration NN B-noun.event	of IN 0	NovoLog NNP B-noun.person	, , 0	but CC 0	that IN 0	the DT 0	time NN B-noun.time	to TO 0	peak VB B-verb.social	and CC 0	the DT 0	total JJ B-adj.all	bioavailability NN B-noun.cognition	of IN 0	NovoLog NNP B-noun.person	were VBD B-verb.stative	not RB B-adv.all	significantly RB B-adv.all	affected VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d99.s24	Discontinuation NN B-noun.person	of IN 0	cimetidine NN B-noun.act	in IN 0	well RB 0	- : 0	controlled VBN B-verb.social	patients NNS B-noun.person	receiving VBG B-verb.communication	tricyclic_antidepressants NNS B-noun.person	and CC 0	cimetidine NN B-noun.act	may MD 0	decrease VB B-verb.cognition	the DT 0	plasma NN B-noun.plant	levels NNS B-noun.state	and CC 0	efficacy NN B-noun.person	of IN 0	the DT 0	antidepressants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d151.s1	Preliminary JJ B-adj.all	animal NN B-noun.animal	and CC 0	human JJ B-adj.all	studies NNS B-noun.group	have VBP 0	shown VBN B-verb.cognition	that IN 0	small JJ B-adj.all	quantities NNS B-noun.quantity	of IN 0	systemically RB B-adv.all	administered VBN B-verb.possession	leucovorin NN B-noun.person	enter VBP B-verb.social	the DT 0	CSF NNP 0	primarily RB 0	as IN 0	5-methyltetrahydro JJ 0	- : 0	folate NN B-noun.person	and CC 0	, , 0	in IN 0	humans NNS B-noun.animal	, , 0	remain VBP B-verb.stative	1 CD B-adj.all	to TO 0	3 CD B-adj.all	orders NNS B-noun.quantity	of IN 0	magnitude NN B-noun.person	lower JJR B-adj.all	than IN 0	the DT 0	usual JJ B-adj.all	methotrexate NN B-noun.object	concentrations NNS B-noun.possession	following VBG B-verb.stative	intrathecal JJ B-adj.all	administration NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d395.s17	Antacids NNS B-noun.person	containing VBG B-verb.stative	aluminum_hydroxide RB 0	and CC 0	magnesium_hydroxide MD 0	reduce VB B-verb.change	the DT 0	oral JJ B-adj.all	absorption NN B-noun.process	of IN 0	enoxacin NN B-noun.phenomenon	by IN 0	75 CD 0	% NN 0	. . 0	. . 0
DDI-DrugBank.d485.s23	Griseofulvin NNP B-noun.person	, , 0	Griseofulvin NNP B-noun.location	may MD 0	induce VB B-verb.cognition	the DT 0	metabolism NN B-noun.attribute	of IN 0	combination_hormonal_contraceptives NNS B-noun.person	causing VBG B-verb.communication	menstrual JJ B-noun.body	changes NNS I-noun.body	, , 0	. . 0
DDI-MedLine.d8.s1	The DT 0	antimicrobial JJ B-adj.all	effect NN B-noun.cognition	of IN 0	a DT 0	benzoxazinorifamycin NN B-noun.person	, , 0	KRM-1648 NNP B-noun.other	, , 0	either CC 0	alone RB 0	or CC 0	in IN 0	combination NN 0	with IN 0	ofloxacin NN B-noun.person	, , 0	was VBD 0	evaluated VBN B-verb.change	in IN 0	vitro NN 0	against IN 0	two CD 0	type JJ B-adj.all	strains NNS B-noun.artifact	and CC 0	six CD 0	clinical JJ B-adj.all	isolates NNS B-noun.time	of IN 0	Mycobacterium NNP B-noun.person	ulcerans NNS I-noun.person	. . 0	. . 0
DDI-DrugBank.d423.s1	Because IN 0	dexfenfluramine NN B-noun.person	is VBZ B-verb.stative	a DT 0	serotonin NN B-noun.person	releaser NN I-noun.person	and CC 0	reuptake VB B-verb.communication	inhibitor NN B-noun.person	, , 0	dexfenfluramine NN B-noun.person	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	a DT 0	MAO_inhibitor NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d76.s26	Theophylline PRP 0	, , 0	The DT 0	effect NN B-noun.cognition	of IN 0	steady JJ B-adj.all	- : 0	state NN B-adj.all	fluvoxamine NN B-noun.communication	l50 CD 0	mg NN B-noun.quantity	bid NN 0	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	Theophylline NNP B-noun.person	( ( 0	375 CD 0	mg NN B-noun.quantity	) ) 0	as IN 0	442 CD 0	mg IN 0	aminophylline NN B-noun.person	was VBD 0	evaluated VBN B-verb.change	in IN 0	12 CD B-adj.all	healthy JJ B-adj.all	non NN B-noun.person	- : 0	smoking NN B-verb.consumption	, , 0	male NN B-noun.person	volunteers NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d61.s4	During IN 0	amiodarone JJ B-adj.all	administration NN B-noun.person	, , 0	systemic JJ B-adj.all	clearance NN B-noun.attribute	of IN 0	digoxin NN B-noun.person	was VBD 0	reduced VBN B-verb.change	from IN 0	234 CD 0	+ . 0	/- $ 0	72 CD 0	ml RB 0	/ JJ 0	min NN 0	( ( 0	mean VB B-verb.stative	+ : 0	/- PRP$ 0	standard JJ B-adj.all	deviation NN B-noun.event	) ) 0	to TO 0	172 CD 0	+ . 0	/- $ 0	33 CD 0	ml RB 0	/ JJ 0	min NN 0	( ( 0	p IN 0	less JJR B-noun.quantity	than IN 0	0.01 CD 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d399.s1	If IN 0	leprosy JJ B-adj.all	- : 0	associated VBN B-verb.cognition	inflammatory JJ B-adj.all	reactions NNS B-noun.motive	develop VBP B-verb.stative	in IN 0	patients NNS B-noun.artifact	being VBG 0	treated VBN B-verb.change	with IN 0	dapsone NN B-noun.person	and CC 0	clofazimine NN B-noun.person	, , 0	it PRP 0	is VBZ B-verb.stative	still RB B-adv.all	advisable JJ B-adj.all	to TO 0	continue VB B-verb.creation	treatment NN I-verb.creation	with IN 0	both DT 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d76.s28	Therefore RB 0	, , 0	if IN 0	theophylline PRP 0	is VBZ B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	fluvoxamine_maleate JJ B-adj.all	, , 0	its PRP$ 0	dose NN B-noun.attribute	should MD 0	be VB 0	reduced VBN B-verb.change	to TO 0	one CD 0	third NN B-noun.act	of IN 0	the DT 0	usual JJ B-adj.all	daily JJ B-adj.pert	maintenance NN B-noun.state	dose NN I-noun.state	and CC 0	plasma NN B-noun.plant	concentrations NNS B-noun.attribute	of IN 0	theophylline PRP 0	should MD 0	to TO 0	monitored VBN B-verb.perception	. . 0	. . 0
DDI-MedLine.d18.s1	The DT 0	effect NN B-noun.cognition	of IN 0	a DT 0	pulmonary_surfactant JJ B-adj.all	extract NN B-noun.communication	from IN 0	bovine NN 0	lung NN 0	, , 0	Survanta NNP B-noun.person	, , 0	on IN 0	the DT 0	dissolution NN B-noun.event	rate NN B-noun.time	of IN 0	aerosol NN B-noun.phenomenon	particles NNS B-noun.event	of IN 0	budesonide NN B-noun.location	was VBD 0	determined VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d132.s4	Both DT 0	efavirenz NN B-noun.person	and CC 0	nevirapine NN B-noun.act	have VBP 0	been VBN 0	compared VBN B-verb.cognition	to TO 0	triple JJ B-adj.all	therapy NN B-noun.person	with IN 0	the DT 0	PI NNP 0	indinavir NN 0	over IN 0	48 CD 0	weeks NNS B-noun.time	as IN 0	initial JJ B-adj.all	therapy NN B-noun.act	, , 0	with IN 0	similar JJ B-adj.all	responses NNS B-noun.artifact	being VBG 0	observed VBN B-verb.perception	with IN 0	nevirapine JJ B-adj.all	regimens NNS B-noun.artifact	and CC 0	superiority NN B-noun.person	observed VBN B-verb.perception	with IN 0	efavirenz NN B-noun.person	. . 0	. . 0
